Document:

EX-10.2

 Exhibit 10.2 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 
  

 Contract Manufacturing Agreement 

This Contract Manufacturing Agreement, dated as of August 3, 2017 (the “CMA”), is entered into by and between RTI
Surgical, Inc., a Delaware corporation (“Seller”), and A&E Advanced Closure Systems, LLC, a Delaware limited liability company (“Buyer”, and together with Seller, the “Parties”, and each, a
“Party”). 
 WHEREAS, Seller is in the business of manufacturing and selling sternal cable and sternal plate-based
products, including associated instrumentation, for use in the Field; 
 WHEREAS, Buyer wishes to purchase certain Products (as
defined below) in the Field from Seller; and 
 WHEREAS, Seller desires to manufacture and sell the Products to Buyer. 

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 1. Definitions.
Capitalized terms have the meanings set out or referred to in this Section 1 or as otherwise defined in this CMA. Capitalized terms used herein and not otherwise defined herein shall have the meaning ascribed to such terms in the Asset Purchase
Agreement (as defined below). 
 “Action” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry,
audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or other, whether at law, in equity or otherwise. 

“Assets and Resources” has the meaning set forth in Section 2.8(a). 

“Asset Purchase Agreement” means the asset purchase agreement between Buyer and Seller, dated as of August 3, 2017. 

“Basic Purchase Order Terms” means, collectively, any one or more of the following terms specified by Buyer in a Purchase
Order pursuant to Section 3.2: (a) a list of the Products to be purchased, including SKU; (b) the quantity of each of the Products ordered; (c) the delivery date; (d) the unit Price for each of the Products to be purchased;
(e) shipping terms Ex Works at Seller’s facilities and (f) the billing address. 
 “Buyer” has the meaning
set forth in the preamble to this CMA. 
 [****] 

  
 Page 1 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 “Claim” means any Action brought against a Person entitled to
indemnification under Section 10. 
 “COGS” with respect to any Product means the materials, direct labor and
manufacturing overhead costs incurred by Seller in the production of such Product. 
 “Confidential Information” has the
meaning set forth in Section 13.1. 
 “Contract Year” shall mean the period commencing on the Effective Date and
ending on June 30, 2018, and each twelve (12) month period commencing on July 1 of each subsequent year (e.g., July 1, 2018 & July 1, 2019 etc.). For example, if the Effective Date of this CMA was July 14, 2017,
then Contract Year 1 would be July 14, 2017 through June 30, 2018, Contract Year 2 would be July 1, 2018 through June 30, 2019, and so forth. 

“Defective” means not conforming to the Product Warranty under Section 9.3. 

“Defective Products” means goods shipped by Seller to Buyer pursuant to this CMA that are Defective. 

“Disclosing Party” has the meaning set forth in Section 13.1. 

“Effective Date” means August 3, 2017. 

“Ex Works” has the meaning set forth in Section 4.2. 

“Excess Orders” has the meaning set forth in Section 3.2. 

“Excused Violation” means any violation by Buyer of any Law or breach of this Agreement or other Transaction Agreement that
is based upon a condition, occurrence or cause that is essentially a continuation of any condition, occurrence or cause that existed in connection with the Business while Seller still operated the Business; provided that such violation or breach
shall cease to be deemed to be an Excused Violation as of such time, if any, as Buyer receives information that should reasonably have put Buyer on notice of such violation or breach such that Buyer’s continued violation or breach thereof
results from Buyer’s negligence in its operation of the Business. 
 “Field” means all use in humans of cable or
plate-based products involving the sternum or anterior ribs. 
 “Force Majeure Event” has the meaning set forth in
Section 17.21. 
 “Fundamental Default” means (i) that fewer than [****] of the Products ordered for shipment
hereunder over any [****] period are delivered by Seller on time, (ii) Seller breaches Section 2.5, (iii) Seller commits an intentional breach of this Agreement, or (iv) Seller otherwise materially breaches this CMA or the Quality
Agreement and (x) fails to cure such breach within [****] after written notice from Buyer or (y) repeats such breach [****]. 

  
 Page 2 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 “Indemnified Party” has the meaning set forth in Section 10.1. 

“Indemnifying Party” has the meaning set forth in Section 10.1. 

“Initial Term” has the meaning set forth in Section 6.1. 

“Losses” has the meaning set forth in Section 10.1. 

“Managed Version” means (i) Wholly Engineered products; (ii) Thorecon Products; and (iii) [****]. 

“Margin” with respect to any Product means a fraction, the numerator of which is the amount by which the price for which
Seller sells such Product to Buyer hereunder exceeds the COGS associated with such Product and the denominator of which is such price, expressed as a percentage. For example, if the COGS associated with a Product are $100 and the Price is $125, then
the Margin for such Product is ($125 - $100)/$125 = 20%. 
 “New Product” means any product that is not a Managed Version.

 “Nonconforming Products” means any Products received by Buyer from Seller pursuant to a Purchase Order that (i) do
not conform to such Purchase Order, (ii) do not conform to the specifications, (iii) are not properly packaged, (iv) do not include all required documentation or (v) for any other reason are not suitable for immediate release and
sale. 
 “Notice” has the meaning set forth in Section 17.5. 

“Party” has the meaning set forth in the preamble to this CMA. 

“Payment Failure” has the meaning set forth in Section 6.3(a). 

“Personnel” of a Party means any agents, employees, contractors or subcontractors engaged or appointed by such Party. 

“Price” has the meaning set forth in Section 5.1. 

“Product Warranty” has the meaning set forth in Section 9.3. 

“Product(s)” means all products manufactured by Seller for Buyer under this CMA. 

“Purchase Order” means Buyer’s purchase order issued to Seller hereunder. 

  
 Page 3 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 “Quality Agreement” means the Contract Manufacturing Quality Agreement and
the Private Label Quality Agreement of even date herewith by and among the Parties, which sets forth certain obligations of the Parties with respect to the quality and compliance of the Products. 

“Receiving Party” has the meaning set forth in Section 13.1. 

“Regular Planning Meeting” has the meaning set forth in Section 2.8(c). 

“Relationship Manager” has the meaning set forth in Section 2.8(b). 

“Renewal Term” has the meaning set forth in Section 6.2. 

“Responsible Party” means Buyer with respect to the Products constituting CMA Products under the CMA Product Quality
Agreement, and Seller with respect to Products constituting Private Label Products under the Private Label Quality Agreement. 

“Safety Stock” has the meaning set forth in Section 3.4. 

“Seller” has the meaning set forth in the preamble to this CMA. 

“Service Providers” has the meaning set forth in Section 16.3. 

“Service Schedule” has the meaning set forth in Section 16.1(b). 

“Services” means any services provided by Seller pursuant to Section 16. 

“Taxes” means any and all present and future sales, income, stamp and other taxes, levies, imposts, duties, deductions,
charges, fees or withholdings imposed, levied, withheld or assessed by any Governmental Authority, together with any interest or penalties imposed thereon. 

“Term” has the meaning set forth in Section 6.2. 

“Trauma” means physical injuries of sudden onset not caused by medical examination or treatment (for example, damage to the
sternum or anterior ribs done by a cardiothoracic surgeon to gain access to an organ in the human thorax is not deemed to be Trauma). 

“TSA” means the Transition Services Agreement between the Parties. 

“Warranty Period” with respect to any Product means the useful life of such Product as set forth on the documentation
therefor. The useful life of the Sternal Products (including, without limitation, instrumentation) is three (3) years. 

“Wholly Engineered” means a Sternal Product that does not require material engineering of the lower level component drawings.

  
 Page 4 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	2.	Purchase and Sale of Products. 

  

	 	2.1	Purchase and Sale. Subject to the terms and conditions of this CMA, during the Term Buyer shall purchase from Seller, and Seller shall manufacture and/or supply and sell to Buyer, the Products (including the
Sternal Products and all Managed Versions). Schedule 1 contains: (a) a description of the Sternal Products to be manufactured and sold hereunder; and (b) the purchase price for each of the Sternal Products. 

 

	 	2.2	Exclusivity of Seller. Seller will not market or sell any Sternal Products or Managed Versions, or manufacture Sternal Products or Managed Versions for other Persons or for itself or its Affiliates, where Seller
knows, or reasonably should know, that such Sternal Products or Managed Versions will be marketed for use or sale in the Field. Seller shall not be prohibited from manufacturing, marketing, and/or distributing the Sternal Products (including Managed
Versions) for use or sale outside the Field. Further, notwithstanding the foregoing, this Section 2.2 shall not prohibit Seller from manufacturing any products for a third Person that is not an Affiliate of Seller (in the provision by Seller of
contract manufacturing services to such third Person) to treat Trauma generally (including but not limited to Trauma to the sternum or anterior ribs), provided that (i) treatment of Trauma to the sternum or anterior ribs is not a primary
purpose or a substantial focus of the marketing of such products, (ii) such products are marketed and sold solely under trademarks or brands controlled by such third Person and not under any trademark or brand owned or controlled by Seller or
any Affiliate thereof and (iii) Seller provides no design or product engineering services with respect to any such products in the Field. Other than the Sternal Products (including Managed Versions), and to the extent not inconsistent with
Section 6.07 of the Asset Purchase Agreement, no prohibitions shall exist with respect to any products manufactured, marketed, and/or distributed for use or sale by Seller or its Affiliates, whether directly or indirectly, including its
distributors, and/or third-party resellers. For avoidance of doubt, no right is granted for Seller to use, and Seller agrees not to use, any trademark or other designation of source, origin, sponsorship, endorsement of certification of Buyer,
including any of the foregoing included in the Purchased Assets. 

  

	 	2.3	 Exclusivity of Buyer. Subject to Section 2.4 (“Secondary Source”): (1) Buyer will purchase
all Sternal Products, including Managed Versions, from Seller; (2) Seller shall have a right of first negotiation to manufacture for Buyer all New Products that do not otherwise constitute Sternal Products or Managed Versions, provided that the
right of first negotiation shall only apply to products manufactured during the Term and shall in no event apply to products commercially released after the third anniversary of the Closing of the Asset Purchase Agreement or that are or shall be
products, or new versions or line extensions with respect to any product, manufactured by Buyer separately from 

  
 Page 5 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
the Business, and provided, further, that the right of first negotiation shall terminate upon a change of Control of Buyer; and (3) except as may be otherwise agreed to by the Parties, Buyer
will not distribute or sell Sternal Products or Managed Versions to any Person whom Buyer knows, or reasonably should know, will market and use such Products outside the Field. If Seller’s rights under the foregoing right of first negotiation
arise with respect to any product that Buyer wishes to have manufactured, Buyer shall so notify Seller in writing. If Seller wishes to manufacture such product for Buyer, Seller shall so notify Buyer within thirty (30) days after receiving such
notice from Buyer, which notice shall include the terms under which Seller proposes to provide such manufacturing services (the “ROFN Proposal”). Buyer and Seller shall then negotiate in good faith with the view of entering into a
written agreement pursuant to which Seller will provide such manufacturing services to Buyer. Notwithstanding any other provision hereof, if Seller fails to timely provide a ROFN Proposal, or if Buyer and Seller for any reason fail to enter into
such a written agreement within sixty (60) days after Seller provides the ROFN Proposal to Buyer, Seller’s rights under the forgoing right of first negotiation with respect to such product shall terminate, and Buyer shall be free to engage
any third Person to provide manufacturing services with respect to such product, any version thereof or other product related thereto under any terms, at any time, at Buyer’s sole discretion. All restrictions upon and obligations of Buyer under
this Section 2.3 shall terminate and be of no further force or effect upon the occurrence of a Fundamental Default. 

  

	 	2.4	Secondary Source. 

  

	 	(a)	Buyer will have the right to engage a secondary source manufacturer (including the Buyer manufacturing in its own facility) for Sternal Products or any Managed Version upon providing Notice to Seller of such engagement.
Prior to Buyer placing its first purchase order with the secondary source for Sternal Products or Managed Versions for commercial distribution, Buyer will provide Notice to Seller. Upon Seller’s receipt of Buyer’s Notice of placing its
first such purchase order with the secondary source, and provided that Seller shall not have theretofore committed any Fundamental Default, the restrictions in Section 2.2 shall be deemed waived by Buyer without the requirement of any further
Notice; provided, however, that Buyer shall remain subject to Section 3.5 of this CMA and Seller shall remain subject to Section 6.07 of the Asset Purchase Agreement. For avoidance of doubt, notwithstanding Buyer’s purchases of
Sternal Products or Managed Versions from any secondary source, Seller shall remain subject to Section 2.2 in all respects if, prior to such purchases, Seller committed a Fundamental Default. 

  
 Page 6 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(b)	Notwithstanding anything to the contrary in Section 2.3, Buyer will have the right at any time to qualify and otherwise prepare any third Person to manufacture the Sternal Products and Managed Versions for Buyer by
engaging such third Person to manufacture Sternal Products or Managed Versions to the extent required in connection with such qualification and preparation, and Seller shall reasonably assist and cooperate with Buyer in any efforts of Buyer to do
so, but, for so long as Buyer’s obligations under Section 2.3 remain in effect, not for commercial resale. For avoidance of doubt, Seller shall remain subject to Section 2.2 in all respects notwithstanding Buyer’s exercise of its
rights under this Section 2.4(b), including, without limitation, its purchase of Sternal Products and Managed Versions from the secondary source or prospective secondary source in connection with its qualification as, or preparation for
becoming, a secondary source. To the extent that Seller’s performance of its obligations under this Section 2.4(b) to assist and cooperate with Buyer’s to qualify and otherwise prepare a second source to manufacture Sternal Products
and any then-existing Managed Versions require substantial effort, then Seller shall promptly so notify Buyer, and such obligations shall then be conditioned upon Buyer’s acceptance of a Service Schedule therefor under Section 16. Seller
shall promptly prepare and propose such a Service Schedule upon Buyer’s request and shall make all commercially efforts to expeditiously resolve any concerns of Buyer with respect thereto. 

 

	 	2.5	Effect of Change of Control or Sale of Assets. In the event of a change of control of Seller or its business, including a merger, sale of stock or sale by Seller of substantially all of its assets, or in the
event of any other assignment or transfer of Seller’s business or assets relating to or used in its performance of this CMA, Seller shall cause the Person that acquires such assets or business or acquires control of Seller or its business to
assume and agree to perform all of Seller’s obligations under this CMA and the Quality Agreement. Anything in this CMA to the contrary notwithstanding, in the event Seller is subject to a change in control whereby the Person gaining control of
Seller is in the business of manufacturing, marketing, and/or distributing for use or sale medical products and instruments in the Field, nothing herein shall be deemed to prohibit such Person from continuing to conduct and expand its business
(excluding the business purchased from Seller) in the Field. 

  

	 	2.6	Seller Consent to Specification Change for New Products. Seller shall not be obligated to manufacture any New Product until the specification for such New Product is accepted by Seller, in its sole discretion.

  

	 	2.7	Managed Versions. If pursuant to Section 16 or otherwise, Seller develops, either solely or jointly with Buyer, any Managed Version, Seller shall, to the extent Buyer submits and Seller accepts Purchase
Orders therefor pursuant to Section 3, manufacture such Managed Version for Buyer pursuant to and in accordance with this CMA. 

  
 Page 7 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(a)	If Buyer develops, or engages any third Person to develop, any Managed Version and desires to have Seller manufacture such Managed Version hereunder, Buyer shall so notify Seller in writing, which notice includes
proposed specifications for such Managed Version. Within thirty (30) days after receiving such notice, Seller shall respond thereto in writing, which response shall either (i) accept such specifications or (ii) suggest changes to such
specifications, explaining in detail the reasons for such changes (which reasons may include, without limitation, that manufacturing to such specification would not be reasonably practicable or that changing such specification would reduce
manufacturing or other costs). If Seller suggests changes to such specifications, the Parties shall promptly confer in good faith with the view of mutually agreeing to the specifications for such Managed Version. If Buyer and Seller fail to reach an
agreement within ten (10) Business Days regarding such specifications, then the decisions of Buyer with respect thereto shall control, provided that Seller shall in no event be obligated to manufacture to such specifications if it is not
reasonably practicable to do so (and Seller promptly so notifies Buyer), and provided, further, that the price of such Managed Version hereunder shall be based on Seller’s COGS associated with manufacturing to such specifications as
contemplated in Section 5.1(c). Once the specifications for such Managed Version are accepted by Seller or established as otherwise contemplated in this Section 2.7(a), Seller shall, to the extent Buyer submits and Seller accepts Purchase
Orders pursuant to Section 3, manufacture such Managed Version for Buyer pursuant to and in accordance with this CMA. The thirty (30) day period provided above for Seller to respond to Buyer’s notice and the ten (10) Business Day
period for the Parties to attempt to reach agreement regarding new specifications may upon notice from Buyer, be accelerated upon exigent circumstances, including, without limitation, circumstances that could cause an interruption of or material
harm to the Business as a result of the act of the FDA or any other Governmental Authority, market forces or otherwise. Notwithstanding the foregoing, Seller shall have no obligation under this Section 2.7(a) to manufacture any Managed Version,
or to review specifications for any Managed Version that is to be manufactured, using additive manufacturing. 

  

	 	(b)	Promptly upon Seller’s completion of the development or design or a Managed Version or after Buyer’s Notice to Seller that it desires Seller to manufacture any Managed Version as contemplated in
Section 2.7(a), Seller shall provide Buyer a report stating the price thereof hereunder as determined pursuant to Section 5.1(c), which report shall include all information reasonably required or requested by Buyer to confirm that such
price is set correctly. If Buyer so requests, Seller shall be reasonably available under Section 16 to work with Buyer to modify the proposed specifications for any Managed Version in light of Buyer’s concerns regarding such price.

  
 Page 8 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(c)	To the extent that Seller’s performance of its obligations under Sections 2.8(b) or 2.8(c) to review or revise specifications for or determine the price of any Managed Version require substantial effort, then
Seller shall promptly so notify Buyer, and such obligations shall then be conditioned upon Buyer’s acceptance of a Service Schedule therefor under Section 16. Seller shall promptly prepare and propose such a Service Schedule upon
Buyer’s request and shall make all commercially reasonable efforts to expeditiously resolve any concerns of Buyer with respect thereto. 

  

	 	(d)	If any Managed Version constitutes a replacement for a Product then being manufactured by Seller hereunder, such that Buyer ceases to sell the prior version of such Product (a “Discontinued Product”),
then all outstanding Purchase Orders for such Discontinued Product having a delivery date following the release of such Managed Version shall be deemed to be for such Managed Version (with the price thereunder changed as provided herein), and all
forecasts with respect to such Discontinued Product for delivery after release of such Managed Version shall be deemed to be forecasts for such Managed Version. To the extent that Seller has any finished goods inventory of such Discontinued Product
after release of such Managed Version, or has work-in-process, subassemblies or raw materials inventory for such Discontinued Product, in either case that were
manufactured or intended for use in connection with then-pending Purchase Orders or the binding portion of the then most recent forecast that required or forecasted delivery within ninety (90) days of such release date, or that were required to
comply with Seller’s obligations under Section 3.4, and to the extent that Seller is not reasonably able to utilize such inventory in connection with such Managed Version or otherwise, Buyer shall purchase such inventory form Seller at
Seller’s COGS thereof. Seller shall promptly provide buyer such documentation, records, backup and support for such COGS as Buyer shall reasonably request. Nothing herein limits or conditions any of Seller’s obligations hereunder,
including, without limitation, its obligations with respect to product warranties, recalls or indemnification. 

  

	 	2.8	Resource Allocation; Relationship Manager; Resource Planning Committee. 

  

	 	(a)	 Buyer acknowledges that, in addition to manufacturing Products for Buyer hereunder, Seller is engaged in the
business of designing and manufacturing medical devices for sale by Seller under Seller’s brands and of manufacturing medical devices as a contract manufacturer for other customers, and that those businesses of Seller rely on many of the assets
and resources (including equipment, labor, raw materials, components, 

  
 Page 9 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
subcontractors, capital and other manufacturing inputs) that Seller also uses to perform its obligations under this CMA (the “Assets and Resources”). Similarly, Seller
acknowledges that, subject to Section 2.5(a), it is Buyer’s sole source for Products and Services, that, even if Buyer were not restricted hereunder from using alternative suppliers, there are currently no alternative suppliers that could
supply Buyer with Products or Services under acceptable terms, and, consequently, that Buyer’s ability to successfully operate and maintain the value of the Business it purchases from Seller under the Asset Purchase Agreement depends upon, and
in entering into the Asset Purchase Agreement, Buyer has relied upon, Seller’s good faith performance of its obligations under this CMA. Accordingly, Seller shall allocate the Assets and Resources, in terms of both quantity and quality, among
its businesses described above in this Section 2.10(a) fairly and in good faith. In the case of a Force Majeure event, Seller will give equal priority to the needs of Buyer in allocating Seller’s Assets and Resources. 

 

	 	(b)	Each party shall appoint a primary “Relationship Manager” and an alternate for when the primary Relationship Manager is not reasonably available. The Relationship Mangers shall manage the relationship of the
parties under this CMA and in connection with the performance hereof. 

  

	 	(c)	On a regular basis mutually agreed to by the Parties throughout the Term (but not less often than quarterly), the Relationship Managers, and such other representatives of the Parties as the Relationship Managers shall
reasonably decide to include, shall meet in person or via teleconference (“Regular Planning Meetings”). At the Regular Planning Meetings, the Parties shall discuss the allocation of Assets and Resources in light of Buyer’s
forecasts and plans and the needs of Seller’s businesses other than its business of performing under this CMA. Subject to their mutual obligations of confidentiality, each Party shall, to facilitate the constructive dialog and collaborative
planning that the Regular Planning Meetings are intended to foster, share with the other Party such information regarding the Assets and Resources and regarding its business needs, forecasts and plans as the other Party shall reasonably request. The
Parties shall use all commercially reasonable efforts to reach consensus regarding the allocation of Assets and Resources in accordance with the requirements of this Section 2.8 and to amicably resolve any disputes regarding compliance by
Seller with its obligations under Section 2.8(a). All Regular Planning Meetings shall be held at such times and locations as are mutually determined by the Relationship Managers. 

 

	 	(d)	Seller’s obligations under this Section 2.8 are in addition to, and in no way condition, qualify or limit, Seller’s other obligations under this CMA. Accordingly, Seller’s compliance with this
Section 2.8 will in no way excuse any breach by Seller of any other provision of this CMA. 

  
 Page 10 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	2.9	Terms of CMA Prevail Over Buyer’s Purchase Order. The Parties intend for the terms and conditions contained in this CMA and the Basic Purchase Order Terms contained in the applicable Purchase Order to
exclusively govern and control each of the Parties’ respective rights and obligations regarding the subject matter of this CMA, and this CMA is expressly limited to such terms and conditions. Any conflicting or additional terms presented in any
Purchase Order is waived and of no effect. 

  

	 	2.10	Packaging. 

  

	 	(a)	Materials. Packaging materials will utilize Seller’s designs suited to its production capabilities, using Seller’s standard methods of packaging and shipping, and Seller shall maintain records of
packaging specifications; provided that nothing herein shall limit Buyer’s right to change packaging specifications as the Responsible Party. All graphics will be designed by Buyer and shall be within Seller’s current production
capabilities, not add to Seller’s costs, and be compliant with applicable Laws. In addition to any graphic designs transferred to Buyer among the Purchased Assets, as between Buyer and Seller all graphics (other than Seller’s retained
trademarks, if used) shall be Buyer’s Intellectual Property. All costs for graphic designs and costs for implementing graphic design changes shall be borne by Buyer; provided that nothing herein limits any of Seller’s obligations under the
Asset Purchase Agreement with respect to labeling changes and otherwise or requires Buyer to incur any costs in connection therewith. 

  

	 	(b)	Inserts. The Responsible Party shall develop package inserts, shall maintain records of package insert specifications, and shall have control over content. In the event a party becomes aware of a regulatory or
legal insufficiency of a package insert that requires urgent modification to maintain compliance, it shall provide prompt notice to the other party and Seller will make such required change and work with Buyer to determine the process for effecting
such changes with respect to Products in inventory or that have been distributed. Costs and expenses relating to such changes, including any Recalls or other actions required or advisable in the opinion of the Responsible Party with respect to the
affected Products, shall be borne by the at-fault party, unless expressly provided for otherwise under the APA or Section 9.7 of this CMA. 

  
 Page 11 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(c)	Labels. Seller shall utilize package labels developed by the Responsible Party that are within Seller’s current production capabilities, do not add to Seller’s Costs, and are compliant with applicable
laws. In the event a party becomes aware of a regulatory or legal insufficiency of a package label that requires urgent modification to maintain compliance, it shall provide prompt notice to the other party and Seller will make such required change
and work with Buyer to determine the process for effecting such changes with respect to Products in inventory or that have been distributed. Costs and expenses relating to such changes, including any Recalls or other actions required or advisable in
the opinion of the Responsible Party with respect to the affected Products, shall be borne by the at-fault party, unless expressly provided for otherwise under the APA or Section 9.7 of this CMA.

  

	 	2.11	No Conflict Minerals. RTI shall comply with the Dodd-Frank Wall Street Reform and Consumer Protection Act by sourcing conflict-free minerals for use in the manufacturing of metal implants and other products, and
upon request, shall provide documentation of compliance to A&E and regulatory agencies. 

  

	3.	Ordering Procedure. 

  

	 	3.1	Forecasts. Buyer has provided to Seller a rolling forecast (and corresponding Purchase Orders) for the period beginning the first Contract Year which is attached hereto as Exhibit A. Thereafter, by the last
Business Day of each month, Buyer will submit a rolling forecast, listed by SKU, of Buyer’s actual or anticipated designated delivery dates of Products over the 12-month period commencing on the following
month. (For illustrative purposes only, September will be the first month of a rolling forecast submitted on the last Business Day of August.) The first four months of each rolling forecast shall be binding on Buyer. Months 5 through 12 of the
rolling forecast shall not be binding upon Buyer, but are for planning purposes only. All non-binding months of the rolling forecasts shall be based on Buyer’s good faith estimates. Unless otherwise agreed to by Seller, the anticipated
quantities for each Product (both by SKU and cumulatively) specified for month five in a rolling forecast shall neither increase nor decrease by more than [****] upon its conversion to the binding fourth month in the subsequent month’s rolling
forecast. Buyer will use commercially reasonable efforts to provide smooth month-to-month ordering patterns in its rolling forecast (excluding the effect of stocking
orders). 

  

	 	3.2	 Purchase Orders. Buyer shall submit to Seller Purchase Orders for Products correlating to the binding
forecast no later than [****] before the designated delivery date. All accepted Purchase Orders for Products shall be firm and binding on Buyer and Seller. Seller shall accept all Purchase Order submitted by Buyer for Sternal Products, Managed
Versions (except as provided in Section 2.7(a)) and any New Products (to the extent that the Parties have mutually agreed that Seller will manufacture such New Products hereunder); provided, however, that Seller will not be required to accept
Purchase Orders (i) for Managed Versions that are not designed or developed by Seller until the specifications 

  
 Page 12 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
therefor have been established as contemplated in Section 2.7(a), (ii) that designate a delivery date(s) less than [****] from the date of the Purchase Order, or for a quantity of Product on
the specified delivery date(s) that, when aggregated with other outstanding Purchase Orders, exceeds the sum of (x) [****] of the forecasted orders for delivery of such Product on such date(s) plus (y) the then available Safety Stock of such
Products (collectively, the “Excess Orders”), or (ii) that are not in conformity with the applicable requirements of this CMA. Seller will use commercially reasonable efforts to accept all Excess Orders (provided that such Excess
Orders otherwise comply with this CMA). To the extent that Seller cannot accept an Excess Order notwithstanding such commercially reasonable efforts, Seller will confer with Buyer and make commercially reasonable efforts to accept delivery dates
with respect to such Excess Orders that are as close as is commercially practicable to Buyer’s requested delivery date. If accepting an Excess Order would require Seller to incur overtime expenses, Seller’s acceptance of such Excess Order
may include a statement that such acceptance is contingent on Buyer’s agreement to pay such overtime expenses (but only to the extent that such overtime expenses are solely attributable to Seller’s efforts to timely deliver such Excess
Order), which acceptance shall further state Seller’s good faith best estimate of the amount of such overtime expenses. If Buyer does not agree to pay such overtime expenses, such acceptance shall be void, and such Purchase Order shall not be
binding on Buyer and Seller. Seller may invoice Buyer for such overtime expenses incurred by Seller. If Buyer does not respond to any contingent acceptance of an Excess Order within three (3) Business Days after Buyer’s receipt of such
contingent acceptance, Buyer shall be deemed to have declined to pay overtime with respect to such Excess Order. For clarity, overtime expenses shall relate solely to employees of Seller who are not exempt from the requirement to pay overtime under
applicable law and means, with respect to any such employee, the product obtained by multiplying (i) the amount by which the hourly compensation that Seller is required by law to pay to such employee for work performed during overtime periods
(as defined under applicable law) exceeds such employee’s standard hourly compensation, by (ii) the number of hours worked by such employee during applicable overtime periods. Seller shall provide such documentation, records, backup and
support as Buyer shall reasonably request to confirm that any overtime expenses charge hereunder conform to the requirements of this Section 3.2. 

  

	 	3.3	Initial Instrument Set Order. Without limiting any of Seller’s other obligations regarding Purchase Orders and shipping, within thirty (30) days after the closing of the Asset Purchase Agreement, Buyer
will submit, and Seller will accept, a purchase order for [****] set forth in Exhibit B for manufacture by January 31, 2018. Rolling shipments may be made by Seller. 

 

  
 Page 13 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	3.4	Safety Stock. Beginning one hundred twenty (120) days after the Effective Date, Seller will at all times during the Term maintain in inventory a quantity of finished goods sufficient to meet [****] of
Sternal Product demand, based on the binding portion of the forecast with respect to those Sternal Products that account for [****] of Seller’s revenue under this Agreement (the “Safety Stock”). Upon Seller’s full
performance of its obligations under Section 6.9 of the Asset Purchase Agreement, including the release of Products with such changes to labeling and any other modifications as may be required in connection with such performance, the Safety
Stock required hereunder shall thereafter be [****] of Sternal Product demand, based on the binding portion of the forecast with respect to those Sternal Products that account for [****] of Seller’s revenue under this Agreement. Seller shall
not be deemed in default of this provision if the Safety Stock falls below the minimum threshold due to orders made by Buyer in excess of the binding forecasts, provided that Seller shall replenish the Safety Stock to the levels required hereunder
as soon as is reasonably practicable. 

  

	 	3.5	Minimum Annual Performance. 

  

	 	(a)	Buyer must meet or exceed its Minimum Annual Performance (“MAP”) level for each Contract Year as measured by the aggregate fees for Products ordered by Buyer for delivery during such Contract Year. The
MAP for the first Contract Year shall be [****]. Thereafter, the MAP for each Contract Year (including the Contract Year(s) contained in any Renewal Term) shall equal [****] of the amount that Buyer would pay hereunder over such Contract Year if it
ordered all of the Products set forth on the most recent forecast that shall have been submitted hereunder as of the first day of such Contract Year and timely received such Products during such Contract Year. In the event of a Force Majeure Event,
the MAP with respect to the particular Contract Year affected by such Force Majeure Event shall be deemed reduced by the amount that Buyer would have paid hereunder for the Products subject to the Force Majeure Event had they been timely shipped to
Buyer. This Section 3.5 shall terminate and be of no further force or effect upon the occurrence of a Fundamental Default. 

  

	 	(b)	Within thirty (30) calendar days following the end of a Contract Year, Seller shall notify Buyer in the event Buyer failed to satisfy its MAP for the prior Contract Year and shall specify the amount of the
deficiency (a “Deficiency Notice”). Buyer shall have thirty (30) calendar days from receipt of the Deficiency Notice from Seller to cure the deficiency by submitting a Purchase Order to Seller for Products in a quantity
sufficient to require payment that is equal to or greater than the amount of such deficiency, which Purchase Order shall include payment in advance in the amount of such deficiency (with any balance owing under such Purchase Order paid as provided
herein). Such payment in advance shall not count toward Buyer’s MAP requirement for the then-current Contract Year. In the event Buyer fails to satisfy its MAP for the final Contract Year of this CMA, this Section 3.5(b) shall survive for
such minimum amount of time as required for the parties to satisfy their respective cure provisions hereunder. This Section 3.5(b) sets forth Buyer’s sole liability and Seller’s sole and exclusive remedy for any breach of this
Section 3.5. 

  
 Page 14 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	4.	Shipment, Delivery, Acceptance and Inspection. 

  

	 	4.1	Shipment. Seller may make partial shipments of Products to Buyer within the designated delivery window, provided that doing so does not increase shipping costs incurred by Buyer. Buyer will be entitled to
designate the common courier for shipment. In the absence of specific instructions, Seller may select a national courier (e.g., Fedex, UPS, DHL) of its choice. 

  

	 	4.2	Delivery. Seller shall deliver the Products Ex Works at Seller’s facilities as defined in Incoterms 2010. Seller will ship all Products purchased under an accepted binding Purchase Order on time. An on time
shipment shall be deemed to be a shipment made up to seven days before, and up to three days after, the shipment date specified on such Purchase Order. For this purpose, Nonconforming or Defective Products will not be deemed to be shipped until
repaired or replaced Product is shipped. Such Nonconforming or Defective Products shall be replaced, including shipping, at no charge to Buyer. 

  

	 	4.3	Inspection of Shipments Received. Buyer shall inspect Products received under this CMA within five (5) Business Days after Buyer receives such Products at its facility, including without limitation, all
materials and documentation required to release or commercially sell or distribute such Products, and shall either accept or, only if any such Products are Nonconforming Products, reject such Products. Buyer will be deemed to have accepted Products
unless it provides Seller with written Notice of any Nonconforming Products within seven (7) Business Days following receipt of the Products and all such materials and documentation at its facility, stating with specificity all defects and
nonconformities, and furnishing such other written evidence or other documentation as may be reasonably required by Seller (including the subject Products, or a representative sample thereof, which Buyer contends are Nonconforming Products). Seller
acknowledges that inspection of Products shall be limited to inspection of the closed containers in which such Products are shipped to Buyer, without opening any such containers, and of any related documentation and materials provided therewith.
Accordingly, acceptance by Buyer of any Products shall in no way waive or limit any of Seller’s rights under or relating to any Product Warranty or other rights. If Buyer timely notifies Seller of any Nonconforming Products, Seller shall
inspect such Product(s) for nonconformities and, provided a nonconformity exists, Seller shall elect to either: 

  

	 	(a)	replace such Nonconforming Products with conforming Products; or 

  
 Page 15 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(b)	refund to Buyer such amount paid by Buyer to Seller for such Nonconforming Products returned by Buyer to Seller. 

Buyer shall ship all Nonconforming Products to Seller’s facility or to such other location as Seller may instruct Buyer. Seller shall
reimburse Buyer for its shipment costs to Seller for verified Nonconforming Products, and if Seller exercises its option to replace Nonconforming Products, Seller shall ship to Buyer, at Seller’s expense and risk of loss, the replacement
Products. 
 EXCEPT AS OTHERWISE PROVIDED FOR IN THIS CMA, AND WITHOUT IN ANY WAY LIMITING OR EXCLUDING ANY OF BUYER’S REMEDIES FOR
FAILURE TO COMPLY WITH ANY BINDING PURCHASE ORDER, FOR ANY BREACH OF SECTION 3 OR UNDER SECTION 9.5, SECTION 9.7 OR SECTION 10, THE REMEDIES SET FORTH IN THIS SECTION 4.3 ARE BUYER’S EXCLUSIVE REMEDY FOR THE DELIVERY OF NONCONFORMING PRODUCTS,
SUBJECT TO BUYER’S RIGHTS UNDER SECTION 9.5 WITH RESPECT TO ANY SUCH PRODUCTS FOR WHICH BUYER HAS ACCEPTED DELIVERY UNDER THIS SECTION 4.3. 
  

	 	4.4	Limited Right of Return. Except as provided under Section 4.3 and Section 9.5 or as may be required in connection with any recall or other act of any Governmental Authority, Buyer has no right to return
Products shipped to Buyer pursuant to this CMA. 

  

	5.	Price and Payment. 

  

	 	5.1	Product Price. 

  

	 	(a)	With respect to all Sternal Products currently offered for sale by Seller, as well as those Sternal Products labeled “Thorecon” in Schedule 1, Buyer shall purchase such products from Seller at the prices
calculated [****] and set forth on Schedule 1 attached hereto, with such prices being fixed for the Term, except as otherwise provided for in this CMA (“Prices”). 

 

	 	(b)	Seller represents and warrants that the Price of each Sternal Product currently offered for sale by Seller and of each of Seller’s Thoracon Products has been set to provide Seller [****] with respect to such
Product, assuming that the COGS with respect to each such Sternal Product currently offered by Seller is equal to [****]. 

  

	 	(c)	 The price at which Seller shall sell any Managed Versions to Buyer hereunder shall be set so as to [****]. Seller
represents and warrants that, to the best of its knowledge as of the date that it reports [****] to Buyer pursuant to Section 2.7(c), all information in such report and in any associated documentation, backup, records or support shall be
complete and correct. Once accepted by Buyer, Managed Version prices hereunder 

  
 Page 16 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 
[****]; provided that if such Managed Version is released at any time during the last twelve (12) months of the Initial Term or any Renewal Term, and if this CMA is then renewed for a
Renewal Term after such release, then [****]. 
  

	 	(d)	The Parties shall in good faith negotiate fair and competitive pricing for New Products and if the Parties reach agreement, amend this CMA to add the prices and other terms and conditions for the New Product.

  

	 	5.2	Shipping Charges, Insurance and Taxes. All Prices are exclusive of, and Buyer is solely responsible for, and shall pay, and shall hold Seller harmless from, all Taxes, with respect to, or measured by, the sale,
shipment, use or Price of the Products or any Services (including interest and penalties thereon); provided, however, that Buyer shall not be responsible for any Taxes imposed on, or with respect to, Seller’s income, revenues, gross receipts,
use, Personnel or real or personal property or other assets. 

  

	 	5.3	Services Prices. 

  

	 	(a)	As full and complete consideration for provision of the Services, Buyer shall pay Seller to provide the Services in accordance with the following fee schedule: 

 

			
	 Skills required
	  	Hourly Rate
	Skilled Technical Staff	  	[****]
	Engineer I, II & Process Engineer; Specialist / Sr. Specialist RA / QA	  	[****]
	Engineer III and Project Manager; Mgr / Sr. Mgr RA / QA	  	[****]
	Director of Engineering / RA / QA	  	[****]

  

	 	(b)	All charges must in any event be reasonable and appropriately documented. 

  

	 	(c)	Each of the Parties acknowledges that, over the course of the Term, the titles and job descriptions of Seller’s engineering and other technical personnel, as well as Seller’s costs associated with such
personnel, may change. If, as a result of any such changes, it would be reasonable and appropriate for the job titles or hourly rates set forth above in this Section 5.3 to change, the Parties shall discuss and make reasonable efforts to agree
upon appropriate changes thereto at the Regular Planning Meetings. 

  

	 	(d)	Buyer will reimburse Seller for out-of-pocket costs incurred by Seller in providing services (such as the cost of materials included in
deliverables provided to Buyer) to the extent that such out-of-pocket costs are described in reasonable detail in the applicable Service Schedule. 

  
 Page 17 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(e)	Seller shall promptly provide buyer such documentation, records, backup and support for any charges related to the Services as Buyer shall reasonably request. 

 

	 	5.4	Payment Terms. Seller shall issue invoices to Buyer for all Products ordered by Buyer at or after the time that such Products are shipped and for all Services provided in any month at or after the end of such
month (or as otherwise specified in the applicable Service Schedule), setting forth in reasonable detail the amounts payable by Buyer under this CMA. Buyer shall pay to Seller all undisputed invoiced amounts with thirty (30) days of the date of
such invoice (and shall pay amounts disputed pursuant to Section 5.5 within thirty (30) days after such dispute is resolved). Buyer shall make all payments in US dollars by check or wire transfer, in accordance with the following wire
instructions: 

  

			
	ABA Routing Number:	  	[****]
	Account Number:	  	[****]
	Banking Institution:	  	[****]
	Bank Address:	  	[****]
	Company Contact:	  	[****]

  

	 	5.5	Invoice Disputes. Buyer shall notify Seller in writing of any dispute with any invoice (along with substantiating documentation and a reasonably detailed description of the dispute) within fifteen
(15) Business Days from the date of such invoice, provided that if Buyer inadvertently fails to review in a timely fashion any invoice received hereunder, then Buyer may dispute such invoice at any time within five (5) Business Days after
receiving Notice from Seller that such payment is past due. Buyer will be deemed to have accepted all invoices for which Seller does not receive timely notification of dispute, and shall pay all undisputed amounts due under such invoices within the
period set forth in Section 5.4. The Parties shall seek to resolve any such disputes expeditiously and in good faith. 

  

	 	5.6	Late Payments. Buyer shall pay interest on all late payments (whether during the Term or after the expiration or earlier termination of the Term), calculated daily and compounded monthly, at the lesser of the
rate of [****] per annum or the highest rate permissible under applicable Law. Buyer shall also reimburse Seller for all reasonable costs incurred by Seller in collecting any late payments, and Seller shall reimburse Buyer for all reasonable costs
incurred by Buyer to defend any collection claim by Seller that is found to lack merit, including in each case attorneys’ fees and court costs. In addition to all other remedies available under this CMA or at Law (which Seller does not waive by
the exercise of any rights under this CMA), if Buyer fails to pay any undisputed amounts when due under this CMA, Seller may (a) suspend the delivery of any Products, (b) reject Buyer’s Purchase Orders. 

  
 Page 18 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	5.7	No Set-off Right. Buyer shall not, and acknowledges that it will have no right to, offset any amounts owed to Seller under this CMA against any other amounts owed (or to
become due and owing) to it by Seller or Seller’s Affiliates, whether relating to Seller’s or its Affiliates’ breach or non-performance of this CMA, any Purchase Order or any other agreement.

  

	6.	Term; Termination. 

  

	 	6.1	Initial Term. The term of this CMA commences on the Effective Date and continues for a period of five (5) years, unless it is earlier terminated pursuant to the terms of this CMA (the “Initial
Term”). 

  

	 	6.2	Renewal Term. Upon expiration of the Initial Term, the term of this CMA will automatically renew for one additional two (2) year term unless either Party provides written Notice of non-renewal at least one (1) year prior to the end of the Initial Term (the “Renewal Term” and together with the Initial Term, the “Term”), unless the Renewal Term is earlier
terminated pursuant to the terms of this CMA. 

  

	 	6.3	Seller’s Right to Terminate. Seller may terminate this CMA, by providing written Notice to Buyer: 

  

	 	(a)	if Buyer fails to pay any undisputed amount when due under this CMA if such failure to pay is not cured by Buyer within thirty (30) days after Buyer’s receipt of written Notice of such failure to pay
(“Payment Failure”); 

  

	 	(b)	if Buyer is in material breach of any representation, warranty or covenant of Buyer under this CMA (other than committing a Payment Failure), and either the breach cannot be cured or, if the breach can be cured, it is
not cured by Buyer within thirty (30) days after Buyer’s receipt of written Notice of such breach; 

  

	 	(c)	if Buyer (i) becomes insolvent, (ii) files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any
domestic or foreign bankruptcy or insolvency Law, or (iii) applies for or has appointed a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of
its property or business; or 

  
 Page 19 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(d)	in the event of a Force Majeure Event affecting Buyer’s performance under this CMA for more than one hundred twenty (120) consecutive days. 

Any termination under this Section 6.3 will be effective on Buyer’s receipt of Seller’s written Notice of termination or such
later date (if any) set forth in such Notice. 
  

	 	6.4	Buyer’s Right to Terminate. Buyer may terminate this CMA, by providing written Notice to Seller: 

  

	 	(a)	if Seller commits a Fundamental Default; 

  

	 	(b)	if Seller (i) becomes insolvent, (ii) files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any
domestic or foreign bankruptcy or insolvency Law, or (iii) applies for or has appointed a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of
its property or business; or 

  

	 	(c)	in the event of a Force Majeure Event affecting Seller’s performance under this CMA for more than one hundred twenty (120) consecutive days. 

 

	 	6.5	Effect of Expiration or Termination. 

  

	 	(a)	Upon the expiration or earlier termination of this CMA, to the extent that Seller has any finished goods inventory of Product, or has
work-in-process, subassemblies or raw materials inventory for Product, in each case that were manufactured or intended for use in connection with then-pending Purchase
Orders or the binding portion of the then most recent forecast that required or forecasted delivery within ninety (90) days of such termination, or were required to comply with Seller’s obligations under Section 3.4, and to the extent
that Seller is not reasonably able to utilize such inventory, Buyer shall purchase such inventory form Seller at Seller’s COGS thereof. Seller shall promptly provide buyer such documentation, records, backup and support for such COGS as Buyer
shall reasonably request. 

  

	 	(b)	Expiration or termination of the Term will not affect Buyer’s obligation to pay for any Products shipped to Buyer hereunder nor any rights or obligations of the Parties that: 

 

	 	(i)	come into effect upon or after termination or expiration of this CMA; or 

  
 Page 20 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(ii)	otherwise survive the expiration or earlier termination of this CMA pursuant to Section 17.4 and were incurred by the Parties prior to such expiration or earlier termination. 

 

	 	(c)	Except as provided in Section 6.5(d), any Notice of termination under this CMA automatically operates as a cancellation of any deliveries of Products to Buyer that are scheduled to be made, or of Services that are
to be provided, subsequent to the effective date of termination, whether or not any orders for such Products or the applicable Service Schedules had been accepted by Seller. 

 

	 	(d)	Notwithstanding any other provision hereof, if this Agreement terminates pursuant to Section 6.3(b) or 6.4 before Buyer has fully qualified a second source that is fully ready and able to assume full responsibility
for manufacturing the Products as required by Buyer, and provided that Buyer does not commit or timely cures any Payment Default, the Parties’ respective obligations under this CMA shall survive any such termination hereof until such time as
Buyer has fully qualified a second source of supply that is ready to commence fulfilling Buyer’s requirements for Products, such time to qualify a second source not to exceed the period commencing upon termination of this CMA and ending on the
earlier of (i) the first (1st) anniversary of such termination and (ii) the fifth (5th) anniversary of the Effective Date, if this CMA is terminated during its Initial Term, or the seventh (7th) anniversary of the Effective Date, if this
CMA is terminated during the Renewal Term, provided that in either case such period may be extended if Seller fails in any material respect to fully perform its obligations under Section 2.4(b) or 16 hereof or any of its obligations under the
Asset Purchase Agreement, Transition Services Agreement, or any other Transaction Documents that relate to or affect Buyer’s practical ability to assume full responsibility for manufacturing the Products. 

 

	7.	Certain Obligations of Buyer. 

  

	 	7.1	Certain Prohibited Acts. Notwithstanding anything to the contrary in this CMA, neither Buyer nor any Buyer Personnel shall make any representations, warranties, guarantees, indemnities, similar claims or
other commitments actually, apparently or ostensibly on behalf of Seller. 

  

	 	7.2	Credit Risk on Resale of the Products to Customers. Without limiting Seller’s obligations or Buyer’s rights under the Asset Purchase Agreement or any other Transaction Document, Seller shall not be
responsible under this CMA for any credit risks with respect to, and for collecting payment for, all products (including Products) sold to Buyer’s customers, whether or not Buyer has made full payment to Seller for such products. The inability
of Buyer to collect the purchase price for any product shall not be a condition to Buyer’s obligation to pay Seller for any Products. 

  
 Page 21 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	8.	Compliance with Laws. Both Parties shall at all times comply with all Laws applicable to this CMA and each Party’s respective performance of its obligations hereunder. Without limiting the
generality of the foregoing, each Party shall (a) at its own expense, maintain all certifications, credentials, licenses and permits necessary to conduct its business relating to the manufacture, purchase, use or resale of the Products and
(b) not engage in any activity or transaction involving the Products, by way of resale, lease, shipment, use or otherwise, that violates any Law. Notwithstanding the foregoing, Buyer shall not be deemed to breach this Section 8 by reason
of any Excused Violation. 

  

	9.	Representations and Warranties. 

  

	 	9.1	Buyer’s Representations and Warranties. Buyer represents and warrants to Seller that: 

  

	 	(a)	it is a limited liability company, duly organized, validly existing and in good standing under the laws of the State of Delaware; 

  

	 	(b)	it has the full right, power and authority to enter into this CMA and to perform its obligations hereunder; 

  

	 	(c)	the execution of this CMA by its Representative whose signature is set forth at the end of this CMA, and the delivery of this CMA by Buyer, have been duly authorized by all necessary action on the part of Buyer;

  

	 	(d)	the execution, delivery and performance of this CMA by Buyer will not violate, conflict with, require consent under or result in any breach or default under (i) any of Buyer’s organizational documents or
(ii) any applicable Law; 

  

	 	(e)	this CMA has been executed and delivered by Buyer and (assuming due authorization, execution and delivery by Seller) constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance
with its terms; 

  

	 	(f)	it is in material compliance with all applicable Laws relating to this CMA, the Products and the operation of its business, except for any Excused Violations; and 

 

	 	(g)	it is not insolvent. 

  
 Page 22 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	9.2	Seller’s Representations and Warranties. Seller represents and warrants to Buyer that: 

  

	 	(a)	it is a corporation, duly organized, validly existing and in good standing under the laws of the State of Delaware; 

  

	 	(b)	it has the full right, power and authority to enter into this CMA and to perform its obligations hereunder; 

  

	 	(c)	the execution of this CMA by its Representative whose signature is set forth at the end of this CMA, and the delivery of this CMA by Seller, have been duly authorized by all necessary action on the part of Seller; and

  

	 	(d)	the execution, delivery and performance of this CMA by Seller will not violate, conflict with, require consent under or result in any breach or default under (i) any of Seller’s organizational documents, or
(ii) any applicable Law; 

  

	 	(e)	this CMA has been executed and delivered by Seller and (assuming due authorization, execution and delivery by Buyer) constitutes the legal, valid and binding obligation of Seller, enforceable against Seller in
accordance with its terms; 

  

	 	(f)	it is in material compliance with all applicable Laws relating to this CMA, the Products and the operation of its business; and 

  

	 	(g)	to the Knowledge of the Seller, there exist no conditions, occurrences or causes that would be reasonably expected to lead to any Excused Violations; and 

 

	 	(h)	it is not insolvent. 

  

	 	9.3	Product Warranty. Subject to the provisions of Sections 9.4 through 9.6, Seller warrants to Buyer (the “Product Warranty”) that: 

 

	 	(a)	During the applicable Warranty Period, each Product will materially conform to the applicable specifications, will be free from defects in materials and workmanship, will be manufactured in compliance with all
applicable Laws and will comply in all respects with all requirements of the Quality Agreement. 

  

	 	(b)	Buyer will receive good and valid title to all Products, free and clear of all encumbrances and liens of any kind. 

  

	 	9.4	Product Warranty Limitations. The Product Warranty does not apply to any Product that: 

  

	 	(a)	has been subjected to use contrary to any instructions issued by Seller, including, without limitation, any of the following to the extent specifically defined in such instructions: abuse, misuse, neglect, negligence,
accident, improper testing, improper installation, improper storage, improper handling, abnormal physical stress or abnormal environmental conditions; 

  
 Page 23 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(b)	has not been used, stored and maintained in accordance with the documentation therefor; or 

  

	 	(c)	has been reconstructed, repaired or altered by Persons other than Seller or its authorized Representative. 

Buyer shall notify Seller of any changes to the documentation for any Product relating to the use, storage or maintenance thereof and shall
make commercially reasonable efforts to address any concerns expressed by Seller that such changes would impair the reliability or durability of such Products. 
  

	 	9.5	Buyer’s Exclusive Remedy for Defective Products. Buyer’s remedy under this Section 9.5 is conditioned upon Buyer’s compliance with its obligations under Section 9.5(a) and
Section 9.5(b) below. During the Warranty Period, with respect to any allegedly Defective Products: 

  

	 	(a)	Buyer shall notify Seller, in writing, of any claim of a violation of the Product Warranty within thirty (30) days from the date Buyer discovers such violation, stating with specificity all defects to Buyer’s
knowledge, and making commercially reasonable efforts to furnish such other written evidence or other documentation as may be reasonably requested by Seller; 

  

	 	(b)	To the extent reasonably feasible, Buyer shall ship such allegedly Defective Products to Seller’s facility located at Marquette, Michigan for inspection and testing by Seller; 

 

	 	(c)	Seller’s shall inspect and test such Products and, except for any defect that has been caused by any of the factors described in Section 9.4 above, subject to Section 9.5(a) and Section 9.5(b),
Seller shall elect to either (i) replace such Defective Products with conforming Products; or (ii) refund to Buyer such amount paid by Buyer to Seller for such Defective Product; and 

 

	 	(d)	Seller shall reimburse Buyer for its shipment costs to Seller for verified Defective Products, and if Seller exercises its option to replace Defective Products, Seller shall ship to Buyer, at Seller’s expense and
risk of loss, the replacement Products. 

  
 Page 24 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 Buyer has no right to return any Product except as set forth in this Section 9.5 or
Section 4.3 or as may be required in connection with any recall or other act of any Governmental Authority. In no event shall Buyer reconstruct, repair, alter or replace any Product, in whole or in part, either itself or by or through any third
party. 
 EXCEPT AS OTHERWISE PROVIDED FOR IN THIS CMA, AND WITHOUT IN ANY WAY LIMITING OR EXCLUDING ANY OF BUYER’S REMEDIES FOR FAILURE
TO COMPLY WITH ANY BINDING PURCHASE ORDER, FOR ANY BREACH OF SECTION 3 OR SECTION 16.2 OR UNDER SECTION 4.3, SECTION 9.7 OR SECTION 10, THE REMEDIES SET FORTH IN THIS SECTION 9.5 ARE BUYER’S EXCLUSIVE REMEDY FOR THE DELIVERY OF DEFECTIVE
PRODUCTS. 
 9.6 DISCLAIMER OF OTHER REPRESENTATIONS AND WARRANTIES; NON-RELIANCE. EXCEPT FOR
THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 9.2 AND THE PRODUCT WARRANTY SET FORTH IN SECTION 9.3, AND EXCEPT FOR ANY WARRANTIES PROVIDED IN SECTION 16, (A) NEITHER SELLER NOR ANY PERSON ON SELLER’S BEHALF HAS MADE OR MAKES
ANY EXPRESS, IMPLIED, STATUTORY, OR OTHER REPRESENTATION OR WARRANTY UNDER THIS CMA, EITHER ORAL OR WRITTEN, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE,
NON-INFRINGEMENT OR PERFORMANCE OF GOODS OR PRODUCTS TO STANDARDS SPECIFIC TO THE COUNTRY OF IMPORT, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE, ALL OF WHICH
ARE EXPRESSLY DISCLAIMED, AND (B) BUYER ACKNOWLEDGES THAT IT HAS NOT RELIED UPON ANY REPRESENTATION OR WARRANTY MADE BY SELLER, OR ANY OTHER PERSON ON SELLER’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN SECTIONS 9.2 AND 9.3 OF THIS CMA, IN
THE ASSET PURCHASE AGREEMENT, OR IN ANY OTHER TRANSACTION DOCUMENT. 
  

	 	9.7	Recalls; Market Withdrawals; Field Corrections. The Parties shall conduct recalls, market withdrawals, field corrections, or their foreign equivalents (collectively, “Recalls”) in accordance with
Laws applicable to the Products and jurisdictions where such Recall is applicable. The responsibilities of the Parties in effecting Recalls shall be in accordance with the requirements of applicable Laws with respect to the respective activities and
roles filled by the Parties under this CMA, and as otherwise may be required under the Parties’ Quality Agreement. The at-fault Party whose actions or omissions gave rise to the Recall shall reimburse the
Party not at fault for its reasonable out-of-pocket costs incurred in connection with conducting the Recall. The Parties will in good faith cooperate with each other in
the conduct of a Recall. For the avoidance of doubt, Seller shall be deemed to be at-fault for any Recall attributable to an Excused Violation, and, subject to the foregoing, if any Recall is attributable to a
breach of this Agreement, the Quality Agreement or any other Transaction Agreement by, either Party, such Party shall be deemed to be the at-fault Party with respect to such Recall. 

  
 Page 25 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	10.	Indemnification. 

  

	 	10.1	Mutual Indemnification. Subject to the terms and conditions of this CMA, including those set forth in Section 10.2 and Section 10.3, each Party (as “Indemnifying Party”) shall
indemnify, defend and hold harmless the other Party and its Representatives/officers, directors, employees, agents, Affiliates, successors and permitted assigns (collectively, “Indemnified Party”) against any and all losses,
damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees, fees and the costs of enforcing any right to
indemnification under this CMA and the cost of pursuing any insurance providers (collectively, “Losses”), arising out or resulting from any third-party Claim alleging: 

 

	 	(a)	a material breach or non-fulfillment of any representation, warranty or covenant under this CMA or the Quality Agreement by Indemnifying Party or Indemnifying Party’s
Personnel; 

  

	 	(b)	any negligent or more culpable act or omission of Indemnifying Party or its Personnel (including any recklessness or willful misconduct) in connection with the performance of this CMA or the Quality Agreement;

  

	 	(c)	any bodily injury, death of any Person or damage to real or tangible personal property caused by the willful or negligent acts or omissions of Indemnifying Party or its Personnel; 

 

	 	(d)	any failure by Indemnifying Party or its Personnel to materially comply with any applicable Laws (provided that, for the purposes of this Section 10(d), Seller shall be responsible for any Excused Violation); or

  

	 	(e)	any claim made by any employee, agent or representative of Seller or any other Service Provider against an Indemnified Party relating in any way to such employee’s, agent’s or representative’s involvement
in the Services (it being understood that, for any claims under this Section 10.1(e), Seller shall be the Indemnifying Party and the Indemnified Party shall be Buyer or any of its Representatives/officers, directors, employees, agents,
Affiliates, successors or permitted assigns). 

  

	 	10.2	Exceptions and Limitations on Indemnification. Notwithstanding anything to the contrary in this CMA, an Indemnifying Party is not obligated to indemnify or defend (if applicable) an Indemnified Party against any
Claim if such Claim or corresponding Losses arise out of or result from, in whole or in part, the Indemnified Party’s or its Personnel’s: 

  
 Page 26 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(a)	negligence or more culpable act or omission (including recklessness or willful misconduct); or 

  

	 	(b)	bad faith failure to comply with any of its obligations set forth in this CMA. 

  

	 	10.3	Indemnification Procedure. To receive the foregoing indemnities, the Party seeking indemnification (“Indemnitee”) must: (i) provide Notice to be received by the indemnifying Party
(“Indemnitor”) within ten (10) Business Days of Indemnitee’s first notice of the Claim, provided however, that any failure or delay in providing written notice shall not affect the Indemnitor’s indemnification obligations,
except to the extent the Indemnitor is prejudiced by such failure or delay; (ii) tender to Indemnitor full control and authority over the defense of the Claim; (iii) cooperate as reasonably requested by Indemnitor (at Indemnitor’s
expense) in Indemnitor’s defense of the Claim; and (iv) not enter into any settlement or compromise of such Claim defended by Indemnitor without the express written authorization of Indemnitor. Indemnitor shall not settle or compromise a
Claim without Indemnitee’s prior written consent (which consent shall not be unreasonably withheld or delayed), unless: (i) the sole relief provided in such settlement or compromise constitutes monetary damages borne in full by Indemnitor;
and (ii) such settlement or compromise does not include any finding or admission of a violation by Indemnitee of any Laws or third party’s rights; or require any changes in the Indemnitor’s or Indemnitee’s business practices that
would impair performance of either Party’s obligations under this CMA. 

  

	11.	Limitation of Liability. 

  

	 	11.1	NO LIABILITY FOR CONSEQUENTIAL OR INDIRECT DAMAGES. EXCEPT AS PROVIDED IN SECTION 11.3, IN NO EVENT SHALL EITHER PARTY OR THEIR REPRESENTATIVES BE LIABLE FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL,
EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE, ARISING OUT OF OR RELATING TO ANY BREACH OF THIS CMA, REGARDLESS OF (A) WHETHER SUCH DAMAGES WERE FORESEEABLE, (B) WHETHER OR NOT THE OTHER PARTY WAS
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND (C) THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED OR OTHER REMEDY OF ITS ESSENTIAL PURPOSE.

  
 Page 27 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	11.2	MAXIMUM LIABILITY FOR DAMAGES. EXCEPT AS PROVIDED IN SECTION 11.3, IN NO EVENT SHALL EACH PARTY’S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THIS CMA, WHETHER ARISING OUT OF OR RELATED TO BREACH OF
CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EXCEED THE TOTAL OF THE AMOUNTS PAID AND AMOUNTS ACCRUED BUT NOT YET PAID TO SELLER PURSUANT TO THIS CMA IN THE ONE YEAR PERIOD PRECEDING THE EVENT GIVING RISE TO THE CLAIM. 

 

	 	11.3	Exceptions. Notwithstanding any other provision hereof, this Section 11 shall not apply to, and shall neither exclude any damages or other remedies nor limit any liability of Seller arising out of or in
connection with, Seller’s or its Affiliates’ (i) intentional misconduct or recklessness giving rise to a breach of this CMA or the termination hereof, (ii) breach of Section 13 or (iii) obligations under Section 10.

  

	12.	Intellectual Property. Except as provided in Section 16, neither Party shall obtain from the other Party, whether expressly, impliedly, or by estoppel, any rights to the Intellectual Property of the
other Party by operation of this CMA, except that the Parties will grant, and do hereby grant, a limited license to its Intellectual Property solely to the extent reasonably necessary for each Party to satisfy its respective performance obligations
or exercise its rights under this CMA. Nothing in this CMA shall be deemed to otherwise affect the transfer and/or license of Intellectual Property rights conferred in the Asset Purchase Agreement, Intellectual Property License Agreement, or any
other Transaction Documents. 

  

	13.	Confidentiality. 

  

	 	13.1	Scope of Confidential Information. From time to time during the Term, either Party (as the “Disclosing Party”) may disclose or make available to the other Party (as the “Receiving
Party”) information about its business affairs, goods and services, forecasts, confidential information and materials comprising or relating to Intellectual Property, trade secrets, third-party confidential information and other sensitive
or proprietary information. Such information, as well as the terms of this CMA, whether orally or in written, electronic or other form or media, and whether or not marked, designated or otherwise identified as “confidential,” is
collectively referred to as “Confidential Information” hereunder. Buyer shall be deemed to be the Disclosing Party and Seller shall be deemed to be the Receiving Party with respect to all Confidential Information included, or the
rights to which are included, in the Purchased Assets. Notwithstanding the foregoing, Confidential Information does not include information that, at the time of disclosure and as established by documentary evidence: 

 

	 	(a)	is or becomes generally available to and known by the public other than as a result of, directly or indirectly, any breach of this Section 13 by the Receiving Party or any of its Representatives; 

 

	 	(b)	is or becomes available to the Receiving Party on a non-confidential basis from a third-party source, provided that such third party is not and was not prohibited from disclosing
such Confidential Information; 

  
 Page 28 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(c)	was known by or in the possession of the Receiving Party or its Representatives prior to being disclosed by or on behalf of the Disclosing Party; 

 

	 	(d)	was or is independently developed by the Receiving Party without reference to or use of, in whole or in part, any of the Disclosing Party’s Confidential Information; or 

 

	 	(e)	is required to be disclosed pursuant to applicable Law or rules or regulations of any stock exchange. 

  

	 	13.2	Protection of Confidential Information. The Receiving Party shall, for so long as it retains any Confidential Information that qualifies as a trade secret under applicable law, and for five (5) years from
disclosure of any Confidential Information that does not qualify as a trade secret: 

  

	 	(a)	protect and safeguard the confidentiality of the Disclosing Party’s Confidential Information with at least the same degree of care as the Receiving Party would protect its own Confidential Information, but in no
event with less than a commercially reasonable degree of care; 

  

	 	(b)	not use the Disclosing Party’s Confidential Information, or permit it to be accessed or used, for any purpose other than to exercise its rights or perform its obligations under this CMA; and 

 

	 	(c)	not disclose any such Confidential Information to any Person, except to the Receiving Party’s Representatives who need to know the Confidential Information to assist the Receiving Party, or act on its behalf, to
exercise its rights or perform its obligations under this CMA. 

 The Receiving Party shall be responsible for any breach of
this Section 13 caused by any of its Representatives. At any time during or after the Term, at the Disclosing Party’s written request, the Receiving Party and its Representatives shall promptly return all Confidential Information and
copies thereof that it has received under this CMA. 

  
 Page 29 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	14.	Tooling. Any injection molds, equipment or other items used by Seller in the manufacture of Products that are sold to Buyer under the Asset Purchase Agreement or later purchased by Buyer for
Seller’s use shall be loaned by Buyer to Seller solely for use in manufacturing Products for Buyer. Seller shall maintain such items and assume responsibility for any loss thereof or damage thereto, except for normal wear and tear and will
segregate and appropriately mark such items and keep them free of liens and encumbrances. In the event any molds included among the Purchased Assets are held on Seller’s behalf by a supplier of Seller, Seller shall notify such supplier of the
transfer of ownership and direct them accordingly. If Buyer so requests, Seller shall promptly return all such molds, equipment or other items upon notice from Buyer at Buyer’s expense; provided, however, that upon Seller’s return of such
molds or other items to Buyer, Seller’s obligation to supply Products created with such molds or other items shall terminate. All tooling not expressly sold to Buyer under the Asset Purchase Agreement or later purchased by Buyer for
Seller’s use that is used to manufacture the Products is owned by Seller. Buyer has no right, title, or interest in or to any such tooling. 

  

	15.	Insurance. During the Term and for a period of five (5) years thereafter each Party shall, at its own expense, maintain and carry in full force and effect, subject to appropriate levels of
self-insurance, commercial general liability insurance (including product liability coverage) in a sum no less than $10,000,000 with financially sound and reputable insurers, and upon the other Party’s request, shall provide the other Party
with a certificate of insurance evidencing the insurance coverage specified in this Section. 

  

	16.	Engineering Services. 

  

	 	16.1	Provision of Services. 

  

	 	(a)	Seller agrees to provide, or to cause its Affiliates to provide 

  

	 	(i)	 Instrument Evaluation and Reworking: at Buyer’s request Seller shall: (1) accept instruments for
potential rework and refurbishment; (2) evaluate such instruments for potential rework and refurbishment; (3) provide quotation of pricing for rework and refurbishment of such instruments; and (4) perform quoted rework and
refurbishment on such instruments (“Instrument Evaluation and Reworking”). Without limiting the forgoing, Instrument Evaluation and Reworking will, if requested by Buyer, include: (v) Seller service personnel promptly training
Buyer personnel to provide Instrument Evaluation and Reworking services; (w) Seller working with Product customers to transition Instrument Evaluation and Reworking service relationships to Buyer personnel; (x) Seller continuing to provide
Instrument Evaluation and Reworking service to customers in the same manner as prior to the transition; (y) Seller providing any other services reasonably requested by Buyer to ensure that the transition to Buyer is

  
 Page 30 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
seamless from the customers’ perspective; and (z) Seller providing any other services reasonably requested by Buyer to ensure the same level of Instrument Evaluation and Reworking
service is provided to customers at all times after transition to Buyer. 

  

	 	(ii)	Engineering Services: any and all services pertaining to product design or manufacturing, research, development, or engineering, in each case to the extent relating to any Sternal Product or any Managed Version. Without
limiting the forgoing, Engineering Services will, if requested by Buyer, include: (1) Seller transferring any and all Sternal Product and Managed Version related manufacturing know-how, trade secrets, and
information to Buyer; (2) Seller maintaining the Sternal Products and Managed Versions; and (3) Seller undertaking (x) the design, research (but not including preclinical animal studies or clinical research), development, and
engineering of Managed Versions and (y) related manufacturing engineering. 

  

	 	(iii)	Quality and Regulatory Services: any and all services pertaining to interfacing with any Governmental Authority or that relate to any requirements imposed thereby, relating to any Sternal Product or Managed Version;
obtaining, maintaining, or transferring any registrations, licenses, or approvals with respect to any such Sternal Product or Managed Version; or repairing or correcting any such Sternal Product or any Managed Version. Without limiting the forgoing,
Quality and Regulatory Services will, if requested by Buyer, include: (1) Seller managing or assisting with the transfer of any FDA or other licenses, registrations, or approvals for the Products from Seller to Buyer; (2) Seller
identifying any problems or potential problems relating to the Products; (3) Seller repairing or correcting any problems of potential problems relating to the Products; and (4) Seller carrying out sustaining quality work for the Products.

  

	 	(b)	 Buyer shall notify Seller in any form or manner of Buyer’s choosing of any Services that Buyer wishes to
procure under this Section 16. For all Services requested by Buyer that are estimated by Seller to take [****], but in any event not to exceed a cumulative total of [****] (as calculated in accordance with the rates set forth herein) (such
Services, the “De Minimis Services”), Seller shall notify Buyer of such estimated cost and, upon receiving approval from Buyer (which approval may be oral or in writing), Seller shall promptly undertake the De Minimis Services in
accordance with and subject to the terms and conditions of this Section 16. All Services that are not De Minimis Services shall be specified on a service schedule (each such schedule, a “Service Schedule”). Each

  
 Page 31 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
Service shall become subject to the terms and conditions of this CMA and execution of a Service Schedule related thereto. In addition, if any services, functions, responsibilities or other
components of work for any Service are not specifically requested by Buyer or described in the applicable Service Schedule but are inherent to or a necessary part of the Services described therein, or are reasonably required for proper performance
or provision of such Services, they shall be deemed to be “Services” for all purposes under this CMA. 

  

	 	(c)	The Parties acknowledge that some of the Services available hereunder may overlap with services available or to be provided or performed under the Asset Purchase Agreement and/or the TSA. In the event of any such
overlap, to the extent that any Services are, at the relevant time, available under the Asset Purchase Agreement or the Asset Purchase Agreement requires performance thereof, such Services shall be deemed to be provided thereunder; to the extent
that any Services are, at the relevant time, not available or required to be performed under the Asset Purchase Agreement but are available or required to be performed under the TSA, they shall be deemed to be provided thereunder; and Services that,
at the relevant time, are neither available nor required to be performed under the Asset Purchase Agreement or the TSA shall be deemed to be provided hereunder. 

  

	 	16.2	Standard of Service. Seller represents, warrants, and agrees that the Services shall be provided in good faith, in accordance with Law and in a professional and workmanlike manner, and that the
quality of the functions, activities and efforts that constitute the Services, including, without limitation, the experience and qualifications of the Seller or other Service Provider personnel providing the Services, shall be not less than the
quality of such functions, activities and efforts before the date of the Asset Purchase Agreement. Seller further represents, warrants, and agrees that the Services will be performed in accordance with any performance standards set forth in the
applicable Service Schedule. Buyer will cooperate reasonably and make commercially reasonable efforts to provide any necessary information to enable Seller to perform the Services. 

 

	 	16.3	Delegation to Affiliates; Third-Party Service Providers. Seller shall have the right to delegate obligations hereunder to its Affiliates and/or hire other third-party subcontractors (collectively with Seller, the
“Service Providers”) to provide all or part of any Service hereunder, in a manner consistent with Seller’s ordinary business practices. Seller shall in all cases retain responsibility for the provision to Buyer of Services to
be performed by any Service Provider (including, without limitation, any of Seller’s Affiliates). 

  
 Page 32 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	16.4	Access to Premises. 

  

	 	(a)	In order to enable the provision of the Services by Seller, Buyer agrees that it shall provide, at no cost to Seller, the Service Providers with reasonable access to the facilities and information of the Business to the
extent necessary for Seller to fulfill its obligations under this Section 16, subject to such conditions (such as execution of confidentiality agreements) as Buyer shall reasonably impose. 

 

	 	(b)	Seller agrees that the Service Providers, when on the property of Buyer or when given access to any equipment, computer, software, network or files owned or controlled by Buyer, shall conform to the applicable policies
and procedures of Seller concerning health, safety and security as well as any such policies and procedures of Buyer which are made known to Seller. 

  

	 	16.5	Responsibility for Wages and Fees. For such time as any employees of Seller or any of its Affiliates are providing the Services to Buyer under this Section 16, (a) such employees will be deemed employees of
Seller or such Affiliate, as applicable, and shall not be deemed to be employees of Buyer for any purpose, and (b) Seller or such Affiliate, as applicable, shall be solely responsible for the payment and provision of all wages, bonuses and
commissions, employee benefits, including severance and worker’s compensation, and the withholding and payment of applicable taxes relating to such employment. 

 

	 	16.6	Intellectual Property. 

  

	 	(a)	As used herein, “Work Product” shall include, without limitation, any and all technology of any kind, including, without limitation, designs, inventions, works of authorship, mask works, know-how, trade secrets, discoveries, ideas, data, information, processes, drawings, designs, computer programs and software,
work-in-progress, and technical information, including, but not limited to, material specifications, processing instructions, equipment specifications, product
specifications, electronic files, research notebooks, invention disclosures, research and development reports and the like related thereto, and all amendments, modifications, derivatives, and improvements of or to any of the foregoing, that are
created, developed or conceived by or on behalf of any Service Providers (alone or with others), or delivered to Buyer by any Service Providers, in connection with the Services, including, without limitation, all Managed Versions. As used herein,
“Intellectual Property Rights” means all intellectual property and proprietary rights of any kind or nature anywhere in the world, including, without limitation: (i) patent rights; (ii) rights of authorship, including
copyrights, moral rights, and rights of attribution; (iii) rights in trade secrets, know how, and confidential information; and (iv) all other rights of any kind or nature in any Work Product. 

  
 Page 33 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	(b)	Seller, on behalf of itself and all Service Providers, hereby irrevocably and unconditionally assigns and agrees to assign to Buyer, without additional consideration, all right, title and interest in and to all Work
Product, whether currently existing or created or developed later, including, without limitation, all Intellectual Property Rights related thereto, whether existing now or in the future, effective immediately upon the inception, conception, creation
or development thereof. Seller shall (and shall cause all Service Providers to) (i) disclose promptly to Buyer all Work Product, and (ii) execute such written instruments and do such other acts as may be necessary in the opinion of Buyer
to obtain a patent, register a copyright or otherwise evidence or enforce Buyer’s rights in and to such Work Product (and Seller hereby irrevocably appoints Buyer and any of its officers as its attorney in fact to undertake such acts in its
name). If any Work Product, or any Intellectual Property Rights therein, including moral rights, cannot (as a matter of law) be assigned to Buyer then (1) Seller, on behalf of itself and all Service Providers, unconditionally and irrevocably
waives the enforcement of such rights and all claims and causes of action of any kind against Buyer with respect to such Work Product, and (2) to the extent Seller cannot (as a matter of law) make such waiver, Seller, on behalf of itself and
all Service Providers, unconditionally grants to Buyer an exclusive, perpetual, irrevocable, worldwide, fully assignable, fully-paid and royalty-free license, with the right to sublicense through multiple levels of sublicensees, under any and all
such rights to exercise any and all present or future rights in the Work Product without any restriction. 

  

	 	(c)	Seller represents, warrants, and agrees that (i) the Work Product shall be the original work of Seller or the Service Providers, and any individuals involved in the development of Work Product have executed (or
prior to any such involvement, shall execute) a written agreement with Seller or a Service Provider in which such individuals (1) assign to Seller or such Service Provider (as applicable) all right, title and interest in and to the Work
Product, and (2) agree to be bound by confidentiality and non-disclosure obligations no less restrictive than those set forth in this CMA; (ii) all Service Providers have executed (or prior to any
such involvement, shall execute) a written agreement with Seller in which the Service Providers (1) assign to Seller all right, title and interest in and to the Work Product, and (2) agree to be bound by confidentiality and non-disclosure obligations no less restrictive than those set forth in this CMA; (iii) Seller has the right to grant the rights and assignments granted herein, without the need for any consents, assignments,
releases, immunities or other rights not yet obtained; (iv) the Services and Work Product do not and shall not infringe, misappropriate or violate any Intellectual Property Rights of any third party; and (v) neither the Work Product nor
any element thereof shall be subject to any license, lien, security interest, option, right, or other encumbrance of any kind. 

  
 Page 34 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	17.	Miscellaneous. 

  

	 	17.1	Further Assurances. Upon a Party’s reasonable request, the other Party shall, at its sole cost and expense, execute and deliver all such further documents and instruments, and take all such further acts,
necessary to give full effect to this CMA. 

  

	 	17.2	Relationship of the Parties. The relationship between Seller and Buyer is solely that of vendor and vendee, and they are independent contracting parties. Nothing in this CMA creates any agency, joint venture,
partnership or other form of joint enterprise, employment or fiduciary relationship between the Parties. Neither Party has any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party
or to bind the other Party to any contract, agreement or undertaking with any third party. 

  

	 	17.3	Entire Agreement. This CMA, the Quality Agreement and the Asset Purchase Agreement, including any related exhibits and schedules, together constitute the sole and entire agreement of the Parties with respect to
the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter. 

 

	 	17.4	Survival; Statute of Limitations. Subject to the limitations and other provisions of this CMA: (a) the representations and warranties of the Parties contained herein, as well as any payment obligation that
accrued during the Term, will survive the expiration or earlier termination of this CMA for a period of 12 months after such expiration or termination; and (b) Sections 1, 2.9, 4 (but only to the extent of orders still pending delivery), 6.5,
8, 9.3, 9.4, 9.5, 9.6, 9.7, 10, 11, 12, 13, 14, 15 and 17 of this CMA, as well as any other provision that, in order to give proper effect to its intent, should survive such expiration or termination, will survive the expiration or earlier
termination of this CMA for the period specified therein, or if nothing is specified for a period of 12 months after such expiration or termination. All other provisions of this CMA will not survive the expiration or earlier termination of this CMA.
Notwithstanding any right under any applicable statute of limitations to bring a claim, no Action for breach of this CMA may be brought by either Party after the earlier of (i) expiration of the applicable limitations period under applicable
law with respect to such breach or (ii) the date that is two (2) years after such Party knew or should have known of such breach. 

  

	 	17.5	 Notices. All notices, requests, consents, claims, demands, waivers and other communications under this CMA
(each, a “Notice”) must be in writing and addressed to the other Party at its address set forth below (or to such other address that the receiving Party may designate from time to time in accordance with this section). All Notices
shall be delivered by personal delivery or by nationally-recognized courier (e.g. FedEx, UPS) with all fees pre-paid. Notwithstanding the 

  
 Page 35 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
foregoing, solely for the purposes of Sections 3.1 and 3.2, notice by facsimile or e-mail (with confirmation of transmission) will satisfy the requirements
of this Section 17.5. Except as otherwise provided in this CMA, a Notice is effective only (a) on receipt by the receiving Party, and (b) if the Party giving the Notice has complied with the requirements of this Section.

 To Buyer: 
 Vance Street Capital LLC

 11150 Santa Monica Blvd. #750 
 Los Angeles, CA 90025 

Attention: Brian Martin 
  

			
	To Seller:	  	With a copy to:
	RTI Surgical, Inc.	  	RTI Surgical, Inc.
	Attn: Chief Financial Officer	  	Attn: Legal Department
	11621 Research Circle	  	11621 Research Circle
	Alachua, FL 32615	  	Alachua, FL 32615

  

	 	17.6	Interpretation. For purposes of this CMA: (a) the words “include,” “includes” and “including” are deemed to be followed by the words “without limitation”; (b) the word
“or” is not exclusive; (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this CMA as a whole; (d) words denoting the singular have a comparable meaning
when used in the plural, and vice-versa; and (e) words denoting any gender include all genders. Unless the context otherwise requires, references in this CMA: (x) to sections, exhibits, schedules, attachments and appendices mean the
sections of, and exhibits, schedules, attachments and appendices attached to, this CMA; (y) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time
to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. The Parties drafted this CMA
without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any instrument to be drafted. The exhibits, schedules, attachments and appendices referred to herein are an
integral part of this CMA to the same extent as if they were set forth verbatim herein. 

  

	 	17.7	Headings. The headings in this CMA are for reference only and do not affect the interpretation of this CMA. 

  

	 	17.8	 Severability. If any term or provision of this CMA is invalid, illegal or unenforceable in any
jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this CMA or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon such

  
 Page 36 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	
determination that any term or provision is invalid, illegal or unenforceable, the Parties shall negotiate in good faith to modify this CMA to effect the original intent of the Parties as closely
as possible in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 

  

	 	17.9	Amendment and Modification. No amendment to this CMA is effective unless it is in writing and signed by an authorized Representative of each Party. 

 

	 	17.10	Waiver. 

  

	 	(a)	No waiver under this CMA is effective unless it is in writing and signed by an authorized representative of the Party waiving its right. 

 

	 	(b)	Any waiver authorized on one occasion is effective only in that instance and only for the purpose stated, and does not operate as a waiver on any future occasion. 

 

	 	(c)	None of the following constitutes a waiver or estoppel of any right, remedy, power, privilege or condition arising from this CMA: 

  

	 	(i)	any failure or delay in exercising any right, remedy, power or privilege or in enforcing any condition under this CMA; or 

  

	 	(ii)	any act, omission or course of dealing between the Parties. 

  

	 	17.11	Cumulative Remedies. Except as otherwise provided for in the CMA, all rights and remedies provided in this CMA are cumulative and not exclusive, and the exercise by either Party of any right or remedy does not
preclude the exercise of any other rights or remedies that may now or subsequently be available at law, in equity, by statute, in any other agreement between the Parties or otherwise. 

 

	 	17.12	Equitable Remedies. Each Party acknowledges and agrees that (a) a breach or threatened breach by such Party of any of its obligations under Section 13 would give rise to irreparable harm to the other
Party for which monetary damages would not be an adequate remedy and (b) in the event of a breach or a threatened breach by such Party of any such obligations, the other Party shall, in addition to any and all other rights and remedies that may
be available to such Party at law, at equity or otherwise in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a
court of competent jurisdiction, without any requirement to post a bond or other security, and without any requirement to prove actual damages or that monetary damages will not afford an adequate remedy. Each Party agrees that such Party will not
oppose or otherwise challenge the appropriateness of equitable relief or the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the terms of this Section 17.12. 

  
 Page 37 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

	 	17.13	Assignment. Either Party may assign in its sole discretion this CMA inclusive of its exhibits and the Quality Agreement, provided that any assignment by Seller or any direct or indirect assignee thereof must be
to a Person that assumes all of Seller’s obligations hereunder and under the Quality Agreement and obtains from Seller all of the Assets and Resources. 

  

	 	17.14	Successors and Assigns. This CMA is binding on and inures to the benefit of the Parties and their respective permitted successors and permitted assigns. 

 

	 	17.15	No Third-Party Beneficiaries. This CMA benefits solely the parties to this CMA and their respective permitted successors and permitted assigns and nothing in this CMA, express or implied, confers on any other
Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this CMA. 

  

	 	17.16	Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. 

  

	 	(a)	This CMA shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any
other jurisdiction). 

  

	 	(b)	ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS CMA OR THE TRANSACTIONS CONTEMPLATED HEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA OR THE COURTS OF THE STATE OF
DELAWARE, IN EACH CASE LOCATED IN THE CITY OF WILMINGTON AND COUNTY OF NEW CASTLE, AND EACH PARTY HERETO IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. THE PARTIES HERETO IRREVOCABLY AND
UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT
HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. 

  

	 	(c)	 EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS CMA IS LIKELY TO
INVOLVE COMPLICATED AND DIFFICULT ISSUES 

  
 Page 38 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 
AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS CMA OR THE
TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY TO THIS CMA CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HERETO HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING
WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS CMA BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 17.16(c). 
  

	 	17.17	Counterparts. This CMA may be executed in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement. A signed copy of this CMA delivered by
facsimile, e-mail or other means of electronic transmission is deemed to have the same legal effect as delivery of an original signed copy of this CMA. 

 

	 	17.18	Force Majeure. Seller shall not be deemed to breach this CMA to the extent that Seller is prevented from or delayed in performing its obligations hereunder due to any causes that are, and that would
notwithstanding the exercise of reasonable diligence be expected to be, beyond Seller’s reasonable control (such causes, “Force Majeure Events”), but only to the extent that (i) the effects of such Force Majeure Events
upon the functions, activities and efforts of Seller to perform its obligations hereunder is not greater or more than its effects on such ( or similar or related functions, activities or efforts of Seller or its vendors performed in connection with
Seller’s own business and (ii) Seller uses its commercially reasonable efforts to mitigate the effects of the Force Majeure Events, including without limitation, by working around any constraints on Seller’s ability of perform its
obligations hereunder that arise as a result of such Force Majeure Event (“Work-Around Efforts”). Upon any Force Majeure Event, Seller shall give notice of such event as soon as reasonably practicable to Buyer stating the extent and
duration of the impact that such event will have on its performance of its obligations hereunder and the cause thereof, and Seller shall resume the performance of its obligations as soon as reasonably practicable. Seller shall not be liable for the
nonperformance or delay in performance of its obligations under this CMA when such failure is true to a Force Majeure Event, provided that Seller implements any feasible Work-Around Efforts. 

  
 Page 39 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 [SIGNATURE PAGE(S) FOLLOWS] 

  
 Page 40 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 IN WITNESS WHEREOF, the Parties hereto by their duly-authorized representatives have executed
this Contract Manufacturing Agreement as of August __, 2017. 
  

			
	RTI SURGICAL, INC.
		
	By:	 	  

	Name:	 	Camille I. Farhat
	Title:	 	President & Chief Executive Officer

 Signature Page to Contract Manufacturing Agreement 

  

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 IN WITNESS WHEREOF, the Parties hereto by their duly-authorized representatives have executed
this Contract Manufacturing Agreement as of August __, 2017. 
  

			
	A&E ADVANCED CLOSURE SYSTEMS, LLC
		
	By:	 	 
	Name:	 	Michael Janish
	Title:	 	Chief Executive Officer and President

 Signature Page to Contract Manufacturing Agreement 

  

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 SCHEDULE 1 

PRICING 
 [****] 

Thorecon Products shall be priced at [****] in accordance with Section 5.1(a). 

* The products having Material Numbers [****] are subject to a contract between Seller and the supplier of the additional products, including a territorial
restriction imposed by Seller’s supplier. Buyer may therefore distribute and sell any such products that it purchases from Seller only within the territory to which Seller is restricted, i.e. all states, jurisdictions, commonwealths and
territories comprising the United States of America, including without limitation, Guam and Puerto Rico, and the European Union. Notwithstanding any other provision of this CMA, including, without limitation, Section 2.3, Buyer may purchase
such products directly from the manufacturer or from any third party, instead of or in addition to its purchase of such products from Seller. The territorial restrictions specified herein shall not apply to any such products that Buyer purchases
from any source other than Seller. 

  
 Page 43 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 EXHIBIT A 

ROLLING FORECAST 
 [****] 

  
 Page 44 of 45 

 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST, AND
HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 EXHIBIT B 

TRITIUM TOOLSET CONFIGURATION 
 [****] 

  
 Page 45 of 45EX-10.3

 Exhibit 10.3 

THIRD AMENDED AND RESTATED LOAN AGREEMENT 

RTI SURGICAL, INC., 
 as
Borrower 
 and 

TD BANK, N.A., 
 as
Administrative Agent, 
 and 

TD BANK, N.A. 
 and

 FIRST TENNESSEE BANK NATIONAL ASSOCIATION, 

as Lenders 
 and 

TD SECURITIES “USA” LLC, as Bookrunner and Joint Lead Arranger, and 

FIRST TENNESSEE BANK NATIONAL ASSOCIATION, as Joint Lead Arranger 

Dated as of August 3, 2017 

 THIRD AMENDED AND RESTATED LOAN AGREEMENT 

This Third Amended and Restated Loan Agreement (this “Agreement”) is dated August 3, 2017 (the “Amendment
Date”), by and among: (i) RTI Surgical, Inc., a Delaware corporation formerly known as RTI Biologics, Inc. (“Borrower”); (ii) TD Bank, N.A., a national banking association, as administrative agent for the Lenders (in
such capacity, including any successor thereto, the “Administrative Agent”); and (iii) each of the Lenders from time to time a party hereto. 

Borrower desires to modify its financing arrangements with Lenders and Lenders are willing to modify Borrower’s existing loans and
extensions of credit under the terms and provisions set forth in this Agreement. 
 This Agreement amends and restates in its entirety that
certain Second Amended and Restated Credit Agreement, dated July 16, 2013, by and among Borrower, the Administrative Agent and the Lenders, as amended by: (i) that certain First Amendment to Second Amended and Restated Loan Agreement,
dated December 30, 2013; (ii) that certain Second Amendment to Second Amended and Restated Loan Agreement, dated October 15, 2014; (iii) that certain Third Amendment to Second Amended and Restated Loan Agreement, dated June 29, 2015,
(iv) that certain Fourth Amendment to Second Amended and Restated Loan Agreement, dated June 29, 2016, (v) that certain Fifth Amendment to Second Amended and Restated Loan Agreement, dated November 7, 2016, and (vi) that certain Sixth
Amendment to Second Amended and Restated Loan Agreement, dated February 28, 2017 (the “Prior Loan Agreement”). 
 Upon
the execution and delivery of this Agreement and effective upon the Amendment Date, First Tennessee Bank National Association shall become a Joint Lead Arranger with respect to the financing arrangements contemplated by this Agreement. By their
execution and delivery of this Agreement, Lenders hereby provide their consent to Borrower’s sale of its CTS Business (as defined herein) for a cash purchase price of not less than $54,000,000. 

The parties desire to define the terms and conditions of their relationship in writing. 

Now, therefore, the parties hereto, intending to be legally bound, hereby agree that the Prior Loan Agreement is hereby amended and restated
in its entirety as follows: 
 SECTION 1 

DEFINITIONS AND INTERPRETATIONS 

1.1    Terms Defined. As used in this Agreement, the following terms have the following respective meanings: 

(a) “Account” means all of the “accounts” (as that term is defined in the UCC) of Borrower, whether now existing or
hereafter arising. 
 (b) “Account Debtor” means any Person obligated on any Account owing to Borrower. 

(c) “Acquired Entity” is defined in Section 6.1(b). 

 (d) “Adjusted LIBOR Rate” means a per annum interest rate determined pursuant to
the following formula: 
  

			
	 Adjusted LIBOR Rate     =
	  	London Interbank Offered Rate
		  	1 – LIBOR Reserve Percentage

 (e) “AdvaMed Code” is defined in Section 4.14(i). 

(f) “Advance(s)” means any monies advanced or credit extended to Borrower by Lender under the Revolving Credit. 

(g) “Advance Date” is defined in Section 2.3(b)(ii). 

(h) “Advance Request” is defined in Section 2.3(b)(ii). 

(i) “Affiliate” means with respect to any Person, (i) any Person which, directly or indirectly through one or more
intermediaries controls, or is controlled by, or is under common control with, such Person, or (ii) any Person who is a director or officer (A) of such Person, (B) of any Subsidiary of such Person, or (C) of any person described
in clause (i) above. For purposes of this definition, control of a Person shall mean the power, direct or indirect, (x) to vote five percent (5%) or more of the Capital Stock having ordinary voting power for the election of directors (or
comparable equivalent) of such Person, or (y) to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Control may be by ownership, contract, or otherwise. 

(j) “Alternate Rate” is defined in Section 2.12. 

(k) “Anti-Terrorism Laws” means any statute, treaty, law (including common law), ordinance, regulation, rule, order, opinion,
release, injunction, writ, decree or award of any Governmental Authority relating to terrorism or money laundering, including Executive Order No. 13224 and the USA Patriot Act. 

(l) “Applicable Basis Points” is defined in Section 2.9(b). 

(m) “Asset Sale” means the sale, transfer, lease, license or other disposition by Borrower, or by any Subsidiary of Borrower,
to any Person other than Borrower or any such Subsidiary, of any Property (excluding any such disposition permitted by Section 6.2) now owned, or hereafter acquired, of any nature whatsoever in any transaction or series of
related transactions other than the sale of Inventory in the ordinary course of business. An “Asset Sale” includes, but is not limited to, a merger, consolidation, division, conversion, dissolution or liquidation. 

(n) “Assignment of Claims Act” means the Federal Assignment of Claims Act, 31 U.S.C. § 3727 et seq., as amended
from time to time. 
 (o) “Authorized Officer” means any officer (or comparable equivalent) of Borrower authorized by
specific resolution of Borrower to request Advances or execute Covenant Compliance Certificates as set forth in the authorization certificate delivered to Lender substantially in the form of Exhibit B. 

(p) “Bank Affiliate” means with respect to any Lender, any Person which, directly or indirectly, is in control of, is
controlled by, or is under common control with Lender. For purposes of this definition, control of a Person shall mean the power, direct or indirect, (i) to vote twenty-five percent (25%) or more of any class of Capital Stock having ordinary
voting power for the election of directors of such Person or other Persons performing similar functions for any such Person, or (ii) to direct or cause the direction of the management and policies of such Person whether by ownership of Capital
Stock, contract or otherwise. 

  
 -2- 

 (q) “Bankruptcy Code” means Title 11 of the United States Code entitled
“Bankruptcy”, as now or hereinafter in effect, or any successor statute. 
 (r) “Blocked Person” is defined in
Section 4.25(b). 
 (s) “Borrowing Certificate” means the certificate delivered to Administrative
Agent by Borrower substantially in the form of Exhibit F. 
 (t) “Business Day” means any day other than a Saturday,
Sunday or federal holiday (or a day on which commercial banks in New York City are required or permitted to close) on which Administrative Agent is open and conducting its customary banking transactions. 

(u) “Capitalized Lease Obligations” means any Indebtedness represented by obligations under a lease that is required to be
capitalized for financial reporting purposes in accordance with GAAP, consistently applied. 
 (v) “Capital Expenditures”
means, for any period, the aggregate of all expenditures (including that portion of Capitalized Lease Obligations attributable to that period) made in respect of the purchase, construction or other acquisition of fixed or capital assets, determined
in accordance with GAAP. 
 (w) “Capital Stock” means any and all shares, interests, participations or other equivalents
(however designated) of capital stock of a corporation, any and all other ownership interests in a Person (other than a corporation) and any and all warrants or options to purchase any of the foregoing, but excluding from all of the foregoing any
debt securities convertible into or exchangeable for Capital Stock (and/or cash based on the value of Capital Stock). 
 (x) “Cash
Collateral Pledge Agreement” means that Cash Collateral Pledge Agreement to be executed by Borrower granting a first perfected security interest in the CTS Tax Escrow Account in favor of Administrative Agent and Lenders. 

(y) “Change of Control” means the earliest to occur of (i) a “person” or “group” (as such terms are
used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act, but excluding any employee benefit plan of such person and its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of
any such plan), shall become the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Securities Exchange Act), directly or indirectly, of
more than fifty percent (50%) of the then outstanding voting stock of Borrower, and (ii) during any period of twelve (12) consecutive months, the board of directors of Borrower shall cease to consist of a majority of the Continuing
Directors. 
 (z) “Closing” is defined in Section 3.6. 

(aa) “Code” means the Internal Revenue Code of 1986, as amended, as the same may be in effect, from time to time. 

(bb) “Collateral” means all of the Property and interests in Property described in Section 2.15 and
all other Property, and interests in Property that now or hereafter secure payment of the Obligations and satisfaction by Borrower of all covenants and undertakings contained in this Agreement and the other Loan Documents. 

  
 -3- 

 (cc) “Consolidated Amortization Expense” means, for any period, the aggregate
consolidated amount of amortization expenses of Borrower, as determined in accordance with GAAP. 
 (dd) “Consolidated Depreciation
Expense” means for any period, the aggregate, consolidated amount of depreciation expenses of Borrower, as determined in accordance with GAAP. 

(ee) “Consolidated EBITDA” means, for any period, Borrower’s Consolidated Net Income (or deficit) plus
(i) Consolidated Interest Expense, plus (ii) Consolidated Depreciation Expense, plus (iii) Consolidated Amortization Expense, plus (iv) Consolidated Tax Expense, plus (v) Extraordinary Expenses minus (vi) Extraordinary
Income, all as determined in accordance with GAAP. For purposes of the financial covenant calculations contemplated by Section 5.12, Borrower’s quarterly Consolidated EBITDA, inclusive of authorized one time charges
and excluding EBITDA generated by Borrower’s CTS Business shall be as set forth on Appendix 1 attached hereto. 
 (ff)
“Consolidated Interest Expense” means, for any period (without duplication), the aggregate, consolidated amount of interest expense required to be paid or accrued during such period on all Indebtedness of Borrower outstanding during
all or any part of such period, as determined in accordance with GAAP. 
 (gg) “Consolidated Net Income” means, for any
period, consolidated net income after taxes of Borrower as such would appear on Borrower’s consolidated statement of income, prepared in accordance with GAAP. 

(hh) “Consolidated Tax Expense” means, for any period, the aggregate consolidated amount of income tax expenses of Borrower,
as determined in accordance with GAAP. 
 (ii) “Continuing Directors” shall mean the directors of Borrower on the Amendment
Date, and each other director, if, in each case, such other directors’ nomination for election to the board of directors of Borrower is recommended by a majority of the then Continuing Directors. 

(jj) “Contract” means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any
nature (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, letters of intent and purchase orders) as of the Amendment Date or as may hereafter be in effect. 

(kk) “Covenant Compliance Certificate” is defined in Section 5.15. 

(ll) “CTS Business” means Borrower’s Cardiothoracic Segments (CTS) business. 

(mm) “CTS Tax Escrow Account” means the deposit account at First Tennessee Bank into which Borrower shall deposit not less
than $12,000,000 of cash proceeds received upon the closing of the sale of Borrower’s CTS Business. 
 (nn) “Default”
means any event, act, condition or occurrence which with notice, or lapse of time or both, would constitute an Event of Default hereunder. 

(oo) “Defaulting Lender” means any Lender that: (i) has failed, within two (2) Business Days of the date required
to be funded or paid, to (A) fund any portion of its Loan or (B) pay over to 

  
 -4- 

 
Borrower any other amount required to be paid by it under this Agreement, unless, in the case of clause (A) above, such Lender notifies the Administrative Agent in writing that such failure
is the result of such Lender’s good faith determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied; (ii) has notified Borrower in writing, or has made
a public statement to the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such Lender’s good faith
determination that a condition precedent (specifically identified and including the particular default, if any) to funding a loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to extend credit; or
(iii) has become the subject of a bankruptcy, insolvency or similar event. 
 (pp) “Director Indemnification
Agreement” means that certain Indemnification Agreement, dated July 16, 2013, by and between Borrower and its directors. 

(qq) “Disqualified Stock” means any Capital Stock which by its terms (or by the terms of any security into which it is
convertible or for which it is exchangeable) or upon the happening of any event (i) matures or is mandatorily redeemable for any reason, (ii) is convertible or exchangeable for Indebtedness or Capital Stock that meets the requirements of
clauses (i) and (ii), or (iii) is redeemable at the option of the holder thereof, in whole or in part, in each case on or prior to the Term Loan Maturity Date. 

(rr) “Disposition” or “Dispose” means the sale, transfer, license, lease or other disposition (including any
sale and leaseback transaction) of any property by any Person (or the grant of any option or other right to do any of the foregoing), including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts
receivable or any rights and claims associated therewith or entering into an agreement to do any of the foregoing. 
 (ss)
“Distribution” means: 
 (i)    Cash dividends or other cash distributions on any now or
hereafter outstanding Capital Stock of Borrower; 
 (ii)    The redemption, repurchase, defeasance or
acquisition of such Capital Stock or of warrants, rights or other options to purchase such Capital Stock; and 

(iii)    Any loans or advances (other than salaries), to any shareholder(s), partner(s) or member(s) of
Borrower or any Subsidiary of Borrower. 
 (tt) “Dividend Payment” is defined in
Section 2.2(c)(i). 
 (uu) “Dividend Payment Date” is defined in
Section 2.2(c)(i). 
 (vv) “Dollar,” “Dollars,” “U.S. Dollars”
and the symbol “$” mean the lawful money of the United States of America. 
 (ww) “Domestic Subsidiary”
shall mean any Subsidiary that is organized under the laws of the United States of America, any state thereof or the District of Columbia. 

(xx) “Domestic Subsidiary Patent Security Agreement” means that certain security agreement dated July 16, 2013
executed by each Domestic Subsidiary (other than RTI Donor Services) granting a security interest in the Patent Collateral of such Domestic Subsidiary (as defined in such Domestic Subsidiary Patent Security Agreement) in favor of Administrative
Agent and Lenders. 

  
 -5- 

 (yy) “Domestic Subsidiary Security Agreement” means that certain security
agreement dated July 16, 2013 executed by each Domestic Subsidiary (other than RTI Donor Services) in favor of Administrative Agent and Lenders. 

(zz) “Domestic Subsidiary Trademark Security Agreement” means that certain security agreement dated July 16, 2013
executed by each Domestic Subsidiary (other than RTI Donor Services) granting a security interest in the Trademarks of such Domestic Subsidiary (as defined in such Domestic Subsidiary Trademark Security Agreement) in favor of Administrative Agent
and Lenders. 
 (aaa) “Environmental Laws” means any and all applicable foreign, federal, state, local or municipal laws,
rules, orders, regulations, statutes, ordinances, codes, decrees and any and all common law requirements, rules and bases of liability regulating, relating to or imposing liability or standards of conduct concerning pollution, protection of the
environment, or the impact of Hazardous Substances on human health or the environment, as now or may at any time hereafter be in effect from time to time. 

(bbb) “ERISA” means the Employee Retirement Income Security Act of 1974, as the same may be in effect, from time to time.

 (ccc) “Escrow Agreement” means that certain Escrow Agreement to be executed by Borrower and First Tennessee Bank setting
forth the terms and conditions of Borrower’s cash deposit of not less than $12,000,000 for payment of taxes payable by reason of the sale of Borrower’s CTS Business. 

(ddd) “Event of Default” is defined in Section 7.1. 

(eee) “Executive Order No. 13224” means Executive Order No. 13224 on Terrorist Financing, effective
September 24, 2001, as the same has been, or shall hereafter be, renewed, extended, amended or replaced and as may be in effect from time to time. 

(fff) “Expenses” is defined in Section 9.6. 

(ggg) “Extraordinary Income” shall consist of one-time
non-recurring income items, including, but not limited to, gains on sale and acquisition related recapture of contingent or escrowed purchase money payments. 

(hhh) “Extraordinary Expenses” means any one-time expenses such as: (i) non-cash intangible asset impairment charges; (ii) non-cash stock based compensation; (iii) currently authorized one time charges of (A) $3,300,000 in
proxy, severance and restructure charges in the Quarter ending June 30, 2016, (B) $3,550,000 in review, severance and executive retirement charges in the Quarter ending September 30, 2016, (C) $15,624,000 in inventory, abandonment and
executive retirement charges in the Quarter ending December 31, 2016, and (D) $4,000,000 in severance charges in the Quarter ending March 31, 2017; (iv) severance charges not exceeding $3,500,000 to be taken in the Quarter ending
June 30, 2017 related to restructuring charges in Europe and certain other executive positions; and (v) severance charges and other related charges as approved by Lenders not exceeding $4,000,000 in the aggregate to be taken in Quarters
ending September 30, 2017 and/or December 31, 2017. The restructuring and severance expenses referred to in clauses (iv) and (v) are subject to good faith review and approval by the Required Lenders for determination of eligibility
under the defined categories. 

  
 -6- 

 (iii) “FDA” is defined in Section 4.14(a). 

(jjj) “FDCA” is defined in Section 4.14(a). 

(kkk) “Fixed Charge Coverage Ratio” means, for any period, on a consolidated basis, the ratio (i) Consolidated EBITDA
minus cash taxes (excluding taxes arising from the sale of the CTS Business), minus Distributions, minus increases in due from and/or investments in Affiliates, minus Unfunded Capital Expenditures divided by
(ii) required annual principal and interest payments, all as determined in accordance with GAAP. 
 (lll) “GAAP” means
generally accepted accounting principles as in effect on the Amendment Date applied in a manner consistent with the most recent audited financial statements of Borrower furnished to Lenders and described in Section 4.7.

 (mmm) “Governmental Authority” means any foreign, federal, state or local government or political subdivision, or any
agency, authority, bureau, central bank, commission, department or instrumentality of either, or any court, tribunal, grand jury, or arbitration. 

(nnn) “Guarantor” means each of the Domestic Subsidiaries of Borrower (other than RTI Donor Services) and any other Person
who may hereafter guaranty, as surety, all of the Obligations. 
 (ooo) “Guaranty Agreement” means that certain guaranty
agreement dated July 16, 2013 by each Guarantor in favor of Lenders. 
 (ppp) “Hazardous Substances” means any
substances defined or designated as hazardous or toxic waste, hazardous or toxic material, hazardous or toxic substance or similar term, under and regulated pursuant to any Environmental Law. 

(qqq) “Hedging Agreements” means any Interest Hedging Instrument or any other interest rate protection agreement, foreign
currency exchange agreement, commodity purchase or option agreement, or any other interest rate hedging device or swap agreement (as defined in 11 U.S.C. § 101 et. seq.). 

(rrr) “Indebtedness” of any Person, means, at any date, without duplication, (i) all indebtedness of such Person for
borrowed money (including with respect to Borrower, the Obligations) or for the deferred purchase price of property or services (other than current trade liabilities incurred in the ordinary course of business and payable in accordance with
customary practices), (ii) any other indebtedness of such Person which is evidenced by a note, bond, debenture or similar instrument, including, without limitation, any debt securities convertible into or exchangeable for Capital Stock,
(iii) all Capitalized Lease Obligations of such Person, (iv) the face amount of all letters of credit issued for the account of such Person and all drafts drawn thereunder, (v) all obligations of other Persons which such Person has
guaranteed, (vi) Disqualified Stock, (vii) all Obligations of such Person under Hedging Agreements, and (viii) all liabilities secured by any Lien on any property owned by such Person even though such Person has not assumed or
otherwise become liable for the payment thereof. 
 (sss) “Intellectual Property” means all intellectual property,
regardless of form, including: (i) patents and patent applications, published and unpublished works of authorship, including audiovisual works, collective works, computer programs, compilations, databases, derivative works, literary works, mask
works, and sound recordings; (ii) inventions and discoveries, including articles of manufacture, business methods, compositions of matter, improvements, machines, methods, and processes and new uses for any of the preceding items;
(iii) words, names, symbols, devices, designs, and 

  
 -7- 

 
other designations, and combinations of the preceding items, used to identify or distinguish a business, good, group, product, or service or to indicate a form of certification, including logos,
product designs, and product features (“Trademarks”); and (iv) trade secrets, confidential information, and information that is not generally known or readily ascertainable through proper means, whether tangible or intangible,
including algorithms, ideas, designs, formulas, know-how, methods, processes, programs, prototypes, systems, and techniques. 

(ttt) “Interest Hedging Instrument” means any documentation evidencing any interest rate swap, interest “cap” or
“collar” or any other interest rate hedging device or swap agreement (as defined in 11 U.S.C. § 101 et. seq.) between Borrower and Lender (or any Affiliate of Lender). 

(uuu) “Inventory” means all of the “inventory” (as that term is defined in the UCC) of Borrower, whether now
existing or hereafter acquired or created. 
 (vvv) “Investor Rights Agreement” means that certain Investor Rights
Agreement, dated July 16, 2013, by and between Borrower and WSHP Biologics Holdings. 
 (www) “IRS” means the
Internal Revenue Service. 
 (xxx) “Lenders” shall mean (i) the Persons listed on Exhibit A (other than any
such Person that has ceased to be a party hereto) and (ii) any Person that has become a party hereto pursuant to an assignment. The amount of each Lender’s commitment with respect to the Revolving Credit (each, a
“Commitment”) and each Lender’s applicable percentage of the Term Loans (each, an “Applicable Percentage”) is set forth on such Exhibit A. 

(yyy) “Leverage Ratio” means, at any time, on a consolidated basis, the ratio of Borrower’s (i) Total Funded
Indebtedness, to (ii) Consolidated EBITDA. 
 (zzz) “LIBOR Interest Period” means, initially, the first (1st) LIBOR
Interest Period hereunder commenced on July 16, 2013 and ended on and included July 31, 2013 (date immediately preceding the first reset date). Thereafter, each “LIBOR Interest Period” shall commence on and include the 1st calendar day of every calendar month immediately following the previous LIBOR Interest Period (the “Reset Date”); provided, however, (i) if any LIBOR Interest
Period would end on a day for which there is no numerically corresponding day in the calendar month, such LIBOR Interest Period shall end on the last day of the relevant calendar month and (ii) no LIBOR Interest Period shall extend beyond the
Term Loan Maturity Date. 
 (aaaa) “LIBOR Reserve Percentage” means, for any day, that percentage (expressed as a decimal)
which is in effect from time to time under Regulation D, as such regulation may be amended from time to time or any successor regulation, as the maximum reserve requirement (including, without limitation, any basic, supplemental, emergency, special,
or marginal reserves) applicable with respect to Eurocurrency liabilities as that term is defined in Regulation D (or against any other category of liabilities that includes deposits by reference to which the interest rate of LIBOR Rate loans is
determined), whether or not Lender has any Eurocurrency liabilities subject to such reserve requirement at that time. LIBOR Rate loans shall be deemed to constitute Eurocurrency liabilities and as such shall be deemed subject to reserve requirements
without benefits of credits for proration, exceptions or offsets that may be available from time to time to Lender. The Adjusted LIBOR Rate shall be adjusted automatically on and as of the effective date of any change in the LIBOR Reserve
Percentage. 
 (bbbb) “LIBOR Spread” is defined in Section 2.4(c). 

  
 -8- 

 (cccc) “LIBOR Spread Applicable Basis Points” is defined in
Section 2.4(c). 
 (dddd) “Lien” means any interest of any kind or nature in property securing an
obligation owed to, or a claim of any kind or nature in property by, a Person other than the owner of the Property, whether such interest is based on the common law, statute, regulation or contract, and including, but not limited to, a security
interest or lien arising from a mortgage, encumbrance, pledge, conditional sale or trust receipt, a lease, consignment or bailment for security purposes, a trust, or an assignment. For the purposes of this Agreement, Borrower shall be deemed to be
the owner of any Property which it has acquired or holds subject to a conditional sale agreement or other arrangement pursuant to which title to the Property has been retained by or vested in some other Person for security purposes. 

(eeee) “Loans” means, collectively, the unpaid balance of cash Advances under the Revolving Credit and the Term Loan. 

(ffff) “Loan Documents” means, collectively, this Agreement, the Note(s), the Security Documents, and all agreements,
instruments and documents executed and/or delivered in connection therewith, all as may be supplemented, restated, superseded, amended or replaced from time to time. 

(gggg) “London Banking Days” means any day on which commercial banks are open for general business (including dealings in
foreign exchange and foreign currency deposits) in London, England. 
 (hhhh) “London Interbank Offered Rate” means the
rate of interest (rounded upwards, at Administrative Agent’s option, to the next 100th of one percent) equal to the British Bankers’ Association LIBOR (“BBA LIBOR”) for the equivalent LIBOR Interest Period as published by
Bloomberg (or such other commercially available source providing quotations of BBA LIBOR as designated by Lender from time to time) at approximately 11:00 A.M. (London time) two (2) London Banking Days prior to the Reset Date; provided however,
if more than one BBA LIBOR is specified, the applicable rate shall be the arithmetic mean of all such rates. If, for any reason, such rate is not available, the term London Interbank Offered Rate shall mean, with respect to any LIBOR Interest
Period, the rate of interest per annum determined by administrative Agent to be the average rate per annum at which deposits in dollars are offered for such Interest Period by major banks in London, England at approximately 11:00 A.M. (London time)
two (2) London Banking Days prior to the Reset Date. 
 (iiii) “Material Adverse Effect” means a material adverse
effect with respect to (i) the business, assets, properties, financial condition, contingent liabilities, or results of operations of Borrower and its Subsidiaries, (ii) Borrower’s ability to pay the Obligations in accordance with the
terms hereof, or (iii) the validity or enforceability of this Agreement or any of the other Loan Documents or the rights and remedies of Lenders hereunder or thereunder. 

(jjjj) “Material Contract” means, with respect to Borrower or any Subsidiary of Borrower: (i) any distributor, original
equipment manufacturer, reseller, value added reseller, sales, agency or manufacturer’s representative Contract pursuant to which any Person has a right to market, resell or distribute any products involving in the case of any such Contract
more than Ten Million and 00/100 Dollars ($10,000,000.00) per annum; (ii) other than Standard Outbound IP Agreements, all licenses, sublicenses and other Contracts involving consideration in excess of Ten Million and 00/100 Dollars
($10,000,000.00) pursuant to which any Person is granted any rights to Intellectual Property or pursuant to which Borrower and/or any Subsidiary has agreed to any restriction on the right of Borrower and/or any Subsidiary to use or enforce any
rights in or with respect to any Intellectual Property or pursuant to which Borrower and/or any Subsidiary agrees to encumber, transfer or sell rights in or with respect to any Intellectual Property; (iii) other than Standard Inbound IP
Agreements, all licenses, 

  
 -9- 

 
sublicenses and other Contracts involving consideration in excess of Ten Million and 00/100 Dollars ($10,000,000.00) pursuant to which Borrower and/or any Subsidiary acquired or is granted any
rights to intellectual property owned by a third party or pursuant to which Borrower and/or any Subsidiary is granted the right to market, resell or distribute any products, technology or services of any Person; (iv) any other Contract
involving payment of more than Ten Million and 00/100 Dollars ($10,0000.00) per annum; and (v) any amendment, supplement, and modification (whether oral or written) in respect of any of the foregoing. 

(kkkk) “Maximum Acquisition and Investment Amount” means with respect to any Permitted Acquisitions and Permitted Capital
Stock Investments, taken together, (i) Twenty Million and 00/100 Dollars ($20,000,000.00) in any twelve (12)-month period or (ii) Ten Million and 00/100 Dollars ($10,000,000.00) with respect to any individual transaction. 

(llll) “Maximum Revolving Credit Amount” means the sum of Forty-Two Million Five
Hundred Thousand and 00/100 Dollars ($42,500,000.00). 
 (mmmm) “Non-Encumbrance
Agreement” means that certain agreement not to encumber real property dated July 16, 2013 by Borrower and each Domestic Subsidiary in favor of Administrative Agent and Lenders. 

(nnnn) “Note(s)” mean, collectively, the Revolving Credit Notes and Term Loan Notes. 

(oooo) “Obligations” mean all existing and future debts, liabilities and obligations of every kind or nature at any time
owing by Borrower to Lenders or any other subsidiary of Lenders or any Bank Affiliate, whether under this Agreement, or any other existing or future instrument, document or agreement, between Borrower or Lenders or any other subsidiary of Lenders or
any Bank Affiliate, whether joint or several, related or unrelated, primary or secondary, matured or contingent, due or to become due (including debts, liabilities and obligations obtained by assignment), and whether principal, interest, fees,
indemnification obligations hereunder or Expenses (specifically including interest accruing after the commencement of any bankruptcy, insolvency or similar proceeding with respect to Borrower, whether or not a claim for such post-commencement
interest is allowed), including, without limitation, debts, liabilities and obligations in respect of the Revolving Credit and Term Loan and any extensions, modifications, substitutions, increases and renewals thereof; any amount payable by Borrower
or any Subsidiary of Borrower pursuant to an Interest Hedging Instrument; the payment of all amounts advanced by Lenders or any other subsidiary of Lenders or any Bank Affiliate to preserve, protect and enforce rights hereunder and in the
Collateral; and all Expenses incurred by Lenders or any other subsidiary of Lenders or any Bank Affiliate. Without limiting the generality of the foregoing, Obligations shall include any other debts, liabilities or obligations owing to Lenders or
any other subsidiary of Lenders or any Bank Affiliate in connection with any lockbox, cash management, or other services (including electronic funds transfers or automated clearing house transactions) provided by Lenders or any other subsidiary of
Lenders or any Bank Affiliate to Borrower, as well as any other loan, advances or extension of credit, under any existing or future loan agreement, promissory note, or other instrument, document or agreement between Borrower and any Lender or any
other subsidiary of such Lender or any Bank Affiliate. 
 (pppp) “Patent Rights” is defined in
Section 4.13(b). 
 (qqqq) “Patent Security Agreement” means that certain security agreement
dated July 16, 2013 executed by Borrower granting a security interest in the Patent Collateral (as defined in the Patent Security Agreement) in favor of Administrative Agent and Lenders. 

  
 -10- 

 (rrrr) “PBGC” means the Pension Benefit Guaranty Corporation. 

(ssss) “Pension Plan” is defined in Section 4.11(a). 

(tttt) “Perfection Certificate” means each Perfection Certificate provided by Borrower and each Domestic Subsidiary to
Administrative Agent on or prior to the Amendment Date in form and substance satisfactory to Administrative Agent. 
 (uuuu)
“Permitted Acquisition” is defined in Section 6.1(b)(vi). 
 (vvvv) “Permitted Capital
Stock Investment” means any acquisition of the Capital Stock of any Person that does not become a direct or indirect Subsidiary of Borrower as a result of such acquisition. 

(wwww) “Permitted Indebtedness” means: (i) Indebtedness to Lenders in connection with the Revolving Credit, Term Loan or
otherwise pursuant to the Loan Documents; (ii) trade payables incurred in the ordinary course of Borrower’s business; (iii) Indebtedness outstanding on the date hereof and listed in Exhibit C; (iv) additional purchase
money Indebtedness (including Capitalized Lease Obligations) hereafter incurred by Borrower to finance the purchase of fixed assets; provided that, (A) the aggregate amount of any such Indebtedness at any time outstanding shall not exceed Two
Million and 00/100 Dollars ($2,000,000.00), (B) such Indebtedness shall not exceed the purchase price of the assets funded, (C) such Indebtedness shall be incurred within ninety (90) days of the acquisition of the assets funded, and
(D) no such Indebtedness may be refinanced for a principal amount in excess of the principal amount outstanding at the time of such refinancing; (v) any Subordinated Indebtedness; (vi) additional Indebtedness the aggregate amount of
which outstanding at any time shall not exceed Two Million and 00/100 Dollars ($2,000,000.00); (vii) Indebtedness of Borrower to any Subsidiary and of any Subsidiary to Borrower or any other Subsidiary; and (viii) Indebtedness which represents
a replacement, refinancing, refunding or renewal of any Indebtedness described in sub-clauses (iii) through (v) above; provided, however, that the amount of any Indebtedness referenced in clause
(viii) shall not be increased at the time of such refinancing, renewal or extension except by fees and expenses reasonably incurred in connection with such refinancing; and, provided, further, that the terms relating to principal amount,
amortization, maturity, collateral (if any) and subordination (if any), and other material terms taken as a whole, of any such refinancing, renewal or extension shall be no less favorable in any material respect to Borrower and its Subsidiaries or
to Lenders than the terms of the Indebtedness being refinanced, renewed or extended. 
 (xxxx) “Permitted Investments”
means: (i) obligations issued or guaranteed by the United States of America or any agency thereof; (ii) commercial paper with maturities of not more than 180 days and a published rating of not less than
A-1 or P-1 (or the equivalent rating) by a nationally recognized investment rating agency; (iii) certificates of time deposit and bankers’ acceptances having
maturities of not more than one hundred eighty (180) days and repurchase agreements backed by United States government securities of a commercial bank if (A) such bank has a combined capital and surplus of at least Five Hundred Million and
00/100 Dollars ($500,000,000.00), or (B) its debt obligations, or those of a holding company of which it is a Subsidiary, are rated not less than A (or the equivalent rating) by a nationally recognized investment rating agency, and
(iv) U.S. money market funds that invest solely in obligations issued or guaranteed by the United States of America or an agency thereof. 

(yyyy) “Permitted Liens” means: (i) Liens securing taxes, assessments, business improvement charges, water
charges, sewer rents or governmental charges or levies not delinquent for a period of thirty (30) days or which are being contested in good faith and by appropriate proceedings for which adequate reserves (if required by GAAP) with respect
thereto have been established; (ii) Liens incurred or deposits made in the ordinary course of business in connection with workers’ compensation, 

  
 -11- 

 
unemployment insurance, social security and other like laws; (iii) Liens on fixed assets security purchase money Indebtedness permitted under Section 6.7;
provided, that such Lien attached to such assets concurrently, or within ninety (90) days of the acquisition of such assets, and only to the assets so acquired; (iv) Liens existing on the Amendment Date and shown on Exhibit
D; (v) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than thirty (30) days or which
are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP; (vi) deposits to secure the
performance of bids and contracts, statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business; (vii) Liens to
secure obligations to landlords, lessors or renters under leases or rental agreements; (viii) with respect to any real property, (A) applicable zoning Requirements of Law, building codes and other land use Requirements of Law,
(B) Liens and other matters of record in existence on the date hereof listed on Exhibit D, (C) non-monetary Liens and other matters that would be shown by an accurate title insurance policy or
an accurate survey, and (D) rights of any landlords and sublandlords; (ix) Liens not otherwise permitted so long as the aggregate outstanding principal amount of the Obligations secured thereby does not exceed (as to Borrower and all
Subsidiaries in the aggregate) Five Hundred Thousand and 00/100 Dollars ($500,000.00) at any one time; (x) easements, rights-of-way, restrictions and other similar
encumbrances incurred in the ordinary course of business that, in the aggregate, are not substantial in amount and that do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary
conduct of the business of the Borrower or any of its Subsidiaries; (xi) any Lien arising out of the refinancing, replacement, renewal or refunding of any secured Permitted Indebtedness; and (xii) Liens in favor of Administrative Agent or
Lenders securing the Obligations. 
 (zzzz) “Person” means an individual, partnership, corporation, trust, limited
liability company, limited liability partnership, unincorporated association or organization, joint venture or any other entity. 
 (aaaaa)
“Preferred Stock” means that certain preferred stock of Borrower designated as Series A Preferred Stock, $0.001 par value per share, having the rights, preferences, privileges and designations set forth in the Preferred Stock
Certificate of Designation, issued to WSHP Biologics Holdings pursuant to the Preferred Stock Investment Agreement. 
 (bbbbb)
“Preferred Stock Certificate of Designation” means that certain Series A Preferred Stock Certificate of Designation of Borrower as in effect on July 13, 2016. 

(ccccc) “Preferred Stock Investment Agreement” means that certain Investment Agreement, dated June 12, 2013, by and
between Borrower and WSHP Biologics Holdings. 
 (ddddd) “Property” means any interest of Borrower or any Subsidiary in any
kind of property or asset, whether real, personal or mixed, or tangible or intangible. 
 (eeeee) “Quarter” means each of
the following calendar quarters: (i) January 1 through March 31; (ii) April 1 through June 30; (iii) July 1 through September 30; and (iv) October 1 through December 31. 

(fffff) “Quarter End” means the day on which each Quarter ends (i.e., (i) March 31; (ii) June 30; (iii) September 30;
and (iv) December 31); provided, however, to the extent such day is not a Business Day, payments shall be due on the first following day that is a Business Day. Such extension of time will not be included in the calculation of
interest due. 

  
 -12- 

 (ggggg) “Reaffirmation Agreements” means those agreements described in
Section 2.16 hereof. 
 (hhhhh) “Regulated Products” is defined in
Section 4.14(a). 
 (iiiii) “Regulation D” means Regulation D of the Board of Governors of the
Federal Reserve System comprising Part 204 of Title 12, Code of Federal Regulations, as in effect from time to time, and any successor thereto. 

(jjjjj) “Required Lenders” shall mean, at any time: (i) if there are two (2) or fewer unaffiliated Lenders, all of
the Lenders; and (ii) if there are three (3) or more unaffiliated Lenders, then Lenders having Loans representing more than sixty-seven percent (67%) of the sum of all Loans outstanding at such time. 

(kkkkk) “Requirement of Law” means, collectively, all international, foreign, federal, state and local laws, statutes,
treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation
or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law. 

(lllll) “Reset Date” is defined in the definition of LIBOR Interest Period. 

(mmmmm) “Restricted Cash” means restricted cash as defined by GAAP and in any event not subject to any Lien (other than in
favor of Lenders) and not designated for a specific purpose or held in a trust account or reserve account. 
 (nnnnn) “Revolving
Credit” is defined in Section 2.1(a). 
 (ooooo) “Revolving Credit Closing Fee” is
defined in Section 2.6(a). 
 (ppppp) “Revolving Credit Maturity Date” means September 15,
2019, or such later date as Lender may, in its sole and absolute discretion, designate in writing to Borrower. 
 (qqqqq) “Revolving
Credit Note(s)” is defined in Section 2.1(b). 
 (rrrrr) “RTI Donor Services” means RTI
Donor Services, Inc., a Delaware non-profit corporation. 
 (sssss) “Scheduled Intellectual
Property” is defined in Section 4.13(b). 
 (ttttt) “Securities Pledge Agreement” means
that certain securities pledge agreement dated July 16, 2013 by Borrower (and each applicable Subsidiary of Borrower) in favor of Administrative Agent and Lenders. 

(uuuuu) “Security Agreement” means that certain security agreement dated July 16, 2013 executed by Borrower in favor of
Administrative Agent and Lenders. 
 (vvvvv) “Security Documents” means, collectively, the Guaranty Agreement, the Security
Agreement, the Patent Security Agreement, the Trademark Security Agreement, the Domestic Subsidiary Security Agreement, the Domestic Subsidiary Patent Security Agreement, the Domestic 

  
 -13- 

 
Subsidiary Trademark Security Agreement, the Non-Encumbrance Agreements, the U.S. Patent Non-Encumbrance Agreement,
the Securities Pledge Agreement, the Cash Collateral Pledge Agreement, the Reaffirmation Agreements, the Perfection Certificates, and all agreements, instruments and documents executed and/or delivered in connection therewith, all as may be
supplemented, restated, superseded, amended or replaced from time to time. 
 (wwwww) “Social Security Act” is defined in
Section 4.14(f). 
 (xxxxx) “Spread Adjustment Date” means the first Business Day of the Quarter
after Borrower’s quarterly financial statements first reflect that Borrower’s one-time Extraordinary Expenses comprise less than twenty-five percent (25%) of Borrower’s Consolidated EBITDA for
any rolling four fiscal-quarter period occurring during the period this Agreement is in effect. 
 (yyyyy) “Standard Inbound IP
Agreements” means (i) non-disclosure agreements granting to Borrower a limited right to use a third party’s confidential information entered into by Borrower in the ordinary course of its
business, consistent with past practice, (ii) “shrink wrap” and similar generally available commercial end-user licenses to software that is not redistributed with the products, (iii) employment
agreements and consulting agreements pursuant to which Borrower obtains rights to use Intellectual Property created in the scope of such employment or provision of services for Borrower, (iv) agreements granting Borrower a right to use the
third party Trademarks in connection with Company’s marketing or advertising of Borrower, or Borrower’s products or such third party’s products; and (v) other agreements pursuant to which Borrower has been granted a license to
use Intellectual Property in the ordinary course of business consistent with past practices. 
 (zzzzz) “Standard Outbound IP
Agreements” means (i) non-disclosure agreements granting to a third party a limited right to use Borrower’s confidential information entered into by Borrower in the ordinary course of its
business, consistent with past practice, (ii) non-exclusive licenses to Borrower’s products (which, to the extent such products are software, are licenses to object code) granted by Borrower or other
agreements pursuant to which Borrower has granted a license to Intellectual Property in the ordinary course of its business consistent with past practice, and (iii) agreements granting a third party a right to use Borrower’s Trademarks in
connection with such third party’s marketing or advertising of Borrower or Borrower’s products. 
 (aaaaaa) “Subordinated
Debt” means Indebtedness of Borrower subject to payment terms and subordination provisions set forth in a Subordination Agreement. 

(bbbbbb) “Subordination Agreement” means an agreement between Borrower, the Administrative Agent and the holders of any
Indebtedness, containing the terms of subordination and related provisions and otherwise reasonably acceptable to the Required Lenders. 

(cccccc) “Subsidiary” with respect to any Person at any time, means: (i) any corporation more than fifty percent
(50%) of whose voting stock is legally and beneficially owned by such Person or owned by a corporation more than fifty percent (50%) of whose voting stock is legally and beneficially owned by such Person; (ii) any trust of which a majority of
the beneficial interest is at such time owned directly or indirectly, beneficially or of record, by such Person or one or more Subsidiaries of such Person; (iii) any corporation, partnership, joint venture, limited liability company or other
entity of which ownership interests having ordinary voting power to elect a majority of the board of directors or other Persons performing similar functions are at such time owned directly or indirectly, beneficially or of record, by, or which is
otherwise controlled directly, indirectly or through one or more intermediaries by, such Person or one or more Subsidiaries of such Person. 

  
 -14- 

 (dddddd) “Term Loan” is defined in Section 2.2(a).

 (eeeeee) “Term Loan Maturity Date” means September 15, 2019. 

(ffffff) “Term Loan Note(s)” is defined in Section 2.2(b). 

(gggggg) “Term Loan Closing Fee” is defined in Section 2.6(b). 

(hhhhhh) “Third Party Intellectual Property Rights” is defined in Section 4.13(b). 

(iiiiii) “Total Funded Indebtedness” means, as of any date of determination with respect to Borrower and its Subsidiaries on
a consolidated basis, without duplication, the sum of: (a) all obligations for borrowed money (including the Obligations but excluding Subordinated Debt) and all obligations evidenced by bonds, debentures, notes, loan agreements or other
similar instruments; (b) the maximum amount available to be drawn under Letters of Credit (including standby and commercial), bankers’ acceptances, bank guaranties, surety bonds (excluding any bid or performance bonds so long as such
obligations are contingent) and similar instruments; (c) all non-contingent obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary
course of business); (d) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned by Borrower or any Subsidiary (including indebtedness arising under conditional sales or other title retention agreements), whether or not
such indebtedness shall have been assumed by Borrower or such Subsidiary or is limited in recourse; (e) all obligations to purchase, redeem, retire, defease or otherwise make any payment prior to the Revolving Credit Maturity Date or the Term
Loan Maturity Date in respect of any of Borrower’s equity interests or any warrant, right or option to acquire such equity interest, valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary
liquidation preference plus accrued and unpaid dividends; (f) any earn out obligations to the extent that the same are no longer contingent in nature; (g) all guarantees with respect to Indebtedness of the types specified in clauses
(a) through (f) above of another Person; and (h) all Indebtedness of the types referred to in clauses (a) through (g) above of any partnership or joint venture (other than a joint venture that is itself a corporation, limited
liability company or limited liability partnership) in which Borrower or any Subsidiary is a general partner or joint venturer, but only to the extent that there is direct recourse to Borrower or such Subsidiary for the payment of such Indebtedness.
For the purposes of determining Total Funded Indebtedness for covenant calculation only (i) the outstanding Indebtedness associated solely with the Revolving Credit Note (but no other Indebtedness) shall be reduced by the amount of Unrestricted
Cash maintained by Borrower, on a consolidated basis, in excess of Ten Million and 00/100 Dollars ($10,000,000.00) (the “Covenant Net Debt Adjustment”), provided in no event shall the Covenant Net Debt Adjustment be an amount greater than
the outstanding balance under the Revolving Credit Note and (ii) for the Quarter ending June 30, 2017 only, Total Funded Indebtedness for the purpose of the Leverage Ratio calculation required under
Section 5.12(b) shall (A) be calculated using the outstanding principal balance of the Term Loan after the Borrower’s $22,000,000 reduction in principal contemplated herein and (B) the Covenant Net Debt
Adjustment for the Quarter ending June 30, 2017 shall include Unrestricted Cash of Borrower arising from the sale of the CTS Business (but such Unrestricted Cash shall not, for these purposes, include (1) RTI’s closing costs relating
to the CTS Business sale, (2) the $22,000,000 principal reduction contemplated herein, or (3) the $12,000,000 deposited by Borrower into the CTS Tax Escrow Account). 

(jjjjjj) “Trademark Security Agreement” means that certain security agreement dated July 16, 2013 executed by Borrower
granting a security interest in the Trademarks of Borrower in favor of Administrative Agent and Lenders. 

  
 -15- 

 (kkkkkk) “UCC” means the Uniform Commercial Code as adopted in the State of
Florida, as in effect from time to time. 
 (llllll) “Unfunded Capital Expenditures” means Capital Expenditures that are
not financed through interest bearing Indebtedness. 
 (mmmmmm) “Unrestricted Cash” means all cash less any Restricted
Cash. 
 (nnnnnn) “U.S. Patent Non-Encumbrance Agreement” means that certain
agreement not to encumber any United States patent dated July 16, 2013 by each Subsidiary of Borrower that is not a Domestic Subsidiary but holds a United State patent, in favor of Administrative Agent and Lenders. 

(oooooo) “Waterstreet Agreements” means (i) the Preferred Stock Investment Agreement, (ii) the Preferred Stock
Certificate of Designation, (iii) the Director Indemnification Agreement and (iv) the Investor Rights Agreement. 
 (pppppp)
“WSHP Biologics Holdings” means WSHP Biologics Holdings, LLC, a Delaware limited liability company. 

1.2    Other Capitalized Terms. Any other capitalized terms used without further definition herein shall have the
respective meaning set forth in the UCC. 
 1.3    Accounting Principles. Where the character or amount of any
asset or liability or item of income or expense is required to be determined or any consolidation or other accounting computation is required to be made for the purposes of this Agreement, this shall be done in accordance with GAAP as in effect on
the Amendment Date, to the extent applicable, except as otherwise expressly provided in this Agreement. If there are any changes in GAAP after the Amendment Date that would affect the computation of the financial covenants in
Section 5.12, such changes shall only be followed, with respect to such financial covenants, from and after the date this Agreement shall have been amended to take into account any such changes. 

1.4    Construction. No doctrine of construction of ambiguities in agreements or instruments against the interests
of the party controlling the drafting shall apply to any Loan Documents. 
 SECTION 2 

THE LOANS 

2.1    Revolving Credit - Description. 

(a) Subject to the terms and conditions of this Agreement, each Lender hereby severally establishes for the benefit of Borrower a revolving
credit facility (collectively, the “Revolving Credit”) which shall include cash Advances extended by each Lender to or for the benefit of Borrower from time to time hereunder. The aggregate principal amount of unpaid cash Advances
by each Lender shall not at any time exceed each Lender’s Applicable Percentage of the Maximum Revolving Credit Amount as set forth on Exhibit A. Subject to such limitation, the outstanding balance of Advances under the Revolving Credit may
fluctuate from time to time, to be reduced by repayments made by Borrower, to be increased by future Advances which may be made by Lenders, to or for the benefit of Borrower, and, subject to the provisions of Section 7,
shall be due and payable on the Revolving Credit Maturity Date. 
 (b) On or about July 16, 2013, Borrower executed and delivered one
or more promissory notes to Lenders (which promissory notes were thereafter amended and restated in 2015 and 2016) for the 

  
 -16- 

 
Maximum Revolving Credit Amount. Such promissory notes (the “Revolving Credit Note(s)”) have been renewed as of the date hereof. The Revolving Credit Notes shall evidence
Borrower’s unconditional obligation to repay Lenders for all Advances made under the Revolving Credit, with interest as herein provided. Each Advance under the Revolving Credit shall be deemed evidenced by the Revolving Credit Notes, which is
deemed incorporated herein by reference and made part hereof. The Revolving Credit Notes shall be in form and substance satisfactory to Administrative Agent and Lenders. 

(c) Accrued interest on the Revolving Credit will be payable quarterly in arrears on each Quarter End. 

(d) Subject to the terms of this Section 3.1, Lenders agree to issue letters of credit on behalf of Borrower or its
Subsidiaries from time-to-time (the “Letters of Credit”); provided, however, that the maximum aggregate stated amount of all Letters of
Credit outstanding at any time shall not exceed Five Hundred Thousand and 00/100 Dollars ($500,000.00). For purposes of determining availability of Advances, the Revolving Credit Limit shall be reduced by the face amount of all outstanding Letters
of Credit. Borrower shall pay to Lenders a reasonable letter of credit fee. All Letters of Credit shall be in form and substance reasonably satisfactory to Administrative Agent and Lenders. 

(e) The term of the Revolving Credit shall expire on the Revolving Credit Maturity Date. On such date, unless having been sooner accelerated
by Lenders pursuant to the terms hereof, and without impairing any rights under this Agreement or any other Loan Document, all outstanding Advances, all accrued but unpaid interest, and all other sums owing under the Revolving Credit shall be due
and payable in full, and as of and after such date Borrower shall not request and Lenders shall not make any further Advances under the Revolving Credit. 

2.2    Term Loan - Description. 

(a) On or about July 16, 2013, Lenders advanced to Borrower the sum of Sixty Million And 00/100 Dollars ($60,000,000.00), the outstanding
principal balance of which as of the Amendment Date is Twenty-Five Million Three Hundred Seventy-Five Thousand and 00/100 Dollars ($25,375,000.00) (the “Term Loan”). 

(b) On or about July 16, 2013, Borrower executed and delivered one or more promissory notes to Lenders in the original principal amount
of the Term Loan. Such promissory notes (the “Term Loan Note(s)”) have been renewed as of the date hereof. The Term Loan Notes evidence Borrower’s unconditional obligation to repay to Lender the Term Loan with interest as
provided in this Agreement. 
 (c) Principal and accrued interest under the Term Loan shall be payable as follows: 

(i)    Interest will be payable quarterly in arrears, together with quarterly payments of the principal
balance of the Term Loan, commencing October 1, 2017, each in the amount of $1,125,000. 
 (ii)    A
final payment of any and all unpaid principal and any and all accrued unpaid interest outstanding under the Term Loan shall be due and payable on the Term Loan Maturity Date. 

(d) Fifty percent (50%) of any funds remaining in the CTS Tax Escrow Account after Borrower’s payment in full of all federal and state
income taxes arising from Borrower’s sale of its CTS Business shall be paid to Administrative Agent and applied to the then unpaid installments of the principal balance of the Term Loan in inverse order of their maturity. The other fifty
percent (50%) of funds remaining in the CTS Tax Escrow Account at such time shall be released to Borrower. 

  
 -17- 

 2.3    Advances and Payments. 

(a) Except to the extent otherwise set forth in this Agreement (or in the case of an Interest Hedging Instrument under the applicable
agreements), all payments of principal and of interest on the Revolving Credit, Term Loan and all Expenses, fees, indemnification obligations and all other charges and any other Obligations of Borrower, shall be made to Administrative Agent for the
benefit of the Lenders at its banking office at 9715 N. Gate Parkway, Jacksonville, Florida 32246, or such other office as Administrative Agent may designate in writing, in United States dollars, in immediately available funds. Borrower hereby
authorizes Administrative Agent, following notice to Borrower (provided no notice is required for regularly scheduled payments), to charge checking account number 7600277916 maintained at Administrative Agent and further agrees that Administrative
Agent shall have the unconditional right and discretion (and Borrower hereby authorizes Lender) to charge such account, following notice to Borrower (provided no notice is required for regularly scheduled payments), in any event for all of
Borrower’s Obligations as they become due from time to time under this Agreement including, without limitation, interest, principal, fees, indemnification obligations and reimbursement of Expenses. Alternatively, Administrative Agent may in its
discretion, after notice Borrower, (and Borrower hereby authorizes Administrative Agent to) make a cash Advance under the Revolving Credit in a sum sufficient to pay all interest accrued and payable on the Obligations and to pay all costs, fees and
Expenses owing hereunder. Borrower acknowledges that Borrower’s failure to maintain sufficient funds in any checking, operating or deposit account for payment of any of the Obligations, or Administrative Agent’s failure to charge any such
account shall not relieve Borrower of any payment obligation under this Agreement or any other Loan Document. Any payments received prior to 2:00 p.m. Eastern time on any Business Day shall be deemed received on such Business Day. Any payments
(including any payment in full of the Obligations), received after 2:00 p.m. Eastern time on any Business Day shall be deemed received on the immediately following Business Day. 

(b) Cash Advances which may be made by Lenders from time to time under the Revolving Credit shall be made available by crediting such proceeds
to Borrower’s operating account with Administrative Agent. 
 (i)    All cash Advances requested by
Borrower under the Revolving Credit must be in the minimum amount of One Hundred and 00/100 Dollars ($100.00) and integral multiples of One Hundred and 00/100 Dollars ($100.00) in excess thereof. 

(ii)    All cash Advances requested by Borrower under the Revolving Credit are to be in writing pursuant to
a written request (an “Advance Request”). Requests for Advances under the Revolving Credit must be requested three (3) Business Days in advance and must specify the requested date of such Advance (the “Advance
Date”) and the amount of such Advance. Upon Lender’s written request, with each Advance Request, Borrower shall submit a Borrowing Certificate. 

(iii)    Upon receiving a request for an Advance in accordance with subparagraph (ii) above, and
subject to the conditions set forth in this Agreement, each Lender shall make its pro rata share of the requested Advance available to Borrower as soon as is reasonably practicable on the Advance Date. 

(c) The commitment of Lenders to make Advances hereunder shall be several and not joint. 

  
 -18- 

 2.4    Interest. 

(a) The unpaid principal balance of cash Advances under the Revolving Credit shall bear interest, subject to the terms hereof, at a per annum
rate equal to: (i) the Adjusted LIBOR Rate plus (ii) the LIBOR Spread. 
 (b) The unpaid principal balance of the Term Loan
shall bear interest, subject to the terms hereof, at a per annum rate equal to: (i) the Adjusted LIBOR Rate plus (ii) the LIBOR Spread. 

(a) The “LIBOR Spread” shall be (i) three hundred fifty (350) basis points per annum for the period commencing on
the Amendment Date and continuing through, but not including, the Spread Adjustment Date, and (ii) for the period commencing on the Spread Adjustment Date, the LIBOR Spread shall be three hundred (300) basis points. 

2.5    Additional Interest Provisions. 

(a) Interest on the Loans shall be calculated on the basis of a year of three hundred sixty (360) days but charged for the actual number
of days elapsed. 
 (b) After the occurrence and during the continuance of an Event of Default hereunder, at the election of the
Administrative Agent, the per annum effective rate of interest on all outstanding principal under the Loans, shall accrue at the rate otherwise applicable to the Loans plus three hundred (300) basis points. All such increases may, at the
election of the Administrative Agent, be applied retroactively to the date of the occurrence of the Event of Default. Borrower agrees that the default rate payable to Lenders is a reasonable estimate of damages suffered by Lenders and is not a
penalty. 
 (c) All contractual rates of interest chargeable on outstanding principal under the Loans shall continue to accrue and be paid
even after Default, an Event of Default, maturity, acceleration, judgment, bankruptcy, insolvency proceedings of any kind or the happening of any event or occurrence similar or dissimilar. 

(d) In no contingency or event whatsoever shall the aggregate of all amounts deemed interest hereunder and charged or collected pursuant to
the terms of this Agreement exceed the highest rate permissible under any law which a court of competent jurisdiction shall, in a final determination, deem applicable hereto. In the event that such court determines Lender has charged or received
interest hereunder in excess of the highest applicable rate, Lender shall apply, in its sole discretion, and set off such excess interest received by Lender against other Obligations due or to become due and such rate shall automatically be reduced
to the maximum rate permitted by such law. 
 2.6    Fees and Charges. 

(a) At Closing, Lenders shall have fully earned and Borrower shall unconditionally pay to Lender, a
non-refundable fee with respect to the Revolving Credit (the “Revolving Credit Closing Fee”) of One Hundred Six Thousand Two Hundred Fifty and 00/100 Dollars ($106,250.00). 

(b) At Closing, Lenders shall have fully earned and Borrower shall unconditionally pay to Lender a
non-refundable fee with respect to the Term Loan (the “Term Loan Closing Fee”) of Sixty-Three Thousand Four Hundred Thirty-Eight and 00/100 Dollars ($63,438.00). 

  
 -19- 

 2.7    Prepayments. 

(a) Borrower may prepay the Revolving Credit and Term Loan in whole or in part at any time or from time to time, without penalty or premium
except as provided in Section 2.11. Any prepayment shall be accompanied by all accrued and unpaid interest. Any partial prepayment of the Term Loan shall be applied to the Term Loan in the inverse order of maturity. 

 (b) Borrower shall be required to prepay the Term Loan, in whole or in part, immediately upon the receipt of any proceeds from:
(i) the issuance of non-purchase money debt (other than Permitted Indebtedness); (ii) any transaction or series of transactions involving the sale of any asset or assets outside the ordinary course of
business in any calendar year in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00); (iii) any issuance of Capital Stock of Borrower or any of its Subsidiaries except (A) any issuance of Capital Stock in connection with a
Permitted Acquisition that is permitted under Section 6.1(b) or otherwise approved by the Required Lenders, (B) any Capital Stock issued in connection with the conversion of Preferred Stock, and (C) any issues of
Capital Stock to employees of Borrower or its Subsidiaries under a stock plan approved by the board of directors of Borrower. 

2.8    Use of Proceeds. 

(a) The extensions of credit under and proceeds of the Term Loan were by Borrower to fund the acquisition of Pioneer Surgical Technologies,
Inc. 
 (b) The extensions of credit under and proceeds of the Revolving Credit shall be used only for: (i) working capital and general
corporate purposes and (ii) disposition costs associated with the sale of Borrower’s CTS Business. 

2.9    Unused Revolving Credit Fee. Borrower shall pay to Lenders a quarterly fee in arrears based upon the unused
portion of the Revolving Credit. 
 (a) For purposes of this Agreement, “Unused Revolving Credit” means an amount equal to:
(i) the Maximum Revolving Credit Amount (i.e., Forty-Two Million Five Hundred Thousand and 00/100 Dollars ($42,500,000.00); minus (ii) the average daily outstanding principal balance of the
Revolving Credit for the immediately preceding Quarter. 
 (b) The “Unused Revolving Credit Fee” shall be an amount equal
to the Unused Revolving Credit for such immediately preceding Quarter multiplied by the Applicable Basis Points. For purposes of this Agreement, the “Applicable Basis Points” are determined based on Borrower’s financial
performance under the Leverage Ratio as follows: 
  

			
	 Leverage Ratio
	  	
Applicable Basis Points
per annum

	Less than 1x	  	15 basis points
		
	Equal to or greater than 1x but less than 1.5x	  	20 basis points
		
	Equal to or greater than 1.5x but less than 2x	  	25 basis points
		
	Equal to or greater than 2x	  	30 basis points

  
 -20- 

 (c) Changes in the Applicable Basis Points resulting from changes in the Leverage Ratio shall
become effective on the first Business Day after the Borrower’s quarterly financial statements reflect a change in the Leverage Ratio and shall remain in effect until the next change to be effected pursuant to this
Section 2.9(c). 
 2.10    Capital Adequacy. If the adoption of or any change in any
Requirement of Law imposes, modifies, or deems applicable any capital adequacy, capital maintenance or similar requirement which affects the manner in which any Lender allocates capital resources to its commitments (including any commitments
hereunder), and as a result thereof, in the reasonable opinion of such Lender, the rate of return on such Lender’s capital with regard to the Loans is reduced to a level below that which such Lender could have achieved but for such
circumstances, by an amount determined by such Lender to be material, then in such case and upon notice from such Lender to Borrower, from time to time, Borrower shall pay such Lender such additional amount or amounts as shall compensate such Lender
for such reduction in such Lender’s rate of return. Such notice shall contain the statement of such Lender with regard to any such amount or amounts which shall, in the absence of manifest error, be binding upon Borrower. In determining such
amount, such Lender may use any reasonable method of averaging and attribution that it deems applicable. Any rules, regulations, policies, guidelines, directives or similar requirements adopted, promulgated or implemented in connection with
(a) the Dodd-Frank Wall Street Reform and Consumer Protection Act and (b) the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or any United States Governmental
Authority, in each case pursuant to Basel III, shall in all events be deemed to have been imposed, introduced and adopted after the date of this Agreement. A certificate as to any additional amounts payable pursuant to this
Section 2.10 submitted by any Lender to Borrower (with a copy to the Administrative Agent) shall be conclusive in the absence of manifest error. 

2.11    Funding Indemnity. Borrower shall indemnify Administrative Agent and each Lender, and hold Administrative
Agent and each Lender harmless from any loss, damages, liability, or expense which Administrative Agent or such Lender may sustain or incur as a consequence of the making of a prepayment of Loans on a day which is not the last day of a LIBOR
Interest Period with respect thereto. With respect to such Loans, such indemnification shall equal the excess, if any, of (a) the amount of interest which would have accrued on the amount so prepaid for the period from the date of such
prepayment at the applicable rate of interest for such Loans provided for herein over (b) the amount of interest (as reasonably determined by Administrative Agent) which would have accrued to Lenders on such amount by placing such amount on
deposit for a comparable period with leading banks in the London interbank Eurodollar market. This covenant shall survive the termination of this Agreement, and the payment of the Obligations. Borrower shall be liable for any breakage costs
associated with any Interest Hedging Instrument or any Hedging Agreement as a result of any prepayment. 

2.12    Inability to Determine Interest Rate. Notwithstanding any other provision of this Agreement, if
Administrative Agent shall reasonably determine (which determination shall be conclusive and binding absent manifest error) that (a) by reason of circumstances affecting the relevant market, reasonable and adequate means do not exist for
ascertaining the Adjusted LIBOR Rate for a LIBOR Interest Period, or (b) the Adjusted LIBOR Rate does not adequately and fairly reflect the cost to Lenders of funding Advances under the Revolving Credit that Borrower has requested during a
LIBOR Interest Period, Lender shall forthwith give telephone notice of such determination, confirmed in writing, to Borrower at least two (2) Business Days prior to the first day of such LIBOR Interest Period, whereupon the outstanding
principal amount shall bear interest at an equivalent rate then designated by the Administrative Agent (with the approval of the Required Lenders), for general commercial loan reference purposes (the “Alternate Rate”). 

  
 -21- 

 2.13    Illegality. Notwithstanding any other provision of this
Agreement, if the adoption of or any change in any Requirement of Law or in the interpretation or application thereof to Administrative Agent or Lenders by the relevant Governmental Authority shall make it unlawful for Lenders to make or maintain
Advances under the Revolving Credit as contemplated by this Agreement, or to obtain in the interbank Eurodollar market, the funds with which to make such Loans, (a) Administrative Agent shall promptly notify Borrower thereof, (b) the
commitment of Lenders hereunder to make Advances or continue Advances as such shall forthwith be suspended until Administrative Agent shall give notice that the condition or situation which gave rise to the suspension no longer exists, and
(c) each Lender’s Loans then outstanding, if any, shall be converted on the last day of the LIBOR Interest Period for such Loans so as to bear interest at the Alternate Rate. Borrower agrees promptly to pay Administrative Agent and
Lenders, upon its demand, any additional amounts necessary to compensate Administrative Agent and Lenders for actual and direct costs (but not including anticipated profits) reasonably incurred by Administrative Agent and Lenders in connection with
any repayment in accordance with this Section 2.13, including but not limited to, any interest or fees payable by Lenders to lenders of funds obtained by it in order to make or maintain its loans hereunder. A certificate as
to any additional amounts payable pursuant to this Section 2.13 submitted by Administrative Agent to Borrower shall be conclusive evidence (absent manifest error) of such amounts owing. Administrative Agent agrees to use
reasonable efforts to avoid or to minimize any amounts which may otherwise be payable pursuant to this Section 2.13; provided, however, that such efforts shall not cause the imposition on Administrative Agent
or any Lender of any additional costs or legal or regulatory burdens deemed by Administrative Agent or such Lender in its reasonable discretion to be material. 

2.14    Requirements of Law. 

(a) If the adoption of or any change in any Requirement of Law or in the interpretation or application thereof or compliance by Administrative
Agent or any Lender with any request or directive (whether or not having the force of law) from any central bank or other Governmental Authority made subsequent to the date hereof: 

(i)    shall impose, modify, or hold applicable, any reserve, special deposit, compulsory loan, or similar
requirement against assets held by, deposits or other liabilities in, or for the account of, advances, loans, or other extension of credit (including participations therein) by, or any other acquisition of funds by, any office of such Lender which
is not otherwise included in the determination of the LIBOR Rate hereunder; or 
 (ii)    shall impose on
such Lender any other condition; 
 and the result of any of the foregoing is to materially increase the cost to such Lender of making or maintaining
Advances under the Revolving Credit, or to reduce any amount receivable hereunder, or under any Note, then, in any such case, Borrower shall promptly pay such Lender, upon its demand, any additional amounts necessary to compensate such Lender for
such additional costs or reduced amount receivable which such Lender reasonably deems to be material as determined by such Lender, with respect to its Advances. A certificate as to any additional amounts payable pursuant to this
Section 2.14 submitted by such Lender to Borrower shall be presumptive evidence of such amounts owing in the absence of manifest error. Each Lender agrees to use reasonable efforts to avoid, or to minimize, any amounts
which might otherwise be payable pursuant to this Section 2.14; provided, however, that such efforts shall not cause the imposition on such Lender of any additional costs or legal regulatory burdens deemed by
such Lender in good faith to be material. 

  
 -22- 

 (b) A certificate as to any additional amounts payable pursuant to this
Section 2.14 submitted by any Lender to Borrower (with a copy to the Administrative Agent) shall be conclusive in the absence of manifest error. In determining such amount, such Lender shall use a reasonable averaging and
attribution method. Notwithstanding anything to the contrary in this Section 2.14, Borrower shall not be required to compensate a Lender pursuant to this Section 2.14 for any amounts incurred more
than six (6) months prior to the date that such Lender notifies the Borrower of such Lender’s intention to claim compensation therefor; provided that, if the circumstances giving rise to such claim have a retroactive effect, then
such six (6)-month period shall be extended to include the period of such retroactive effect. 
 (c) The agreements in this
Section 2.14 shall survive the termination of this Agreement and payment of the Obligations. 

2.15    Security for Obligations. To secure the payment and performance of the Obligations, Borrower has executed,
and has caused to be executed, the Security Documents, as follows: 
 (a) Pursuant to the Security Agreement, Borrower granted to
Administrative Agent, for the benefit of Lenders, a first priority security interest in and to all of the Property (including, without limitation, Intellectual Property pursuant to the Patent Security Agreement and the Trademark Security Agreement)
of Borrower (excluding any interest in owned or leased real property of Borrower). The Patent Security Agreement and the Trademark Security Agreement have each been amended this date pursuant to that certain First Amendment to Patent Security
Agreement and that certain First Amendment to Trademark Security Agreement, respectively. 
 (b) Pursuant to the Domestic Subsidiary
Security Agreement, each Domestic Subsidiary (other than RTI Donor Services) granted to Administrative Agent, for the benefit of Lenders, a first priority security interest in and to all of the Property (including, without limitation, Intellectual
Property pursuant to the Domestic Subsidiary Patent Security Agreement and the Domestic Subsidiary Trademark Security Agreement, as each has been amended to the date hereof) of such Domestic Subsidiary (excluding any interest in owned or leased real
property of such Domestic Subsidiary). The Domestic Subsidiary Patent Security Agreement and the Domestic Subsidiary Trademark Security Agreement have each been amended this date pursuant to that certain First Amendment to Domestic Subsidiary Patent
Security Agreement and that certain First Amendment to Domestic Subsidiary Trademark Security Agreement, respectively. 
 (c) Pursuant to
the U.S. Patent Non-Encumbrance Agreement, each Subsidiary that (i) is not a Domestic Subsidiary and (ii) owns any United States patent agreed not to allow any Lien to be created on such United
States Patent. 
 (d) Pursuant to the Non-Encumbrance Agreement: (i) Borrower agreed not to
allow any Lien to be created (other than a Permitted Lien) on any interest of Borrower in owned or leased real property of Borrower; and (ii) each Domestic Subsidiary (other than RTI Donor Services) agreed not to allow any Lien to be created
(other than a Permitted Lien) on any interest of such Domestic Subsidiary in owned or leased real property of such Domestic Subsidiary. 

(e) Pursuant to the Securities Pledge Agreement, Borrower and each Subsidiary of Borrower owning any Capital Stock in a Subsidiary that is not
a Domestic Subsidiary pledged to Administrative Agent, for the benefit of Lenders, a first priority security interest in and to sixty-five percent (65%) of the Capital Stock of any Subsidiary of Borrower that is not a Domestic Subsidiary. 

  
 -23- 

 2.16    Representations, Warranties and Agreements – Security
Documents. Borrower hereby represents, warrants and agrees as follows, with respect to the Security Documents: 
 (a) The Security
Agreement, the Patent Security Agreement (as amended this date), the Trademark Security Agreement (as amended this date), the Securities Pledge Agreement and the Non-Encumbrance Agreement, each signed by
Borrower: (i) are each in full force and effect; (ii) that the terms and provisions thereof shall extend to and secure all obligations of Borrower as identified and described in this Agreement and the Loan Documents described herein; and
(iii) that, as of the date hereof, there are no claims, defenses, counterclaims or offsets in favor of Borrower against Lenders, Administrative Agent, or any of them . 

(b) Borrower shall cause each of the Domestic Subsidiaries of Borrower to execute and deliver to Administrative Agent, on behalf of Lenders,
an agreement ratifying and acknowledging the Domestic Subsidiary Security Agreement, the Domestic Subsidiary Patent Security Agreement (as amended to the date hereof) and the Domestic Subsidiary Trademark Security Agreement (as amended to the date
hereof): (i) are in full force and effect, (ii) that the terms and provisions thereof shall extend to and secure all obligations of Borrower as identified and described in this Agreement; and (iii) that as of the date hereof, there are no
claims, defenses, counterclaims or offsets in favor of the such parties against Lenders, Administrative Agent, or any of them. 
 (c)
Borrower shall cause Tutogen Medical, Inc., a Florida corporation, and Pioneer Surgical Technology, Inc., a Michigan corporation, to execute and deliver to Administrative Agent, on behalf of Lenders, an agreement ratifying and acknowledging the
Securities Pledge Agreement executed by them and by Borrower: (i) is in full force and effect, (ii) that the terms and provisions thereof shall extend to and secure all obligations of Borrower as identified and described in this Agreement;
and (iii) that, as of the date hereof, there are no claims, defenses, counterclaims or offsets in favor of the such parties against Lenders, Administrative Agent, or any of them. 

(d) Borrower shall cause Tutogen Medical, GmbH, to execute and deliver to Administrative Agent, on behalf of Lenders, an agreement ratifying
and acknowledging the U.S. Patent Non-Encumbrance Agreement executed by such party: (i) is in full force and effect, (ii) that the terms and provisions thereof shall extend to and secure all
obligations of Borrower as identified and described in this Agreement; and (iii) that, as of the date hereof, there are no claims, defenses, counterclaims or offsets in favor of the such parties against Lenders, Administrative Agent, or any of
them. 
 2.17    Replacement of Lenders. Borrower shall be permitted to replace any Lender that (a) requests
reimbursement for amounts owing pursuant to Section 2.10 or 2.14, (b) is a Defaulting Lender, or (c) does not consent to any proposed amendment, supplement, modification, consent or waiver of any provision of
this Agreement or any other Loan Document that requires the consent of each Lender or each Lender affected thereby (provided that at least Required Lenders’ consent to such proposed amendment, supplement, modification, consent or waiver has
been obtained), with a replacement financial institution; provided that (i) such replacement does not conflict with any Requirement of Law, (ii) no Event of Default shall have occurred and be continuing at the time of such replacement,
(iii) the replacement financial institution shall purchase, at par, all Loans and other amounts owing to such replaced Lender on or prior to the date of replacement, (iv) Borrower shall be liable to such replaced Lender under
Section 9.4 if any Loan owing to such replaced Lender shall be purchased other than on the last day of the Interest Period relating thereto, (v) the replacement financial institution shall be satisfactory to the
Required Lenders in their absolute discretion, (vi) the replaced Lender shall be obligated to make such replacement in accordance with the provisions of Section 9.11, (vii) until such time as such replacement shall be
consummated, the Borrower shall pay all additional amounts (if any) required pursuant to Section 2.10 or 2.14, as the case may be, and (viii) any such replacement shall not be deemed to be a waiver of any rights
that Borrower, the Administrative Agent or any other Lender shall have against the replaced Lender. 

  
 -24- 

 2.18    Defaulting Lenders. Notwithstanding any provision of this
Agreement to the contrary, if any Lender becomes a Defaulting Lender, without limiting any other rights Borrower may have against such Defaulting Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender:

 (a) fees shall cease to accrue on the Unused Revolving Credit of such Defaulting Lender pursuant to
Section 2.9(b); and 
 (b) the Advances and Revolving Credit commitment of such Defaulting Lender shall not be
included in determining whether the Required Lenders have taken or may take any action hereunder (including any consent to any amendment, waiver or other modification); provided that (i) such Defaulting Lender’s Revolving Credit
commitment may not be increased or extended without its consent, (ii) the principal amount of, or interest or fees payable on, Loans may not be reduced or excused or the scheduled date of payment may not be postponed as to such Defaulting
Lender without such Defaulting Lender’s consent, and (iii) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender which affects such Defaulting Lender differently than other Lenders or affected
Lenders, as the case may be, shall require the consent of such Defaulting Lender. 
 2.19    Sharing of Payments by
Lenders. All fees payable to Lenders hereunder, including, without limitation, the fees referred to in Section 2.6 and Section 2.9, shall be paid to Lenders in proportion to their respective Commitments and
Applicable Percentages as set forth on Exhibit A attached. If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of the Loans made by it resulting
in such Lender’s receiving payment of a proportion of the aggregate amount of such Loans and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater proportion shall
(a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments
shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing them, provided that (i) if any such participations are purchased and all or
any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest and (ii) the provisions of this
Section 2.19 shall not be construed to apply to (x) any payment made by Borrower pursuant to and in accordance with the express terms of this Agreement or (y) any payment obtained by a Lender as consideration for
the assignment of or sale of a participation in any of its Loans to any assignee or participant, other than to Borrowers or any Subsidiary of Borrower (as to which the provisions of this Section 2.19 shall apply). Borrower
consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against Borrower rights of setoff and counterclaim with
respect to such participation as fully as if such Lender were a direct creditor of Borrower in the amount of such participation. 

  
 -25- 

 SECTION 3 

CLOSING AND CONDITIONS PRECEDENT TO ADVANCES 

Closing under this Agreement is subject to the following conditions precedent (all instruments, documents and agreements to be in form and
substance satisfactory to Administrative Agent and Lenders): 
 3.1    Resolutions, Opinions, and Other
Documents. Borrower shall have delivered, or caused to be delivered to Administrative Agent the following: 
 (a) this Agreement and
each of the other Loan Documents, all properly executed; 
 (b) all other documents to be executed and/or delivered by Borrower or any other
Person pursuant to this Agreement; 
 (c) certified copies of (i) resolutions of Borrower’s and each applicable Subsidiary’s
board of directors or managing members (as applicable) authorizing the execution, delivery and performance of this Agreement, and each of the other Loan Documents required to be delivered by any Section hereof and (ii) Borrower’s and each
applicable Subsidiary’s articles or certificate of incorporation and by-laws or certificate of formation and operating agreement, as applicable; 

(d) an incumbency certificate for Borrower identifying all Authorized Officers, with specimen signatures; 

(e) a written opinion of Borrower’s independent counsel addressed to Administrative Agent for the benefit of Lenders; 

(f) certification by the president of Borrower that there has not occurred any Material Adverse Effect; 

(g) payment by Borrower of all fees including, without limitation, the Revolving Credit Closing Fee, the Term Loan Closing Fee and Expenses
associated with the Loans; 
 (h) completed Lien searches; 

(i) insurance certificates and policies as required under Section 5.2; 

(j) certification by the president of Borrower that the sale of Borrower’s CTS Business for a minimum sales price of $54,000,000 has
closed on terms previously represented to Lenders; 
 (k) Borrower shall have (i) prepaid the Term Loan by not less than $22,000,000
using a portion of the sales proceeds received from the sale of Borrower’s CTS business, and (ii) deposited not less than $12,000,000 into the CTS Tax Escrow Account; 

(l) Borrower shall have provided Lenders a calculation of tax liability relating to the sale of Borrower’s CTS Business prepared by
Borrower’s accountants and, in the event that Borrower’s tax liability arising from such sale is less than $12,000,000, then Borrower shall have further prepaid the Term Loan by not less than fifty percent (50%) of the difference between
$12,000,000 and Borrower’s actual tax liability as calculated by Borrower’s accountants; and 
 (m) Borrower shall have provided
Lenders an updated financial forecast (that gives effect to the transactions contemplated by this Agreement) by Quarter for 2017. 

3.2    Absence of Certain Events. At the Amendment Date, no Default or Event of Default hereunder shall have
occurred and be continuing. 
 3.3    Warranties and Representations at Closing. The warranties and
representations contained in Section 4 shall be true and correct in all material respects on the Amendment Date with the same effect 

  
 -26- 

 
as though made on and as of that date except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall be true
and correct in all material respects as of such earlier date (except that any representation and warranty that is qualified as to “materiality” or “Material Adverse Effect” shall be true and correct in all respects). 

3.4    Compliance with this Agreement. Borrower shall have performed and complied with all agreements, covenants
and conditions contained herein including, without limitation, the provisions of Sections 5 and 6, which are required to be performed or complied with by Borrower before or at the Amendment Date. 

3.5    Officers’ Certificate. Administrative Agent shall have received a certificate dated the
Amendment Date and signed by the chief financial officer of Borrower certifying that all of the conditions specified in this Section 3 have been fulfilled. 

3.6    Closing. Subject to the conditions of this Section 3, the amendment and
restatement of the Prior Loan Agreement shall become effective on the Amendment Date contemporaneously with the execution hereof (the “Closing”) subject, however, to the prior or simultaneous closing of Borrower’s sale of its
CTS Business for a cash purchase price of not less than $54,000,000 on terms previously represented to Lenders. 

3.7    Waiver of Rights. By completing the Closing hereunder, or by making Advances hereunder, Administrative Agent
and Lenders do not thereby waive a breach of any warranty or representation made by Borrower hereunder or under any agreement, document, or instrument delivered to Administrative Agent on behalf of Lenders or otherwise referred to herein, and any
claims and rights of Lender resulting from any breach or misrepresentation by Borrower are specifically reserved by Administrative Agent and Lenders. 

3.8    Conditions for Advances. The making of Advances under the Revolving Credit in any form following the
Amendment Date is subject to the following conditions precedent (all instruments, documents and agreements to be in form and substance satisfactory to Administrative Agent) following the Amendment Date: 

(a) This Agreement and each of the other Loan Documents shall be effective; 

(b) No event or condition shall have occurred or become known to Borrower, or would result from the making of any requested Advance, which
could reasonably be expected to have a Material Adverse Effect; 
 (c) No Default or Event of Default then exists or after giving effect to
the making of the Advance would exist; 
 (d) Each Advance is within and complies with the terms and conditions of this Agreement including,
without limitation, the notice provisions contained in Section 2.3; 
 (e) No Lien (other than a Permitted Lien)
has been imposed on Borrower or any of its Subsidiaries; and 
 (f) Each representation and warranty set forth in
Section 4 and any other Loan Document in effect at such time (as amended or modified from time to time) is then true and correct in all material respects as if made on and as of such date except to the extent such
representations and warranties are made only as of a specific earlier date. 

  
 -27- 

 SECTION 4 

REPRESENTATIONS AND WARRANTIES 

To induce Administrative Agent and each Lender to complete the Closing, Borrower warrants and represents to Administrative Agent and each
Lender that: 
 4.1    Organization and Validity. 

(a) Borrower (i) is a corporation, duly organized and validly existing under the laws of the State of Delaware, (ii) has the
appropriate power and authority to operate its business and to own its Property and (iii) is duly qualified, is validly existing and in good standing and has lawful power and authority to engage in the business it conducts in each state where
the nature and extent of its business requires qualification, except where the failure to so qualify does not and could not reasonably be expected to have a Material Adverse Effect. 

(b) The making and performance of this Agreement and the other Loan Documents will not violate any Requirement of Law, or the charter, minutes
or bylaw provisions of Borrower, or violate or result in a default (immediately or with the passage of time) under any material contract, agreement or instrument to which Borrower is a party, or by which Borrower is bound. Borrower is not in
violation of any term of any material agreement or instrument to which it is a party or by which it may be bound which violation has or could reasonably be expected to have a Material Adverse Effect, or of its charter, minutes or bylaw provisions,
or of Borrower’s operating agreement or partnership agreement, as applicable. 
 (c) Borrower has all requisite power and authority to
enter into and perform this Agreement and to incur the obligations herein provided for, and has taken all proper and necessary action to authorize the execution, delivery and performance of this Agreement, and the other Loan Documents as applicable.

 (d) This Agreement, the Notes to be issued hereunder, and all of the other Loan Documents, when delivered, will be valid and binding upon
Borrower, and enforceable in accordance with their respective terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting the enforcement of creditors’ rights
generally and by general equitable principles. 
 4.2    Places of Business. As of the Amendment Date, the only
places of business of Borrower and each of its Subsidiaries, and the places where each of Borrower and its Subsidiaries keeps and intends to keep its Property, are at the addresses shown on Schedule 4.2. Schedule 4.2 also lists each
jurisdiction in which Borrower and each Subsidiary is duly qualified to transact business as of the Amendment Date. With respect to each of the place of business listed on Schedule 4.2, Borrower or such Subsidiary is duly qualified, is
validly existing and in good standing and has lawful power and authority to engage in the business it conducts in the state in which such place of business is located, except where the failure to so qualify could not reasonable be expected to have a
Material Adverse Effect. 
 4.3    Pending Litigation. Except as set forth on Schedule 4.3: 

(a) There are no judgments or judicial or administrative orders or proceedings pending, or to the knowledge of Borrower, threatened, against
Borrower or any of its Subsidiaries in any court or before any Governmental Authority that could reasonably be expected to have a Material Adverse Effect. 

  
 -28- 

 (b) To the knowledge of Borrower, there are no investigations (administrative, civil or criminal)
pending or threatened against Borrower or any of its Subsidiaries in any court or before any Governmental Authority that could reasonably be expected to have a Material Adverse Effect. Neither Borrower nor any of its Subsidiaries is in default with
respect to any order of any Governmental Authority that could reasonably be expected to have a Material Adverse Effect. 
 (c) To the
knowledge of Borrower, no shareholder or executive officer of Borrower or any of its Subsidiaries has been indicted in connection with or convicted of engaging in any criminal conduct, or is currently subject to any lawsuit or proceeding or under
investigation in connection with any anti-racketeering or other conduct or activity which may result in the forfeiture of any property to any Governmental Authority. 

4.4    Title to Properties. Except as set forth on Schedule 4.4, Borrower and each of its Subsidiaries has
good and marketable title in fee simple (or its equivalent under applicable law) to all the Property it owns, free from Liens and free from the claims of any other Person, except for Permitted Liens. 

4.5    Governmental Consent. Except as set forth on Schedule 4.5, neither the nature of Borrower or any of
its Subsidiaries or of Borrower’s or any of its Subsidiaries’ business or Property, nor any relationship between Borrower or any of its Subsidiaries and any other Person, nor any circumstance affecting Borrower or any of its Subsidiaries
in connection with the issuance or delivery of this Agreement, the Notes or any other Loan Documents is such as to require a consent, approval or authorization of, or filing, registration or qualification with, any Governmental Authority on the part
of Borrower, except where a consent, approval, authorization, filing, registration or qualification has been obtained or where the failure to do so could not have reasonably expected to have a Material Adverse Effect. 

4.6    Taxes. All material tax returns required to be filed by Borrower and its Subsidiaries in any jurisdiction
have been filed or extended, and all taxes, assessments, fees and other governmental charges upon Borrower or any of its Subsidiaries, or upon any of its Property, income or franchises, which are shown to be due and payable on such returns have been
paid, except for those taxes being contested in good faith with due diligence by appropriate proceedings for which appropriate reserves have been maintained under GAAP and as to which no Lien has been entered. Except as set forth on Schedule
4.6, as of the Amendment Date, Borrower is not aware of any proposed additional tax assessment or tax to be assessed against or applicable to Borrower or any of its Subsidiaries. 

4.7    Financial Statements. The annual audited consolidated (if applicable) balance sheet of Borrower as of
December 31, 2016, and the related statements of profit and loss, stockholder’s equity and cash flow as of such date accompanied by reports thereon from Borrower’s independent certified public accountants (complete copies of which
have been delivered to Administrative Agent), and the interim consolidated (if applicable) balance sheet of Borrower as of March 31, 2017, and the related statements of profit and loss, stockholder’s equity and cash flow as of such date
have been prepared in accordance with GAAP and present fairly the financial position of Borrower as of such dates and the results of its operations for such periods. The fiscal year for Borrower ends on December 31. Borrower’s federal tax
identification number and state organizational identification number for UCC purposes are as shown on the Perfection Certificate for Borrower and each Guarantor. 

4.8    Full Disclosure. The financial statements referred to in Section 4.7 do not, nor
does any other written statement of Borrower to Lender in connection with the negotiation of the Loans, contain, to the knowledge of Borrower, any untrue statement of a material fact. Such statements do not omit a material fact, the omission of
which would make the statements contained therein misleading. 

  
 -29- 

 4.9    Subsidiaries. As of the Amendment Date, Borrower has no
Subsidiaries other than those specifically disclosed in Schedule 4.9. All of the outstanding Capital Stock of each of Borrower’s Subsidiaries has been validly issued, is fully paid and nonassessable and is owned by Borrower or the
applicable Subsidiary and in the amounts, each as specified on Schedule 4.9, and free and clear of all Liens except those created under the Security Documents. 

4.10    Government Regulations. 

(a) The use of the proceeds of and Borrower’s issuance of the Notes will not directly or indirectly violate or result in a violation of
Section 7 of the Securities Exchange Act of 1934, as amended, or any regulations issued pursuant thereto, including, without limitation, Regulations U, T and X of the Board of Governors of the Federal Reserve System, 12 C.F.R.,
Chapter II. Borrower does not own or intend to carry or purchase any “margin stock” within the meaning of said Regulation U. 

(b) Except as set forth on Schedule 4.10(b), Borrower is current with all reports and documents required to be filed with any state or
federal securities commission or similar agency and is in full compliance in all material respects with all applicable rules and regulations of such commissions. 

4.11    Employee Benefits. Except as set forth on Schedule 4.11: 

(a) As of the date hereof, no employee benefit pension plan as defined in Section 3(2) of ERISA which is covered by Section 412 of
the Internal Revenue Code or Section 302 or Title IV of ERISA and which is maintained by Borrower or any Subsidiary of Borrower or under which Borrower or any Subsidiary of Borrower could have any liability under ERISA (a “Pension
Plan”) (i) has failed to meet the minimum funding standards established in Section 302 of ERISA, (ii) has failed to comply in a material respect with all applicable requirements of ERISA and of the Internal Revenue Code, including
all applicable rulings and regulations thereunder except where a failure to so comply is not reasonably expected to result in a material liability to Borrower, (iii) has engaged in or been involved in a
non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Internal Revenue Code which would be reasonably expected to subject Borrower to any material liability, or
(iv) has been terminated if such termination would subject Borrower to any material liability. 
 (b) Neither Borrower nor any
Subsidiary of Borrower has assumed, or received notice of a claim asserted against Borrower or any Subsidiary of Borrower for, withdrawal liability (as defined in Section 4207 of ERISA) with respect to any “multi-employer pension
plan” within the meaning of Section 3(37) of ERISA), either as a participating employer or as a member of any Controlled Group (as defined in ERISA). 

(c) Borrower and each Subsidiary of Borrower has timely made all contributions when due with respect to any multi-employer pension plan in
which it participates and no event has occurred triggering a claim against Borrower or any Subsidiary of Borrower for withdrawal liability pursuant to Title IV of ERISA with respect to any multi-employer pension plan in which Borrower participates.

 (d) All Pension Plans and multi-employer pension plans in which Borrower or any Domestic Subsidiary of Borrower participates are shown on
Schedule 4.11. 
 4.12    Business Interruptions. Except as set forth on Schedule
4.12: 
 (a) Within five (5) years prior to the date hereof, none of the business, Property or operations of Borrower or any
Subsidiary of Borrower have been materially and adversely affected in any way by any casualty, strike, lockout, combination of workers, order of the United States of America, or any state or local government, or any political subdivision or agency
thereof, directed against Borrower or any Subsidiary of Borrower. 

  
 -30- 

 (b) Except as could not reasonably be expected to have a Material Adverse Effect, there are no
pending or, to Borrower’s knowledge, threatened labor disputes, strikes, lockouts or similar occurrences or grievances affecting Borrower or any Subsidiary of Borrower. No labor contract of Borrower or any Subsidiary of Borrower is scheduled to
expire prior to the Revolving Credit Maturity Date. 
 4.13    Intellectual Property. Except as set forth on
Schedule 4.13: 
 (a) Borrower and/or each Subsidiary owns, or is licensed or otherwise possesses legal rights under all Intellectual
Property, and all patents, patent applications, trademarks, trade names, service marks, trade dress, copyrights, domain names, mask works, schematics, technology, know-how, trade secrets, confidential
information, customer lists, technical information, technical data, process technology, plans, drawings and blue prints, inventions, algorithms, devices, systems, processes, computer software programs and applications to the extent the same are used
in and are material to the respective businesses of Borrower and/or any Subsidiary. 
 (b) Schedule 4.13 lists, as of the Amendment
Date, all: (i) patents, patent applications (“Patent Rights”), registered and common law trademarks and service marks, and registered copyrights owned by Borrower and/or each Subsidiary (“Scheduled Intellectual
Property”), including where applicable the jurisdictions, both domestic and foreign, in which each such item of Intellectual Property has been issued or registered or in which any application for such issuance and registration has been
filed; (ii) written licenses, sublicenses and other agreements as to which Borrower or any Subsidiary is a party and pursuant to which any Person is authorized to use any Intellectual Property owned by Borrower other than Standard Outbound IP
Licenses; (iii) written licenses, sublicenses and other agreements to which Borrower or any Subsidiary is a party and pursuant to which Borrower or any Subsidiary is authorized to use any third party’s Intellectual Property (other than,
with respect to such software, off-the-shelf commercial or shrink-wrap software or open source software) (“Third Party Intellectual Property Rights”)
that are incorporated or used in any product or service of Borrower and/or each Subsidiary or which are material to their respective operations other than Standard Inbound IP Licenses; and (iv) all agreements to which Borrower or any Subsidiary
is a party that provide for an optional or contingent license, sublicense or other agreement as described in clauses (ii) or (iii) above in this Section 4.13(b). 

(c) To Borrower’s knowledge, all Scheduled Intellectual Property material to its operations is valid, enforceable, has been duly
maintained, is in full force and effect, and has not been cancelled, expired or abandoned. 
 (d) None of the Patent Rights were developed
under a funding agreement with the Government of the United States of America or with any state governments, pursuant to which the government of the United States of America or any state governments has rights relative thereto. 

(e) Neither Borrower nor any Subsidiary has received any notice from, or demand or claim by, any third party that any of the Intellectual
Property material to its operations, including any Patent Rights are not solely owned by Borrower or any Subsidiary of Borrower or that the Patent Rights are subject to a license. 

(f) No allowable or allowed subject matter of the Patent Rights listed in Schedule 4.13 owned or held by Borrower or any Subsidiary, in
whole or in part, is subject to any competing or interfering claims by any third party (but excluding any patent claims issued to any third parties by the 

  
 -31- 

 
United States Patent and Trademark Office), or claims of ownership by any third party. To the knowledge of Borrower, no allowable or allowed subject matter of the Patent Rights listed in
Schedule 4.13 subject to any exclusive license held by Borrower or any Subsidiary, in whole or in part, is subject to any competing or interfering claims by any third party (but excluding any patent claims issued to any third parties by the
United States Patent and Trademark Office), or claims of ownership by any third party. No allowable or allowed subject matter of such Patent Rights has been the subject of any interference, re-examination or
opposition proceedings or any other post-grant proceedings and, to Borrower’s knowledge, there is no reasonable basis for any such interference, reexamination or opposition proceedings or any other post-grant proceedings. 

(g) Borrower has taken all action necessary to maintain the enforceability and registration of all Scheduled Intellectual Property material to
the operation of Borrower and/or each Subsidiary. 
 (h) All annuities, maintenance fees or other fees necessary to maintain the pendency or
right to assert the Patent Rights and Trademarks due on or before the date hereof have been paid according to proper entity status in the relevant jurisdiction. 

(i) The registrations to Patent Rights and Trademarks material to its operations are in good standing and none of the Patent Rights or
Trademarks have lapsed, been disclaimed or otherwise voluntarily limited in scope, or been dedicated to the public. 
 (j) Neither Borrower
nor any Subsidiary has received any invitation to license or written charge, complaint, claim, demand or notice that Borrower or any Subsidiary has infringed, misappropriated, or acted in conflict with any of the Intellectual Property material to
its operations owned by any third party. To Borrower’s knowledge, neither Borrower nor any Subsidiary has infringed, misappropriated, or acted in conflict with any of the Intellectual Property material to its operations owned by any third
party. 
 (k) To Borrower’s knowledge, there is no unauthorized use, disclosure, infringement or misappropriation of any Intellectual
Property rights, in any such case, material to its operations, of Borrower and/or any Subsidiary, or any Third Party Intellectual Property Rights material to its operations to the extent exclusively licensed to Borrower and/or any Subsidiary, by any
third party, including any employee or former employee of Borrower and/or any Subsidiary. 
 (l) Neither Borrower nor any Subsidiary has, in
the three (3) years preceding the date of this Agreement, sent to or contemplated sending to any third party any written charge, complaint, claim, demand or notice asserting that such Person has infringed, misappropriated, or acted in conflict
with any of the Intellectual Property owned by Borrower and/or any Subsidiary and material to its operations, nor (to Borrower’s knowledge) is any such infringement, misappropriation, or conflict occurring or threatened nor is Borrower aware of
any. 
 (m) Neither Borrower nor any Subsidiary is, nor will be, as a result of the execution and delivery of this Agreement by Borrower, or
the performance of its obligations hereunder, in material breach of any license, sublicense or other agreement. 
 (n) Borrower has entered
into written confidentiality agreements with all employees and third parties to whom Borrower and/or any Subsidiary has disclosed material Borrower-owned confidential Intellectual Property, except where a failure to do so would not have a Material
Adverse Effect. 

  
 -32- 

 (o) Borrower has not obtained any opinions from its inside or outside legal counsel that any of
the material products infringe one or more claims of any third party Intellectual Property. 
 4.14    Regulatory
Compliance. Except as, in the aggregate, could not reasonably be expected to have a Material Adverse Effect or as set forth in Schedule 4.14: 

(a) As to Borrower and each of its Subsidiaries, Affiliates and agents, and as to each product subject to the Federal Food, Drug and Cosmetic
Act of 1938, and the Public Health Service Act Section 361, as amended, and the regulations of the Food and Drug Administration (the “FDA”) promulgated thereunder (the “FDCA”) or similar Requirements of Law
(each such product, a “Medical Device,” a “Biologic,” a “Drug,” or “Human Tissue Intended for Transplantation,” as the case may be, and collectively “Regulated
Products”)) that is or has been developed, manufactured, tested, distributed or marketed by Borrower and its Subsidiaries, Affiliates and agents are in material compliance with, and each such Regulated Product is being developed,
manufactured, tested, distributed and/or marketed in material compliance with, all applicable requirements under the FDCA and other applicable Requirements of Law, including 21 C.F.R. Parts 1270 and 1271 (regulation of Human Cellular and Tissue
Products, or HCTP’s), 21 C.F.R. Part 820 (regulation of Medical Devices), the United States National Organ Transplant Act, 42 U.S.C. §274e, the licensing requirements and other applicable Requirements of Law of the several states of the
United States, European Union Directives, Medical Device Directive 93/42/EC, EU Directive 2004/23/EC (standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and
cells), applicable Requirements of Law of the various member nations of the European Union, American Association of Tissue Banking (AATB) standards, and those Requirements of Law relating to the tissue donor recovery process. Neither Borrower nor
any Subsidiary has received any written communication from the FDA or any other Governmental Authority (i) contesting the premarket clearance or approval of, the uses of or the labeling and promotion of any products of Borrower or any of its
Subsidiaries or (ii) otherwise alleging any violation applicable to any Regulated Product by Borrower or any of its Subsidiaries, Affiliates or agents of any Requirements of Law. 

(b) All material reports, documents, claims and notices required to be filed, maintained, or furnished to any Governmental Authority by
Borrower or any of its Subsidiaries have been so filed, maintained or furnished. 
 (c) No Regulated Product of Borrower or any of its
Subsidiaries has been recalled, withdrawn, suspended or discontinued by Borrower or any of its Subsidiaries in the United States or outside the United States (whether voluntarily or otherwise). No proceedings in the United States or outside of the
United States of which Borrower has knowledge (whether completed or pending) seeking the recall, withdrawal, suspension or seizure of any Regulated Product of Borrower or any of its Subsidiaries are pending against Borrower or any of its
Subsidiaries nor have any such proceedings been pending at any prior time. 
 (d) As to each Regulated Product of Borrower or any of its
Subsidiaries for which a premarket notification submission under Section 510(k) of the FDCA, premarket approval application, biological license application, new drug application, investigational new drug application or similar state or foreign
regulatory application has been cleared or approved, Borrower and its Subsidiaries, Affiliates and agents are in compliance with 21 U.S.C. §§ 355, 360 and 360e, and 42 U.S.C. § 262 and 21 C.F.R. Parts 312, 314, 600, and 601, 807, 812,
814 et seq., as applicable, and similar Requirement of Law and all terms and conditions of such applications, except for any such failure or failures to be in compliance which individually or in the aggregate are not or would not be material. As to
each such Regulated Product of Borrower or any of its Subsidiaries, Borrower and the officers, employees or agents of Borrower have included in the application for such Regulated Product of Borrower or any of its

  
 -33- 

 
Subsidiaries, where required, the certification described in 21 U.S.C. § 335a(k)(1) or any similar Requirement of Law and the list described in 21 U.S.C. § 335a(k)(2) or any similar
Requirement of Law, and each such certification and list was true, complete and correct in all material respects when made. In addition, the Borrower and its Subsidiaries, Affiliates and agents are in substantial compliance with all applicable
registration and listing requirements set forth in 21 U.S.C. § 360, 42 U.S.C. § 262 and 21 C.F.R. Part 207, 601 and 807 and all similar Requirements of Law. 

(e) No article of any Regulated Product manufactured and/or distributed by Borrower or any of its Subsidiaries is (i) adulterated within
the meaning of 21 U.S.C. § 351 (or similar Requirement of Law), (ii) misbranded within the meaning of 21 U.S.C. § 352 (or similar Requirement of Law) or (iii) a product that is in violation of 21 U.S.C. §§ 355, 360, 360e and
42 U.S.C. § 262 (or similar Requirement of Law). 
 (f) Neither Borrower nor any of its Subsidiaries or Affiliates nor, to the
knowledge of Borrower, any officer, employee or agent of Borrower or any of its Subsidiaries or Affiliates has made an untrue statement of a material fact or fraudulent statement to the FDA or any other Governmental Authority that primarily
regulates Medical Devices, Biologics or Drugs, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority that primarily regulates Medical Devices, Biologics or Drugs, or committed an act, made a
statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA or any other Governmental Authority to invoke its policy respecting “Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities,” set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy. Neither Borrower nor any of its Subsidiaries or Affiliates or, to the knowledge of Borrower, any officer, employee or
agent of Borrower or any of its Subsidiaries or Affiliates has been convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. § 335a(a) or any similar Requirement of Law or authorized by 21 U.S.C. §
335a(b) or any similar Requirement of Law. Neither Borrower nor any of its Subsidiaries or Affiliates nor, to the knowledge of Borrower, any officer, employee or agent of Borrower or any of its Subsidiaries or Affiliates has been convicted of any
crime or engaged in any conduct for which such person or entity could be excluded from participating in the federal health care programs under Section 1128 of the Social Security Act of 1935, as amended (the “Social Security
Act”), or any similar Requirement of Law. 
 (g) Neither Borrower nor any of its Subsidiaries has received within the last four
(4) years any written notice that the FDA or any other Governmental Authority has (i) commenced, or threatened to initiate, any action to withdraw its approval or request the recall of any Regulated Product of Borrower or any of its
Subsidiaries, (ii) commenced, or threatened to initiate, any action to enjoin production of any Regulated Product of Borrower or any of its Subsidiaries, (iii) commenced, or threatened to initiate, any action to enjoin the production of
any Regulated Product of Borrower or any of its Subsidiaries produced at any facility where any Regulated Product is manufactured, tested or packaged, (iv) filed a warning letter concerning deviations from the regulations concerning any
Regulated Product or the manufacture or distribution thereof or (v) issued an FDA Form 483, except as listed on Schedule 4.14. 

(h) Borrower and its Subsidiaries are in full compliance with all Medical Device, Drug, Biologic and Human Tissue Intended for Transplantation
reporting requirements promulgated by any Governmental Authority, including FDA, for all Regulated Products manufactured or distributed by Borrower or any of its Subsidiaries, except for failures to be in compliance with the foregoing that
individually or in the aggregate are not or would not be material. 
 (i) Borrower and its Subsidiaries are in full compliance with the
Federal Anti-Kickback Statute, 42 U.S.C.A. §§ 1320a-7b(b), the Stark Law (42 U.S.C. §§ 1395nn) and the AdvaMed Code of 

  
 -34- 

 
Ethics on Interactions with Health Care Professionals (the “AdvaMed Code”), and all of Borrower’s and its Subsidiaries’ contracts, agreements and arrangements with
Health Care Professionals (as defined in the AdvaMed Code) are in full compliance with the AdvaMed Code. 

4.15    Other Associations. Borrower is not engaged and has no interest in any joint venture or partnership with
any other Person except as set forth in Schedule 4.15 or as otherwise permitted by Section 6.7. 

4.16    Environmental Matters. Except as, in the aggregate, could not reasonably be expected to have a Material
Adverse Effect or as set forth in Schedule 4.16: 
 (a) To the best of Borrower’s knowledge after due inquiry, no Property
presently owned, leased or operated by Borrower or any Subsidiary of Borrower contains, or has previously contained within the last ten (10) years, any Hazardous Substances in amounts or concentrations which (i) constitute or constituted a
violation of, or (ii) could give rise to liability under, any Environmental Law. 
 (b) To the best of Borrower’s knowledge after
due inquiry, Borrower and each Subsidiary of Borrower is in compliance, and, for the duration of all applicable statutes of limitations periods, has been in compliance with all applicable Environmental Laws, and there is no contamination at, under
or about any properties presently owned, leased, or operated by Borrower or any Subsidiary of Borrower or violation of any Environmental Law with respect to such properties which could reasonably be expected to interfere with any of their continued
operations or reasonably be expected to impair the fair saleable value thereof. 
 (c) Neither Borrower nor any Subsidiary of Borrower has
received any written notice of violation, alleged violation, non-compliance, liability or potential liability regarding environmental matters or compliance assessment with Environmental Laws and Borrower has
no knowledge that any such notice is being overtly threatened. 
 (d) Hazardous Substances have not been transported or disposed of by
Borrower or a Subsidiary of Borrower in a manner or to a location which are reasonably likely to give rise to liability of Borrower or any Subsidiary of Borrower under any Environmental Law. 

(e) No judicial proceeding or governmental or administrative action is pending, or to the knowledge of Borrower, threatened under any
Environmental Law to which Borrower or any Subsidiary of Borrower is, or to Borrower’s knowledge will be, named as a party, nor are there any consent decrees or other decrees, consent orders, administrative orders or other orders, or other
administrative or judicial requirements outstanding. 
 4.17    Regulation O. No director or executive officer of
Borrower is a director, executive officer or principal shareholder of Lender. For the purposes hereof the terms “director” “executive officer” and “principal shareholder” (when used with reference to Lender), have the
respective meanings assigned thereto in Regulation O issued by the Board of Governors of the Federal Reserve System. 

4.18    Material Contracts. Set forth on Schedule 4.18 is a complete and accurate list of all Material
Contracts as of the Amendment Date, showing as of the date hereof, the name thereof, the parties, the subject matter and the term. Each Material Contract has been duly authorized, executed and delivered by the Borrower or applicable Subsidiary (and
to Borrower’s knowledge, by the other parties thereto), is in full force and effect and is binding upon and enforceable against the Borrower and its Subsidiaries that are parties thereto (and to Borrower’s knowledge, against the other
parties thereto) in accordance with its terms, except to the extent any such Material Contract expires or otherwise terminates in accordance with its terms (other than a termination as a result of breach or default). 

  
 -35- 

 4.19    Solvency. After giving effect to the transactions contemplated
under this Agreement (including, without limitation, the acquisition of Pioneer Surgical Technologies), Borrower and its Subsidiaries, taken as a whole, are solvent, are able to pay its debts as they become due, and have capital sufficient to carry
on its business and all businesses in which it is about to engage, and now owns Property having a value both at fair valuation and at present fair saleble value greater than the amount required to pay Borrower’s debts. Borrower will not be
rendered insolvent by the execution and delivery of this Agreement or any of the other Loan Documents executed in connection with this Agreement or by the transactions contemplated hereunder or thereunder. 

4.20    Perfection and Priority. This Agreement and the other Loan Documents are effective to create in favor of
Administrative Agent legal, valid and enforceable Liens in all right, title and interest of Borrower and the Subsidiaries in the Collateral, and when financing statements have been filed in the offices of the respective jurisdiction of organization
under Borrower’s and each Subsidiary’s name, Borrower and each Guarantor will have granted to Administrative Agent and Administrative Agent will have for the benefit of Lenders perfected first priority Liens in the Collateral, superior in
right to any and all other Liens, existing or future. 
 4.21    Commercial Tort Claims. Except as set forth on
Schedule 4.21, as of the Amendment Date, neither Borrower nor any Subsidiary of Borrower is a party to any Commercial Tort Claims. 

4.22    Letter of Credit Rights. As of the Amendment Date, neither Borrower nor any Subsidiary of Borrower has any
Letter of Credit Rights. 
 4.23    Export Control Laws. Borrower and each Subsidiary has conducted its export
transactions in material compliance with applicable provisions of United States export control laws and regulations. Without limiting the foregoing: (a) Borrower and each Subsidiary has obtained all export licenses and other approvals required
for its exports of products, software and technologies from the United States; (b) Borrower and each Subsidiary is in material compliance with the terms of all applicable export licenses or other approvals; (c) there are no pending or, to
the knowledge of Borrower, claims threatened in writing against Borrower or any Subsidiary with respect to such export licenses or other approvals; and (d) there are no material actions, conditions or circumstances pertaining to the
Borrower’s or any Subsidiary’s export transactions that would reasonably be expected to give rise to any future claims. 

4.24    Foreign Corrupt Practices Act. None of Borrower or any Subsidiary or any predecessor, or, to the knowledge
of Borrower, any employee, representative or other Person associated with or acting on behalf of Borrower or any Subsidiary or any predecessor has, directly or indirectly, (a) used any corporate funds for unlawful contributions, gifts,
entertainment or other unlawful expenses relating to political activity, (b) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns from corporate funds,
(c) established or maintained a secret or unrecorded fund, participated in or co-operated with an international boycott as defined in Section 999 of the Code, (d) violated any provision of
(i) the Foreign Corrupt Practices Act of 1977, as amended, and the rules, regulations and guidance promulgated thereunder, (ii) the U.K. Bribery Act of 2010, as amended, and the rules, regulations and guidance promulgated thereunder or
(iii) any other similar applicable Requirement of Law relating to corruption or bribery, or (e) made any bribe, rebate, payoff, influence, payment, kickback or other similar unlawful payment of any nature. 

  
 -36- 

 4.25    Anti-Terrorism Laws. 

(a) Neither Borrower nor any Affiliate of Borrower is in violation of any Anti-Terrorism Law or engages in or conspires to engage in any
transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law. 

(b) Neither Borrower nor any Affiliate of Borrower, or to Borrower’s knowledge, any of its respective agents acting or benefiting in any
capacity in connection with the Loans or other transactions hereunder, is any of the following (each, a “Blocked Person”): 

(i)    a Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive
Order No. 13224; 
 (ii)    a Person owned or controlled by, or acting for or on behalf of, any
Person that is listed in the annex to, or is otherwise subject to the provisions of, the Executive Order No. 13224; 

(iii)    a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction
by any Anti-Terrorism Law; 
 (iv)    a Person that commits, threatens or conspires to commit or supports
“terrorism” as defined in the Executive Order No. 13224; 
 (v)    a Person that is named
as a “specially designated national” on the most current list published by the U.S. Treasury Department Office of Foreign Asset Control at its official website or any replacement website or other replacement official publication of such
list; or 
 (vi)    a Person who is affiliated with a Person listed above. 

SECTION 5 
 BORROWER’S
AFFIRMATIVE COVENANTS 
 Borrower covenants that until all of the Obligations due under the Loan Documents are paid and satisfied in full
and the Revolving Credit has been terminated, that: 
 5.1    Payment of Taxes and Claims. Borrower and each of
its Subsidiaries shall pay, before they become delinquent, all material taxes, assessments and governmental charges, or levies imposed upon it, or upon Borrower’s and each of its Subsidiaries’ Property, and all claims or demands of
materialmen, mechanics, carriers, warehousemen, landlords and other Persons entitled to the benefit of statutory or common law Liens which, in any case, if unpaid, would result in the imposition of a Lien upon its Property; provided,
however, that Borrower or any Subsidiary of Borrower shall not be required to pay any such tax, assessment, charge, levy, claim or demand if the amount, applicability or validity thereof, shall at the time be contested in good faith and by
appropriate proceedings by Borrower or such Subsidiary, and if Borrower or such Subsidiary shall have set aside on its books adequate reserves in respect thereof, if so required in accordance with GAAP and which deferment of payment is permissible
so long as no Lien other than a Permitted Lien has been entered and the same could not reasonably be expected to have a Material Adverse Effect. 

  
 -37- 

 5.2    Maintenance of Properties and Insurance. 

(a) Property. Borrower and each of its Subsidiaries shall maintain its Property in good condition (normal wear and tear and casualty and
condemnation excepted) make all reasonably necessary renewals, replacements, additions, betterments and improvements thereto consistent with industry and past practice and will pay and discharge when due the cost of repairs and maintenance to its
Property, and will pay all rentals when due for all real estate leased by Borrower and each of its Subsidiaries, to the extent material to its operations. 

(b) Property Insurance, Public and Products Liability Insurance. Borrower and each of its Subsidiaries shall maintain insurance
(i) on all insurable tangible Property against fire, flood, casualty and such other hazards (including, without limitation, extended coverage, workmen’s compensation, boiler and machinery, with inflation coverage by endorsement) and
(ii) against public liability, product liability and business interruption, in each case in such amounts, with such deductibles and with such insurers as are customarily used by companies operating in the same industry as Borrower from insurers
acceptable to Administrative Agent and with an AM Best rating of no lower than A-. At or prior to Closing, Borrower shall furnish Administrative Agent with duplicate original policies of insurance or such
other evidence of insurance as Administrative Agent may require, and any certificates of insurance shall be issued on Accord Form-27. In the event Borrower or any of its Subsidiaries fails to procure or cause
to be procured any such insurance or to timely pay or cause to be paid the premium(s) on any such insurance, Administrative Agent may do so for Borrower, but Borrower shall continue to be liable for the same. The policies of all such casualty
insurance shall contain standard lender’s loss payable clauses (and, with respect to liability and interruption insurance, additional insured clauses) issued in favor of Administrative Agent on behalf of and for the benefit of Lenders under
which all losses thereunder shall be paid to Administrative Agent, on behalf of and for the benefit of Lenders, as Lenders’ interest may appear. Such policies shall expressly provide that the requisite insurance cannot be altered or canceled
without thirty (30) days prior written notice to Administrative Agent and shall insure Administrative Agent notwithstanding the act or neglect of Borrower. Insurance proceeds paid to the Administrative Agent shall be made available to permit
the restoration of damage with such proceeds to all Property; provided, however, that following the occurrence and continuance of an Event of Default, Borrower hereby appoints Administrative Agent as Borrower’s and each of its
Subsidiaries’ attorney-in-fact, exercisable at Administrative Agent’s option to endorse any check which may be payable to Borrower or any Subsidiary in order
to collect the proceeds of such insurance on behalf of and for the benefit of Lenders, and, pursuant to the provisions of this Section 5.2(b) such proceeds may be applied by Administrative Agent, in its discretion (but with
the approval of the Required Lenders), to any Obligations or to repair, reconstruct or replace the loss of or damage to Property as Administrative Agent, in its discretion (but with the approval of the Required Lenders), may from time to time
determine. Borrower further covenants that all insurance premiums owing under its current policies have been paid. Borrower shall notify Administrative Agent immediately upon Borrower’s or any of its Subsidiaries’ receipt of a notice of
termination, cancellation, or non-renewal from its insurance company of any such policy. 

5.3    Financial Records. Borrower and each of its Subsidiaries shall keep current and accurate books of records
and accounts in which full and correct entries will be made of all of its material business transactions, and will reflect in its financial statements adequate accruals and appropriations to reserves, all in accordance with GAAP. Borrower shall not
change its fiscal year end date without the prior written consent of the Required Lenders. 
 5.4    Corporate
Existence and Rights. Borrower shall do (or cause to be done) all things necessary to preserve and keep in full force and effect its and each of its Subsidiaries existence, good standing, rights and franchises, except to the extent a failure to
do so could not reasonably be expected to 

  
 -38- 

 
have a Material Adverse Effect. Borrower shall (and Borrower shall cause each of its Subsidiaries to) obtain and maintain any and all licenses, permits, franchises or other governmental
authorizations necessary to the ownership of its property or the conduct of its businesses. 
 5.5    Compliance with
Laws. Borrower and each of its Subsidiaries shall: (a) be in compliance in all material respects with any and all Requirements of Law to which it is subject, whether foreign, federal, state or local, including, without limitation,
Environmental Laws and Requirements of Law applicable to Regulated Products; and (b) timely satisfy all assessments, fines, costs and penalties imposed (after exhaustion of all appeals, provided a stay has been put in effect during such appeal)
by any Governmental Authority against Borrower or any of its Subsidiaries or any Property of Borrower or any of its Subsidiaries, except where (i) Borrower or such Subsidiary is contesting any Requirement of Law in good faith by appropriate
proceedings diligently conducted or (ii) the failure to comply could not reasonably be expected to have a Material Adverse Effect. 

5.6    Business Conducted. Borrower shall continue in the business presently operated by it using its best efforts
to maintain its customers and goodwill. Neither Borrower nor any of its Subsidiaries shall engage, directly or indirectly, in any material respect in any line of business substantially different from the businesses conducted by Borrower immediately
prior to the Amendment Date. 
 5.7    Litigation. Borrower shall give prompt notice to Administrative Agent of
any litigation claiming in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00) from Borrower or any of its Subsidiaries, or which could reasonably be expected to have a Material Adverse Effect. 

5.8    Issue Taxes. Borrower and each of its Subsidiaries shall pay all taxes (other than taxes based upon or
measured by any Lender’s income or revenues or any personal property tax), if any, in connection with the issuance of the Notes and the recording of any lien documents. The obligations of Borrower hereunder shall survive the payment of
Borrower’s Obligations hereunder and the termination of this Agreement. 
 5.9    Bank Accounts. Borrower
and each of its Subsidiaries shall maintain its primary depository and disbursement account(s) with Administrative Agent. 

5.10    Employee Benefit Plans. Borrower and each of its Subsidiaries shall (a) fund all of its Pension
Plan(s) in a manner that will satisfy the minimum funding standards of Section 302 of ERISA, (b) furnish Administrative Agent, promptly upon Administrative Agent’s request, with copies of all reports or other statements filed with the
United States Department of Labor, the PBGC or the IRS with respect to all Pension Plan(s), or which Borrower, or any member of a Controlled Group, may receive from the United States Department of Labor, the IRS or the PBGC, with respect to all such
Pension Plan(s), and (c) promptly advise Administrative Agent of the occurrence of any reportable event (as defined in Section 4043 of ERISA, with respect to any Pension Plan, other than a reportable event for which the thirty (30)
day notice requirement has been waived by the PBGC) or a non-exempt prohibited transaction (under Section 406 of ERISA or Section 4975 of the Code) with respect to any such Pension Plan(s) and for
which Borrower or any of its Subsidiaries could reasonably be expected to incur a material liability, and the action which Borrower proposes to take with respect thereto. Borrower and each of its Subsidiaries will make all contributions when due
with respect to any multi-employer pension plan in which it participates and will promptly advise Administrative Agent upon (x) its receipt of notice of the assertion against Borrower or any of its Subsidiaries of a claim for withdrawal
liability, (y) the occurrence of any event which, to the best of Borrower’s knowledge, would trigger the assertion of a claim for withdrawal liability against Borrower or any of its Subsidiaries, and (z) upon the occurrence of any
event which, to the best of Borrower’s knowledge, would be reasonably expected to trigger an indirect withdrawal liability (through a controlled group of which) Borrower or any of its Subsidiaries is a member under Title IV of ERISA, whether
liquidated or contingent. 

  
 -39- 

 5.11    New Subsidiaries. Each newly-created or newly-acquired
Domestic Subsidiary of Borrower shall, within fifteen (15) days of such creation or acquisition, become a party to the applicable Loan Documents by executing and delivering to the Administrative Agent a counterpart of a joinder agreement and
providing such other documentation as the Administrative Agent shall deem reasonably appropriate for such purpose, including, without limitation, amendments to the Security Documents or any other applicable Loan Document, and favorable opinions of
counsel to such Person (which shall cover, among other things, the legality, validity, binding effect and enforceability of, inter alia, the joinder agreement), all in form, content and scope reasonably satisfactory to the Administrative Agent. In
such event, the Administrative Agent is hereby authorized by the parties hereto to amend Schedule 4.9 to include each such new Subsidiary. 

5.12    Financial Covenants. Borrower shall maintain and comply with the following financial covenants: 

(a) Minimum Fixed Charge Coverage Ratio. Borrower, on a consolidated basis, shall maintain a Fixed Charge Coverage Ratio of not less
than 1.25 to 1.0, measured quarterly as of each Quarter End, on a trailing four (4) Quarter basis. Notwithstanding any other provision hereof, historical EBITDA generated by Borrower’s CTS Business shall not be considered part of
consolidated EBITDA beginning with the June 30, 2017 Quarter-End and thereafter. 
 (b)
Leverage Ratio. Borrower, on a consolidated basis, shall maintain a Leverage Ratio of not greater than 3.00 to 1.0, measured as of each Quarter End, on a trailing four (4) Quarter basis. Notwithstanding any other provision hereof,
historical EBITDA generated by Borrower’s CTS Business shall not be considered part of consolidated EBITDA beginning with the June 30, 2017 Quarter-End and thereafter. 

5.13    Minimum Unrestricted Cash. Borrower, on a consolidated basis, shall maintain at all times Unrestricted Cash
in an amount of at least Ten Million and 00/100 Dollars ($10,000,000.00). 
 5.14    Financial and Business
Information. Borrower shall deliver or cause to be delivered to Lender the following: 
 (a) Financial Statements and Collateral
Reports. Such data, reports, statements and information, financial or otherwise, as Lender may reasonably request, including, without limitation: 

(i)    within forty (40) days after the end of each Quarter, the consolidated and consolidating (if
applicable) income and cash flow statements of Borrower and its Subsidiaries for such Quarter and for the expired portion of the fiscal year ending with the end of such month, setting forth in comparative form the corresponding figures for the
corresponding periods of the previous fiscal year, and the consolidated and consolidating (if applicable) balance sheet of Borrower and its Subsidiaries as at the end of such Quarter, setting forth in comparative form the corresponding figures as at
the end of the corresponding periods of the previous fiscal year, all in reasonable detail and certified by Borrower’s chief executive officer or president to have been prepared from the books and records of Borrower; 

(ii)    within seventy-five (75) days after the end of each fiscal year of Borrower, the consolidated
and consolidating (if applicable) income and cash flow statements of Borrower and its Subsidiaries for such year, and the consolidated and consolidating (if applicable) 

  
 -40- 

 
balance sheet of Borrower and its Subsidiaries as at the end of such fiscal year, setting forth in each case in comparative form the corresponding figures as at the end of and for the previous
fiscal year, all in reasonable detail, including all supporting schedules, and audited by an independent public accounting firm acceptable to Administrative Agent, and unqualifiedly certified to have been prepared in accordance with GAAP, and such
independent public accountants shall also unqualifiedly certify that in making the examinations necessary to their certification mentioned above they have reviewed the terms of this Agreement and the accounts and conditions of Borrower during the
accounting period covered by the certificate and that such review did not disclose the existence of any condition or event which constitutes an Event of Default under Sections 5.12 and 5.13, together with copies of any management
letters provided by such accountants to management of Borrower; 
 (iii)    within fifteen (15) days
of the end of each Quarter, Borrower’s accounts receivable aging report, accounts payable aging report, inventory reports and such other reports as Administrative Agent reasonably deems necessary, certified by Borrower’s chief financial
officer as true and correct, all in form and substance reasonably satisfactory to Administrative Agent; and 

(iv)    within fifteen (15) days of filing with the applicable Government Authority, Borrower shall
furnish, or shall cause to be furnished, to Administrative Agent copies of the annual federal and state income tax returns of Borrower for the immediately preceding year; 

(b) Notice of Event of Default. Promptly upon becoming aware of the existence of any condition or event which constitutes a Default (if
the same is continuing) or an Event of Default under this Agreement, a written notice specifying the nature and period of existence thereof and what action Borrower is taking (and proposes to take) with respect thereto; 

(c) Notice of Claimed Default. Promptly upon receipt by Borrower, written notice of default given to Borrower by any creditor for
Indebtedness for borrowed money with an aggregate amount in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00), otherwise holding long term Indebtedness of Borrower; and 

(d) Securities and Other Reports. If Borrower shall be required to file reports with the Securities and Exchange Commission pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, promptly upon its becoming available, one copy of each financial statement, report, notice or proxy statement sent by Borrower to stockholders generally, and a copy of
each regular or periodic report, and any registration statement, or prospectus in respect thereof, filed by Borrower with any securities exchange or with federal or state securities and exchange commissions or any successor agency. 

(e) FDA Actions. Borrower agrees to provide to Administrative Agent copies of all FDA warning letters and FDA Form 483 notices promptly
after Borrower’s receipt. Thereafter, within five (5) days of filing with the FDA, Borrower shall furnish Administrative Agent copies of all responses filed by Borrower with the FDA in response to such warning letters and Form 483
notices. In addition, Borrower shall provide to Administrative Agent a written status report at least once each Quarter of Borrower’s plan to remediate the matters raised by the FDA in any warning letter or Form 483 notice and
Borrower’s progress toward accomplishing such remediation. 

  
 -41- 

 5.15    Officers’ Certificates. Along with the set
of financial statements delivered to Administrative Agent at the end of each fiscal quarter pursuant to Section 5.14(a)(i) and the annual financial statements delivered pursuant to
Section 5.14(a)(ii), Borrower shall deliver to Administrative Agent a certificate (“Covenant Compliance Certificate”) (in the form of Exhibit E) from the chief financial officer, chief executive
officer or president of Borrower (and as to certificates accompanying the annual financial statements of Borrower, also certified by Borrower’s independent certified public accountant) setting forth: 

(a) Event of Default. That the signer has reviewed the relevant terms of this Agreement, and has made (or caused to be made under
his/her supervision) a review of the transactions and conditions of Borrower from the beginning of the accounting period covered by the financial statements being delivered therewith to the date of the certificate, and that such review has not
disclosed the existence during such period of any condition or event which constitutes a Default or an Event of Default or, if any such condition or event exists, specifying the nature and period of existence thereof and what action Borrower has
taken or proposes to take with respect thereto. 
 (b) Covenant Compliance. The information (including detailed calculations)
required in order to establish that Borrower is in compliance with the requirements of Section 5.14 as of the end of the period covered by the financial statements delivered. 

5.16    Audits and Inspection; Appraisals. Borrower shall permit any of Administrative Agent’s officers or
other representatives to visit and inspect on one (1) occasion during any twelve (12)-month period (unless an Event of Default has occurred and is continuing in which case such limitation shall not be applicable) upon reasonable notice during
business hours any of the locations of Borrower and each of its Subsidiaries (provided that, while an Event of Default exists, Administrative Agent may make such visits and inspections at any time without prior notice) to examine and audit all of
Borrower’s Property, books of account, records, reports and other papers, to make copies and extracts therefrom and to discuss its affairs, finances and accounts with its officers, employees and independent certified public accountants all at
Borrower’s expense at the standard rates charged by Administrative Agent for such activities (including with respect to any field examinations), plus Administrative Agent’s reasonable out-of-pocket expenses (all of which amounts shall be Expenses). Administrative Agent may, in its discretion (but with the approval of the Required Lenders), require Inventory appraisals if an Event of
Default exists, at Borrower’s sole cost and expense. Appraisals shall be done by an appraiser reasonably acceptable to Administrative Agent and shall be in form and substance satisfactory to Administrative Agent. 

5.17    Tax Returns, Financial Statements and Other Reports. Borrower further agrees that, if requested by
Administrative Agent, it shall promptly furnish Administrative Agent with copies of all reports filed with any federal, state or local Governmental Authority. 

5.18    Information to Participant. Administrative Agent may divulge to any participant, assignee or co-lender or prospective participant, assignee or co-lender it may obtain in the Revolving Credit or Term Loan or any portion thereof, all information, and furnish to such
Person copies of any reports, financial statements, certificates, and documents obtained under any provision of this Agreement, or related agreements and documents, subject to Section 9.23. 

5.19    Material Adverse Developments. Borrower agrees that promptly upon becoming aware of any development or
other information outside the ordinary course of business and excluding matters of a general economic, financial or political nature which would reasonably be expected to have a Material Adverse Effect it shall give to Administrative Agent notice
specifying the nature of such development or information and such anticipated effect. 

  
 -42- 

 5.20    Places of Business. Borrower shall give thirty (30) days
prior written notice to Administrative Agent of any changes in the location of any of Borrower’s or any of its Subsidiaries’ respective places of business, of the places where records concerning its Accounts or where its Inventory are
kept, or the establishment of any new, or the discontinuance of any existing place of business; provided that Borrower may not establish its principal place of business outside of the United States. 

5.21    Commercial Tort Claims. Borrower will immediately notify Administrative Agent in writing in the event that
Borrower or any its Subsidiaries becomes a party to or obtains any rights with respect to any Commercial Tort Claim with a value in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00). Such notification shall include information
sufficient to describe such Commercial Tort Claim, including, but not limited to, the parties to the claim, the court in which the claim was commenced, the docket number assigned to such claim, if any, and a detailed explanation of the events that
gave rise to the claim. Borrower shall execute and deliver to Administrative Agent all documents and/or agreements necessary to grant Administrative Agent a security interest in such Commercial Tort Claim to secure the Obligations. Borrower
authorizes Administrative Agent to file (without Borrower’s signature) initial financing statements or amendments, as Administrative Agent deems necessary to perfect its security interest in the Commercial Tort Claim. 

5.22    Letter of Credit Rights. Borrower shall provide Administrative Agent with written notice of any letters of
credit with a value in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00) for which Borrower or any of its Subsidiaries is the beneficiary. Borrower shall execute and deliver (and use commercially reasonable efforts to cause to be
executed or delivered) to Administrative Agent all documents and agreements as Administrative Agent may request in order to obtain and perfect its security interest in such Letter of Credit Rights. 

5.23    Cross-Default. THE LOANS CONTEMPLATED BY THIS AGREEMENT SHALL BE CROSS-DEFAULTED WITH ALL OTHER EXISTING
AND FUTURE NOTES AND OTHER LOAN DOCUMENTS FROM BORROWER TO ANY LENDER (COLLECTIVELY, THE “ADDITIONAL LOAN DOCUMENTS”), WHEREBY (a) AN EVENT OF DEFAULT UNDER ANY OF THE ADDITIONAL LOAN DOCUMENTS SHALL BE DEEMED AN EVENT OF
DEFAULT UNDER THIS AGREEMENT AND ALL LOAN DOCUMENTS, AND (b) AN EVENT OF DEFAULT UNDER THIS AGREEMENT OR ANY LOAN DOCUMENTS SHALL BE DEEMED AN EVENT OF DEFAULT UNDER ALL ADDITIONAL LOAN DOCUMENTS. 

SECTION 6 
 BORROWER’S
NEGATIVE COVENANTS 
 Borrower covenants that until all of the Obligations due under the Loan Documents are paid and satisfied in full and
the Revolving Credit has been terminated, that: 
 6.1    Mergers, Consolidation, and Acquisitions. 

(a) Neither Borrower nor any Subsidiary shall merge, dissolve, liquidate, consolidate with or into another Person or make an Asset Sale of
(whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, or acquire all or substantially all of the assets or more than fifty percent
(50%) of the Capital Stock of any other Person (or other interest that would require consolidation of the acquired Person with the Borrower under GAAP). 

  
 -43- 

 (b) At all times prior to the Spread Adjustment Date, neither Borrower nor any Subsidiary shall
acquire all or substantially all of the assets or more than fifty percent (50%) of the Capital Stock of any other Person (or other interest that would require consolidation of the acquired Person with the Borrower under GAAP), without the prior
written consent of the Required Lenders. Notwithstanding Section 6.1(a), Borrower or a Subsidiary may, after the Spread Adjustment Date, acquire all or substantially all the assets of a Person or line of business of such
Person, or not less than fifty-one percent (51%) of the Capital Stock of a Person (referred to herein as the “Acquired Entity”); provided that, with respect to any such transaction: 

(i)    at the time of such acquisition, no Default or Event of Default has occurred and is continuing, and
such acquisition will not otherwise create a Default or an Event of Default hereunder; 
 (ii)    in any
merger or consolidation, the surviving Person shall be either Borrower or a Subsidiary; 
 (iii)    the
business to be acquired is predominantly in the same line of business as Borrower, or in businesses reasonably related or incidental thereto; 

(iv)    the board of directors and (if required by applicable law) the shareholders, or the equivalent of
each thereof, of the business to be acquired have approved such acquisition as evidenced by written resolutions or consents evidencing such approval; 

(v)    (A) in the case of an asset acquisition, all of the assets acquired shall be acquired by Borrower or
by a Domestic Subsidiary, and such Domestic Subsidiary shall, within fifteen (15) days thereafter (or such longer period approved by the Administrative Agent), become a Guarantor hereunder in accordance with
Section 5.11, if it is not already a Guarantor, and shall pledge (or cause to be pledged) all of its assets to the Administrative Agent for the benefit of Lenders or (B) in the case of an acquisition of one hundred
percent (100%) of the Capital Stock of the acquired company, such acquired company shall, within fifteen (15) days thereafter (or such longer period approved by the Administrative Agent), become a Guarantor in accordance with
Section 5.11 and shall grant a first priority security interest (or cause to be granted a first priority security interest) in all of its assets to the Administrative Agent for the benefit of the Lenders, or such acquired
company shall be merged with and into Borrower or a Guarantor (which shall be the surviving entity) and (C) in all such cases, such Person shall otherwise comply with the provisions of Section 5.11 and the other
provisions of this Agreement; and 
 (vi)    the cash consideration to be paid by Borrower or the
applicable Domestic Subsidiary in connection with any acquisition or series of related acquisitions (including in such cash consideration any deferred cash payments, contingent or otherwise, and the aggregate amount of all liabilities (including
Indebtedness) assumed or, in the case of an acquisition of the Capital Stock of the acquisition target, including all liabilities (including Indebtedness) of such acquisition target shall not exceed the Maximum Acquisition and Investment Amount (any
acquisition of an Acquired Entity meeting all the criteria of this Section 6.1(b) being referred to as a “Permitted Acquisition”). 

  
 -44- 

 6.2    Dispositions. Neither Borrower nor any of its Subsidiaries
shall make any Disposition or enter into any agreement to make any Disposition, except: 
 (a) Dispositions of obsolete, abandoned, or worn
out or no longer useful property, whether now owned or hereafter acquired, in the ordinary course of business; 
 (b) Dispositions of
Inventory in the ordinary course of business; 
 (c) casualty events or condemnations to the extent such events are deemed to constitute
Dispositions; 
 (d) compromise and settlement of accounts receivable of disputed accounts and accounts of insolvent customers to the extent
such compromise and settlement is made in the ordinary course of business in amounts; 
 (e) Dispositions of accounts receivable for
purposes of collection in the ordinary course of business; 
 (f) the termination of any lease, sublease, license or sublicense of real
estate to which Borrower or any Subsidiary is party to the extent such real estate is no longer required by such Person in the ordinary course of its business, or the termination of any such lease, sublease, license or sublicense at the end of its
applicable term; 
 (g) Dispositions pursuant to Standard Outbound IP Agreements; or 

(h) other Dispositions of property with an aggregate value not to exceed Five Hundred Thousand and 00/100 Dollars ($500,000.00) during any
calendar year. 
 6.3    Liens and Encumbrances. Neither Borrower nor any of its Subsidiaries shall:
(a) execute a negative pledge agreement with any Person covering any of its Property, or (b) cause or permit or agree or consent to cause or permit in the future (upon the happening of a contingency or otherwise), its Property (including,
without limitation, the Collateral), whether now owned or hereafter acquired, to be subject to a Lien or be subject to any claim except for Permitted Liens. 

6.4    Transactions With Affiliates. 

(a) Borrower shall not enter into any transaction with any Affiliate, including, without limitation, the purchase, sale, or exchange of
Property, or the loaning or giving of funds to any Affiliate unless: (i) such Affiliate is engaged in a business substantially related to the business conducted by Borrower and the transaction is in the ordinary course of and pursuant to the
reasonable requirements of Borrower’s business and upon terms substantially the same and no less favorable to Borrower as it would obtain in a comparable arm’s length transactions with any Person not an Affiliate, and so long as such
transaction is not prohibited hereunder; (ii) such Affiliate is a Subsidiary (other than RTI Donor Services); (iii) such transaction is the issuance of the Preferred Stock to WSHP Biologics Holdings pursuant to the Preferred Stock Investment
Agreement and the other transactions contemplated by the Waterstreet Agreements; or (iv) such transaction is intended for incidental administrative purposes. 

(b) Borrower shall not create or acquire any Subsidiary except (i) as otherwise provided in this Agreement or (ii) in compliance
with Section 5.11. 

  
 -45- 

 6.5    Indebtedness/Guarantees. Excepting the endorsement in the
ordinary course of business of negotiable instruments for deposit or collection, neither Borrower nor any of its Subsidiaries shall become or be liable, directly or indirectly, primary or secondary, matured or contingent, in any manner, whether as
borrower, primary obligor, guarantor, surety, accommodation maker, or otherwise, for the existing or future Indebtedness of any kind of any Person, other than Permitted Indebtedness. 

6.6    Distributions, Bonuses and Other Indebtedness. 

(a)    Except for Distributions by any Subsidiary of Borrower to Borrower or a Domestic Subsidiary of
Borrower and except as set forth in clauses (b) and (c) below, Borrower shall not: (i) declare or pay or make any forms of Distribution to holders of Borrower’s Capital Stock (other than the borrower’s Preferred Stock); (ii) make
any voluntary cash payment of any Distribution on Borrower’s Preferred Stock; (iii) declare or pay any bonus compensation to its officers if an Event of Default exists or would result from the payment thereof; (iv) hereafter incur or
become liable for any Indebtedness other than Permitted Indebtedness; or (v) make any payments on Subordinated Debt. 

(b)    Notwithstanding the provisions of Section 6.6(a) above, Borrower shall
have the right to make Distributions or payments: (i) to holders of Borrower’s Capital Stock upon the prior written consent of the Required Lenders; (ii) subject to Section 6.6(c) on the Preferred Stock in
accordance with the Preferred Stock Certificate of Designation, so long as in the case of any voluntary cash Distributions under the Certificate of Designations (A) no Event of Default has occurred and is continuing and (B) no Event of
Default will result from such Distribution and (iii) on Subordinated Debt, if any, but only to the extent permitted by the applicable Subordination Agreement. 

(c)    Notwithstanding the provisions in Section 6.6(a) above, Borrower may make
voluntary cash Distributions on the Preferred Stock under the Certificate of Designations if (i) the Spread Adjustment Date shall have occurred and (ii) the Borrower’s Leverage Ratio at a Quarter End immediately preceding the making
of such Distribution measured both (A) on historical results as of such Quarter End and (B) on a pro forma basis (after giving effect to the contemplated Distributions) as of such Quarter End is 2.50 to 1.00 or less. 

6.7    Loans and Investments. Neither Borrower nor any of its Subsidiaries shall make or have outstanding loans,
advances, extensions of credit or capital contributions to, or investments in, any Person other than: (a) Permitted Investments; (b) Standard Inbound IP Agreements; (c) loans to Borrower or to Subsidiaries of Borrower;
(d) Investments otherwise permitted under Section 6.1(b); (e) loans to employees of Borrower and its Subsidiaries existing on the Closing in an aggregate amount of less than One Million and 00/100 Dollars
($1,000,000.00); and (f) Permitted Capital Stock Investment so long as the cash consideration to be paid by Borrower or the applicable Subsidiary in connection with such Permitted Capital Stock Investment does not exceed the Maximum Acquisition
and Investment Amount; provided, Borrower shall grant to Administrative Agent a first priority security interest in the Capital Stock acquired as part of such Permitted Capital Stock Investment. 

6.8    Use of Name of Lenders. Neither Borrower nor any of its Subsidiaries shall use Administrative
Agent’s or any Lender’s name in connection with any of its business operations. Nothing herein contained is intended to permit or authorize Borrower to make any contract on behalf of Administrative Agent or any Lender. 

  
 -46- 

 6.9    Miscellaneous Covenants. 

(a) Neither Borrower nor any of its Subsidiaries shall become a party to any contract or agreement which at the time of becoming a party to
such contract or agreement would (i) invalidate any of the Loan Documents or (ii) cause an Event of Default under Sections 5.12 or 5.13 (as measured as of the time of becoming a party to such contract or agreement). 

(b) Neither Borrower nor any of its Subsidiaries shall carry or purchase any “margin stock” within the meaning of Regulations U, T
or X of the Board of Governors of the Federal Reserve System, 12 C.F.R., Chapter II. 
 6.10    Jurisdiction of
Organization. Borrower shall not change its jurisdiction of organization. 
 6.11    Preferred Stock.
Borrower shall not amend its Certificate of Incorporation, including, without limitation, the Preferred Stock Certificate of Designation, as in effect on July 16, 2013 in a manner materially adverse to any Lender. 

SECTION 7 
 DEFAULT 

7.1    Events of Default. Each of the following events shall constitute an event of default (each, an
“Event of Default”): 
 (a) Payments. If Borrower fails to make any payment of principal or interest under the
Obligations within three (3) Business Days of the date such payment is due and payable; or 
 (b) Other Charges. If Borrower
fails to pay any other charges, fees, Expenses or other monetary obligations owing to Lenders arising out of or incurred in connection with this Agreement within three (3) Business Days of the date such payment is due and payable; or 

(c) Loan Document Defaults. If Borrower or any other Person (other than any Lender) party to a Loan Document fails to perform, comply
with or observe any covenant or undertaking contained in any Loan Document and (other than with respect to the covenants contained in Sections 5.11 and 5.12 and Section 6 (excluding
Section 6.9(a)) for which no cure period shall exist), such failure continues for fifteen (15) days (or in the case of Section 6.9(a), thirty (30) days) after a responsible officer of
Borrower has actual knowledge thereof; or 
 (d) Uninsured Loss. If there shall occur any uninsured damage to or loss, theft, or
destruction in excess of Two Million and 00/100 Dollars ($2,000,000.00) in the aggregate with respect to any portion of any Property of Borrower; or 

(e) Warranties or Representations and Financial Statements. If any warranty, representation or other statement by or on behalf of
Borrower contained in or pursuant to this Agreement, the other Loan Documents or in any document statement, report, financial statement, certificate, agreement or instrument furnished in compliance with, relating to, or in reference to this
Agreement, is false, erroneous, or misleading in any material respect when made; or 
 (f) Agreements with Others. (i) If
Borrower shall default beyond any grace period in the payment of principal or interest of any Indebtedness of Borrower with a principal amount in excess of Five Hundred Thousand and 00/100 Dollars ($500,000.00); or (ii) if Borrower otherwise
defaults under the terms of any such Indebtedness if the effect of any such default is to enable the holder of such Indebtedness to accelerate the payment of Borrower’s obligations, which are the subject thereof, prior to the maturity date or
prior to the regularly scheduled date of payment; or 

  
 -47- 

 (g) Other Agreements with Lender. If Borrower breaches or violates the terms of, or if a
default (and expiration of any applicable cure period), or an Event of Default, occurs under, any Interest Hedging Instrument or any other existing or future agreement (related or unrelated) (including, without limitation, the other Loan Documents)
between Borrower and Lender; or 
 (h) Judgments. If any final judgment for the payment of money in excess of One Million and 00/100
Dollars ($1,000,000.00) in the aggregate (i) which is not paid or fully covered by insurance or (ii) for which Borrower has not established a cash or cash equivalent reserve in the full amount of such judgment, shall be rendered by a court
of record against Borrower and such judgment shall continue unsatisfied and in effect for a period of thirty (30) consecutive days without being vacated, discharged, satisfied or bonded pending appeal; or 

(i) Assignment for Benefit of Creditors. If Borrower makes or proposes in writing, an assignment for the benefit of creditors
generally, offers a composition or extension to creditors, or makes or sends notice of an intended bulk sale of any business or assets now or hereafter owned or conducted by Borrower; or 

(j) Bankruptcy, Dissolution. Upon the commencement of any action for the dissolution or liquidation of Borrower, or the commencement of
any proceeding to avoid any transaction entered into by Borrower, or the commencement of any case or proceeding for reorganization or liquidation of Borrower’s debts under the Bankruptcy Code or any other state or federal law, now or hereafter
enacted for the relief of debtors, whether instituted by or against Borrower; provided however, that Borrower shall have thirty (30) days to obtain the dismissal or discharge of involuntary proceedings filed against it, it being understood that
during such thirty (30) day period, Lender shall not be obligated to make Advances hereunder and Lender may seek adequate protection in any bankruptcy proceeding; or 

(k) Receiver. Upon the appointment of a receiver, liquidator, custodian, trustee or similar official or fiduciary for any Borrower or
for Borrower’s Property; or 
 (l) Termination of Business. If Borrower ceases any material portion of its business operations
as presently conducted; or 
 (m) Pension Benefits. If Borrower fails to comply with ERISA so that proceedings are commenced to
appoint a trustee under ERISA to administer Borrower’s employee plans or the PBGC institutes proceedings to appoint a trustee to administer such plan(s), or a Lien is entered against the Borrower to secure any funding deficiency or claim or a
“reportable event” as defined under ERISA occurs (for which notice has not been waived by the PBGC) and any such event or occurrence that results in a Material Adverse Effect; or 

(n) Investigations. Borrower has engaged in any type of activity which results in the forfeiture of any material property of Borrower
to any governmental entity, federal, state or local; or 
 (o) Change of Control. If there shall occur a Change of Control; or 

(p) Liens. If any Lien in favor of Lender on a material part of the Collateral shall cease to be valid, enforceable and perfected and
prior to all other Liens other than Permitted Liens or if Borrower or any Governmental Authority shall assert any of the foregoing. 

  
 -48- 

 7.2    Rights and Remedies on Default. 

(a) In addition to all other rights, options and remedies granted or available to Administrative Agent on behalf of Lenders under this
Agreement or the Loan Documents (each of which is also then exercisable by Administrative Agent at the direction of the Required Lenders), or otherwise available at law or in equity, upon or at any time after the occurrence and during the
continuance of a Default or an Event of Default, each Lender may, in its discretion, withhold or cease making Advances under the Revolving Credit. 

(b) In addition to all other rights, options and remedies granted or available to Administrative Agent on behalf of Lenders under this
Agreement or the Loan Documents (each of which is also then exercisable by Administrative Agent on behalf of Lenders at the direction of the Required Lenders), or otherwise available at law or in equity, upon or at any time after the occurrence and
during the continuance of an Event of Default Administrative Agent on behalf of Lenders, upon the request and at the direction of the Required Lenders, shall terminate the Revolving Credit and declare the Obligations (other than any Obligations
arising under an Interest Hedging Instrument) immediately due and payable, all without demand, notice, presentment or protest or further action of any kind (it also being understood that the occurrence of any of the events or conditions set forth in
Sections 7.1(i), (j) or (k) shall automatically cause an acceleration of the Obligations (other than any Obligations arising under an Interest Hedging Instrument). 

(c) In addition to all other rights, options and remedies granted or available to Lenders under this Agreement or the Loan Documents (each of
which is also then exercisable by Administrative Agent on behalf of Lenders), or otherwise available at law or in equity, upon or at any time after the acceleration of the Obligations following the occurrence of an Event of Default, upon
Administrative Agent’s request, with the approval of the Required Lenders, Borrower shall establish a lockbox with Administrative Agent through which Borrower and its Subsidiaries shall instruct all Account Debtors to make payment on Accounts.
Borrower shall execute such agreements as Administrative Agent may require, to establish the lockbox. 
 (d) In addition to all other
rights, options and remedies granted or available to Lenders under this Agreement or the Loan Documents (each of which is also then exercisable, at the direction of the Required Lenders, by Administrative Agent on behalf of Lenders), or otherwise
available at law or in equity, upon or at any time after the acceleration of the Obligations following the occurrence and continuation of an Event of Default (other than the rights with respect to clause (iv) below which Administrative Agent
may, and upon the request of the Required Lenders shall, exercise at any time after an Event of Default and regardless of whether there is an acceleration), Administrative Agent may, and upon the request of the Required Lenders shall, exercise all
rights under the UCC and any other applicable law or in equity, and under all Loan Documents permitted to be exercised after the occurrence of an Event of Default, including the following rights and remedies (which list is given by way of example
and is not intended to be an exhaustive list of all such rights and remedies): 
 (i)    The right to
take possession of, send notices regarding and collect directly the Collateral, with or without judicial process (including without limitation the right to notify the United States postal authorities to redirect mail addressed to Borrower to an
address designated by Administrative Agent); or 
 (ii)    By its own means or with judicial assistance,
enter Borrower’s premises and take possession of the Collateral, or render it unusable, or dispose of the Collateral on such premises in compliance with subsection (e) below, without any liability for rent, storage, utilities or other
sums, and Borrower shall not resist or interfere with such action; or 

  
 -49- 

 (iii)    Require Borrower at Borrower’s expense to
assemble all or any part of the Collateral (other than real estate or fixtures) and make it available to Administrative Agent at any place designated by Administrative Agent; or 

(iv)    The right to reduce or modify the Maximum Revolving Credit Limit or to modify the terms and
conditions upon which Lender may be willing to consider making Advances under the Revolving Credit or to take additional reserves against the Revolving Credit; or 

(v)    The right to enjoin any violation of Section 7.1, it being agreed that
each Lender’s remedies at law are inadequate. 
 (e) Borrower hereby agrees that a notice received by it at least seven (7) days
before the time of any intended public sale or of the time after which any private sale or other disposition of the Collateral is to be made, shall be deemed to be reasonable notice of such sale or other disposition. If permitted by applicable law,
any perishable inventory or Collateral which threatens to speedily decline in value or which is sold on a recognized market may be sold immediately by Administrative Agent on behalf of Lender without prior notice to Borrower. Borrower covenants and
agrees not to interfere with or impose any obstacle to Administrative Agent’s exercise of its rights and remedies with respect to the Collateral, after the occurrence of an Event of Default hereunder. Administrative Agent shall have no
obligation to clean up or prepare the Collateral for sale. If Administrative Agent sells any of the Collateral upon credit, Borrower will only be credited with payments actually made by the purchaser thereof, that are received by Administrative
Agent on behalf of Lenders. Administrative Agent may, in connection with any sale of the Collateral specifically disclaim any warranties of title or the like. 

(f) In addition to all other rights, options and remedies granted or available to Administrative Agent on behalf of Lenders under this
Agreement or the Loan Documents (each of which is also then exercisable by Administrative Agent), or otherwise available at law or in equity, upon or at any time after the occurrence and during the continuance of an Event of Default, Borrower shall
not make any Distribution on the Preferred Stock (or any other Capital Stock of Borrower) without the prior written consent of the Required Lenders. 

7.3    Nature of Remedies. All rights and remedies granted Administrative Agent on behalf of Lenders under this
Agreement and under the Loan Documents, or otherwise available at law or in equity, shall be deemed concurrent and cumulative, and not alternative remedies, and Administrative Agent may proceed, and upon the request of the Required Lenders shall
proceed, with any number of remedies at the same time until all Obligations are satisfied in full. The exercise of any one right or remedy shall not be deemed a waiver or release of any other right or remedy, and Lender, upon or at any time after
the occurrence of an Event of Default, may proceed against Borrower, at any time, under any agreement, with any available remedy and in any order. 

7.4    Set-Off. In addition to all other rights, options and remedies
granted or available to Administrative Agent on behalf of Lenders under this Agreement or the Loan Documents (each of which is also then exercisable by Lender), upon or at any time after the occurrence and during the continuance of an Event of
Default, Administrative Agent on behalf of Lenders (and any participant) shall have and be deemed to have, without notice to Borrower, the immediate right of set-off against any bank account of Borrower with
any Lender, or of Borrower with any other subsidiary of Lenders or Bank Affiliate or any participant and may apply the funds or amount thus set-off against any of Borrower’s Obligations hereunder. If any
bank account of Borrower with any Lender, any other subsidiary of such Lender or any Bank Affiliate or any participant is attached or otherwise liened or levied upon by any third party, such Lender (and such participant) shall have and be deemed to
have, without notice to Borrower, the immediate right of set-off and may apply the funds or amount thus set-off against any of Borrower’s Obligations hereunder.

  
 -50- 

 SECTION 8 

ADMINISTRATIVE AGENT 

8.1    Appointment. Lenders hereby irrevocably designate and appoint Administrative Agent as administrative agent
to act as specified herein and in the other Loan Documents. Each Lender hereby irrevocably authorizes, and each holder of any Note by the acceptance of such Note shall be deemed irrevocably to authorize, the Administrative Agent to take such action
on its behalf under the provisions of this Agreement, the other Loan Documents and any other instruments and agreements referred to herein or therein and to exercise such powers and to perform such duties hereunder and thereunder as are specifically
delegated to or required of the Administrative Agent by the terms hereof and thereof and such other powers as are reasonably incidental thereto. The Administrative Agent may perform any of its respective duties hereunder by or through its officers,
directors, agents, employees or affiliates. 
 8.2    Nature of Duties. 

(a) The Administrative Agent, the Joint Lead Arrangers, and the Book Runners shall not have any duties or responsibilities except those
expressly set forth in this Agreement and in the other Loan Documents. Neither the Administrative Agent nor any of its officers, directors, agents, employees or affiliates shall be liable for any action taken or omitted by it or them hereunder or
under any other Loan Document or in connection herewith or therewith, unless caused by its or their gross negligence or willful misconduct (as determined by a court of competent jurisdiction in a final and
non-appealable decision). The duties of the Administrative Agent shall be mechanical and administrative in nature; the Administrative Agent shall not have by reason of this Agreement or any other Loan Document
a fiduciary relationship in respect of any Lender or the holder of any Note; and nothing in this Agreement or in any other Loan Document, expressed or implied, is intended to or shall be so construed as to impose upon the Administrative Agent any
obligations in respect of this Agreement or any other Loan Document except as expressly set forth herein or therein. 
 (b) Notwithstanding
any other provision of this Agreement or any provision of any other Loan Document, each Joint Lead Arranger is named as such for recognition purposes only, and in its capacity as such shall have no powers, duties, responsibilities or liabilities
with respect to this Agreement or the other Loan Documents or the transactions contemplated hereby and thereby; it being understood and agreed that each Arranger shall be entitled to all indemnification and reimbursement rights in favor of the
Administrative Agent as, and to the extent, provided for under Section 8.6. Without limitation of the foregoing, each Joint Lead Arranger shall not, solely by reason of this Agreement or any other Loan Documents, have any
fiduciary relationship in respect of any Lender or any other Person. 
 8.3    Lack of Reliance on the Administrative
Agent. Independently and without reliance upon the Administrative Agent, each Lender and the holder of each Note, to the extent it deems appropriate, has made and shall continue to make (i) its own independent investigation of the financial
condition and affairs of Borrower and its Subsidiaries in connection with the making and the continuance of the Loans and the taking or not taking of any action in connection herewith and (ii) its own appraisal of the creditworthiness of
Borrower and its Subsidiaries and, except as expressly provided in this Agreement, the Administrative Agent shall not have any duty or responsibility, either initially or on a continuing basis, to provide any Lender or the holder of any Note with
any credit or other information with respect thereto, whether coming into its possession before the making of the Loans or at any time or times thereafter. Administrative Agent shall not be responsible to any Lender or the holder of any Note for any
recitals, statements, information, representations or warranties herein or in any document, certificate or 

  
 -51- 

 
other writing delivered in connection herewith or for the execution, effectiveness, genuineness, validity, enforceability, perfection, collectibility, priority or sufficiency of this Agreement or
any other Loan Document or the financial condition of Borrower or any of its Subsidiaries or be required to make any inquiry concerning either the performance or observance of any of the terms, provisions or conditions of this Agreement or any other
Loan Document, or the financial condition of Borrower or any of its Subsidiaries or the existence or possible existence of any Default or Event of Default. 

8.4    Certain Rights of the Administrative Agent. If the Administrative Agent requests instructions from the
Required Lenders with respect to any act or action (including failure to act) in connection with this Agreement or any other Loan Document, the Administrative Agent shall be entitled to refrain from such act or taking such action unless and until
the Administrative Agent shall have received instructions from the Required Lenders and the Administrative Agent shall not incur liability to any Lender by reason of so refraining. Without limiting the foregoing, neither any Lender nor the holder of
any Note shall have any right of action whatsoever against the Administrative Agent as a result of the Administrative Agent acting or refraining from acting hereunder or under any other Loan Document in accordance with the instructions of the
Required Lenders. 
 8.5    Reliance. The Administrative Agent shall be entitled to rely, and shall be fully
protected in relying, upon any note, writing, resolution, notice, statement, certificate, telex, teletype or telecopier message, cablegram, radiogram, order or other document or telephone message signed, sent or made by any Person that the
Administrative Agent believed to be the proper Person, and, with respect to all legal matters pertaining to this Agreement and any other Loan Document and its duties hereunder and thereunder, upon advice of counsel selected by the Administrative
Agent. 
 8.6    Indemnification. To the extent the Administrative Agent (or any affiliate thereof) is not
reimbursed and indemnified by the Borrower, the Lenders will reimburse and indemnify the Administrative Agent (and any affiliate thereof) in proportion to their respective “percentage” as used in determining the Required Lenders
(determined as if there were no Defaulting Lenders) for and against any and all liabilities, obligations, losses, damages, penalties, claims, actions, judgments, costs, expenses or disbursements of whatsoever kind or nature which may be imposed on,
asserted against or incurred by the Administrative Agent (or any affiliate thereof) in performing its duties hereunder or under any other Loan Document or in any way relating to or arising out of this Agreement or any other Loan Document; provided
that no Lender shall be liable for any portion of such liabilities, obligations, losses, damages, penalties, claims, actions, judgments, suits, costs, expenses or disbursements resulting from the Administrative Agent’s (or such
affiliate’s) gross negligence or willful misconduct (as determined by a court of competent jurisdiction in a final and non-appealable decision). 

8.7    Administrative Agent in Its Individual Capacity. With respect to its obligation to make Loans under this
Agreement, the Administrative Agent shall have the rights and powers specified herein for a “Lender” and may exercise the same rights and powers as though it were not performing the duties specified herein; and the term “Lender,”
“Required Lenders” or any similar terms shall, unless the context clearly indicates otherwise, include the Administrative Agent in its respective individual capacities. The Administrative Agent and its affiliates may accept deposits from,
lend money to, and generally engage in any kind of banking, investment banking, trust or other business with, or provide debt financing, equity capital or other services (including financial advisory services) to Borrower or any Affiliate of
Borrower (or any Person engaged in a similar business with Borrower or any Affiliate thereof) as if they were not performing the duties specified herein, and may accept fees and other consideration from Borrower or any Affiliate of Borrower for
services in connection with this Agreement and otherwise without having to account for the same to the Lenders. 

  
 -52- 

 8.8    Holders. Administrative Agent may deem and treat the payee of
any Note as the owner thereof for all purposes hereof unless and until a written notice of the assignment, transfer or endorsement thereof, as the case may be, shall have been filed with the Administrative Agent. Any request, authority or consent of
any Person who, at the time of making such request or giving such authority or consent, is the holder of any Note shall be conclusive and binding on any subsequent holder, transferee, assignee or endorsee, as the case may be, of such Note or of any
Note or Notes issued in exchange therefor. 
 8.9    Resignation by the Administrative Agent. 

(a) Administrative Agent may resign from the performance of all its respective functions and duties hereunder and/or under the other Loan
Documents at any time by giving fifteen (15) Business Days’ prior written notice to the Lenders and, unless a Default or an Event of Default then exists, Borrower. Such resignation shall take effect upon the appointment of a successor
Administrative Agent pursuant to clauses (b) and (c) below or as otherwise provided below. 
 (b) Upon any such notice of resignation
by the Administrative Agent, the Required Lenders shall appoint a successor administrative agent hereunder or thereunder who shall be a commercial bank or trust company reasonably acceptable to Borrower, which acceptance shall not be unreasonably
withheld or delayed (provided that Borrower’s approval shall not be required if an Event of Default then exists). 
 (c) If a successor
administrative agent shall not have been so appointed within such fifteen (15)-Business Day period, Administrative Agent, with the consent of Borrower (which consent shall not be unreasonably withheld or delayed, provided that Borrower’s
consent shall not be required if an Event of Default then exists), shall then appoint a successor administrative agent who shall serve as administrative agent hereunder or thereunder until such time, if any, as the Required Lenders appoint a
successor administrative agent as provided above. 
 (d) If no successor administrative agent has been appointed pursuant to clause
(b) or (c) above by the twentieth (20th) Business Day after the date such notice of resignation was given by Administrative Agent, Administrative Agent’s resignation shall nonetheless
become effective and the Required Lenders shall thereafter perform all the duties of Administrative Agent hereunder and/or under any other Loan Document until such time, if any, as the Required Lenders appoint a successor Administrative Agent as
provided above. 
 (e) Upon a resignation of Administrative Agent pursuant to this Section 8.9, the administrative
agent shall remain indemnified to the extent provided in this Agreement and the other Loan Documents and the provisions of this Section 8 (and the analogous provisions of the other Loan Documents) shall continue in effect
for the benefit of the Administrative Agent for all of its actions and inactions while serving as the Administrative Agent. 

8.10    Collateral Matters. 

(a) Each Lender authorizes and directs the Administrative Agent to enter into the Security Documents for the benefit of the Lenders. Each
Lender hereby agrees, and each holder of any Note by the acceptance thereof will be deemed to agree, that, except as otherwise set forth herein, any action taken by the Required Lenders in accordance with the provisions of this Agreement or the
Security Documents, and the exercise by the Required Lenders of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Lenders. The Administrative
Agent is hereby authorized on behalf of all of the Lenders, without the necessity of any notice to or further consent from any Lender, from time to time prior to an Event of 

  
 -53- 

 
Default, to take any action with respect to any Collateral or Security Documents which may be necessary to perfect and maintain perfected the security interest in and liens upon the Collateral
granted pursuant to the Security Documents. 
 (b) The Lenders hereby authorize the Administrative Agent, at its option and in its
discretion, to release any Lien granted to or held by the Administrative Agent upon any Collateral (i) upon termination of this Agreement and payment and satisfaction of all of the Obligations (other than inchoate indemnification obligations)
at any time arising under or in respect of this Agreement or the Loan Documents or the transactions contemplated hereby or thereby, (ii) constituting property being sold or otherwise disposed of (to Persons other than Borrower and its
Subsidiaries) upon the sale or other disposition thereof in compliance with this Agreement, (iii) if approved, authorized or ratified in writing by the Required Lenders or as otherwise may be expressly provided in the relevant documentation
granting such Lien. 
 (c) Administrative Agent shall have no obligation whatsoever to the Lenders or to any other Person to assure that the
Collateral exists or is owned by Borrower or any of its Subsidiaries or is cared for, protected or insured or that the Liens granted to the Administrative Agent herein or pursuant hereto have been properly or sufficiently or lawfully created,
perfected, protected or enforced or are entitled to any particular priority, or to exercise or to continue exercising at all or in any manner or under any duty of care, disclosure or fidelity any of the rights, authorities and powers granted or
available to the Administrative Agent in this Section 8.10 or in any of the Security Documents, it being understood and agreed that in respect of the Collateral, or any act, omission or event related thereto, the
Administrative Agent may act in any manner it may deem appropriate, in its sole discretion, given the Administrative Agent’s own interest in the Collateral as one of the Lenders and that the Administrative Agent shall have no duty or liability
whatsoever to the Lenders, except for its gross negligence or willful misconduct (as determined by a court of competent jurisdiction in a final and non-appealable decision). 

(d) To the extent required by any applicable laws, the Administrative Agent may withhold from any payment to any Lender an amount equivalent
to any applicable withholding Tax. Each Lender shall indemnify and hold harmless the Administrative Agent against, and shall make payable in respect thereof within ten (10) days after demand therefor, any and all Taxes and any and all related
losses, claims, liabilities and expenses (including fees, charges and disbursements of any counsel for the Administrative Agent) incurred by or asserted against the Administrative Agent by the IRS or any other Governmental Authority as a result of
the failure of the Administrative Agent to properly withhold Tax from amounts paid to or for the account of such Lender for any reason (including, without limitation, because the appropriate form was not delivered or not properly executed, or
because such Lender failed to notify the Administrative Agent of a change in circumstance that rendered the exemption from, or reduction of withholding Tax ineffective). A certificate as to the amount of such payment or liability delivered to any
Lender by Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under this Agreement or any other Loan
Document against any amount due Administrative Agent under this Section 8.10(d). The agreements in this Section 8.10(d) shall survive the resignation and/or replacement of Administrative Agent, any
assignment of rights by, or the replacement of, a Lender, and the repayment, satisfaction or discharge of all other obligations. 

8.11    Delivery of Information. Administrative Agent shall not be required to deliver to any Lender originals or
copies of any documents, instruments, notices, communications or other information received by Administrative Agent from Borrower or any of its Subsidiaries, the Required Lenders, any Lender or any other Person under or in connection with this
Agreement or any other Loan Document except (i) as specifically provided in this Agreement or any other Loan Document and (ii) as specifically requested from time to time in writing by any Lender with respect to a specific document,
instrument, notice or other written communication received by and in the possession of Administrative Agent at the time of receipt of such request and then only in accordance with such specific request. 

  
 -54- 

 SECTION 9 

MISCELLANEOUS 

9.1    Governing Law. THIS AGREEMENT, AND ALL MATERS ARISING OUT OF OR RELATING TO THIS AGREEMENT, AND ALL RELATED
AGREEMENTS AND DOCUMENTS, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE SUBSTANTIVE LAWS OF THE STATE OF FLORIDA. THE PROVISIONS OF THIS AGREEMENT AND ALL OTHER AGREEMENTS AND DOCUMENTS REFERRED TO HEREIN ARE TO BE DEEMED
SEVERABLE, AND THE INVALIDITY OR UNENFORCEABILITY OF ANY PROVISION SHALL NOT AFFECT OR IMPAIR THE REMAINING PROVISIONS WHICH SHALL CONTINUE IN FULL FORCE AND EFFECT. 

9.2    Integrated Agreement. The Notes, the other Loan Documents, all related agreements, and this Agreement shall
be construed as integrated and complementary of each other, and as augmenting and not restricting Lenders’ rights and remedies. If, after applying the foregoing, an inconsistency still exists, the provisions of this Agreement shall constitute
an amendment thereto and shall control. 
 9.3    Waiver. No omission or delay by Lender in exercising any right
or power under this Agreement or any related agreements and documents will impair such right or power or be construed to be a waiver of any Default, or Event of Default or an acquiescence therein, and any single or partial exercise of any such right
or power will not preclude other or further exercise thereof or the exercise of any other right, and as to Borrower no waiver will be valid unless in writing and signed by Administrative Agent and Lenders and then only to the extent specified. 

9.4    Indemnity. 

(a) Borrower releases and shall indemnify, defend and hold harmless Administrative Agent and each Lender and each of its respective officers,
employees and agents, of and from any claims, demands, liabilities, obligations, judgments, injuries, losses, damages and costs and expenses (including, without limitation, reasonable legal fees) resulting from (i) acts or conduct of Borrower
under, pursuant or related to this Agreement and the other Loan Documents, (ii) Borrower’s breach or violation of any representation, warranty, covenant or undertaking contained in this Agreement or the other Loan Documents,
(iii) Borrower’s failure to comply with any Requirement of Law, and (iv) any claim by any other creditor of Borrower against Administrative Agent or any Lender arising out of any transaction whether hereunder or in any way related to
the Loan Documents and all costs, expenses, fines, penalties or other damages resulting therefrom, except to the extent resulting from acts or conduct of Administrative Agent or any Lender constituting willful misconduct or gross negligence. 

(b) Promptly after receipt by an indemnified party under Section 9.4(a) of notice of the commencement of any action
by a third party, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof. The omission so to notify the
indemnifying party shall relieve the indemnifying party from any liability which it may have to any indemnified party under such subsection only if the indemnifying party is unable to defend such actions as a result of such failure to so notify. In
case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish,
jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except with the 

  
 -55- 

 
consent of the indemnified party, be counsel to the indemnified party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof,
the indemnifying party shall not be liable to such indemnified party under Section 9.4(a) for any legal expenses of other counsel or any other expenses, in each case subsequently incurred by such indemnified party, in
connection with the defense thereof other than reasonable costs of investigation. 
 9.5    Time. Whenever
Borrower shall be required to make any payment, or perform any act, on a day which is not a Business Day, such payment may be made, or such act may be performed, on the next succeeding Business Day. Time is of the essence in Borrower’s
performance under all provisions of this Agreement and all related agreements and documents. 
 9.6    Expenses of
Lender. At Closing and from time to time thereafter, Borrower will pay, upon demand of Administrative Agent, all reasonable costs, fees and expenses of Administrative Agent and each Lender in connection with (a) the analysis, negotiation,
preparation, execution, administration, delivery and termination of this Agreement, and other Loan Documents and the documents and instruments referred to herein and therein, and any amendment, amendment and restatement, supplement, waiver or
consent relating hereto or thereto, whether or not any such amendment, amendment and restatement, supplement, waiver or consent is executed or becomes effective, search costs, the reasonable fees, expenses and disbursements of counsel for
Administrative Agent, any fees or expenses incurred by Administrative Agent or any Lender under Section 5.11 for which Borrower is obligated thereunder, and reasonable charges of any expert consultant to Administrative
Agent, (b) the enforcement of Administrative Agent’s and each Lender’s rights hereunder, or the collection of any payments owing from Borrower under this Agreement or the other Loan Documents or the protection, preservation or defense
of the rights of Administrative Agent and each Lender hereunder and under the other Loan Documents, and (c) any refinancing or restructuring of the credit arrangements provided under this Agreement and other Loan Documents in the nature of a “work-out” or of any insolvency or bankruptcy proceedings, or otherwise (including the reasonable fees and disbursements of counsel for Administrative Agent and, with respect to clauses (b) and (c),
reasonable allocated costs of internal counsel) (collectively, the “Expenses”). 

9.7    Brokerage. This transaction was brought about and entered into by Administrative Agent, Lenders and Borrower
acting as principals and without any brokers, agents or finders being the effective procuring cause hereof. Borrower represents that it has not committed Administrative Agent or any Lender to the payment of any brokerage fee, commission or charge in
connection with this transaction. If any such claim is made on Administrative Agent or any Lender by any broker, finder or agent or other person, Borrower hereby indemnifies, defends and saves such party harmless against such claim and further will
defend, with counsel satisfactory to Administrative Agent, any action or actions to recover on such claim, at Borrower’s own cost and expense, including such party’s reasonable counsel fees. Borrower further agrees that until any such
claim or demand is adjudicated in such party’s favor, the amount demanded shall be deemed an Obligation of Borrower under this Agreement. 

  
 -56- 

 9.8    Notices. 

(a) Any notices or consents required or permitted by this Agreement shall be in writing and shall be deemed given if delivered in person to the
person listed below or if sent by telecopy or by nationally recognized overnight courier, as follows, unless such address is changed by written notice hereunder: 
  

			
	If to Administrative Agent to:	  	TD Bank, N.A.
		  	2307 W. Kennedy Blvd.
		  	Tampa, Florida 33609
		  	Attention: Mike Nursey
		  	Telecopy No. 813-258-5623
		
	With copies to:	  	Rogers Towers, P.A.
		  	1301 Riverplace Blvd., Suite 1500
		  	Jacksonville, Florida 32207
		  	Attention: J. Kirby Chritton
		  	Telecopy No. 904-396-0663
		
	If to Lenders to:	  	To the addresses set forth on Exhibit A
		
	If to Borrower to:	  	RTI Surgical, Inc.
		  	11631 Research Circle
		  	Alachua, Florida 32015
		  	Attention: Chief Financial Officer
		  	Telecopy No. 386-418-0342
		
	With copies to:	  	RTI Surgical, Inc.
		  	11631 Research Circle
		  	Alachua, Florida 32015
		  	Attention: General Counsel
		  	Telecopy No. 386-418-0342

 (b) Any notice sent by Administrative Agent, any Lender, or Borrower by any of the above methods shall be
deemed to be given when so received. 
 (c) Administrative Agent and Lenders shall be fully entitled to rely upon any telecopy transmission
or other writing purported to be sent by any Authorized Officer (whether requesting an Advance or otherwise) as being genuine and authorized. 

9.9    Headings. The headings of any paragraph or Section of this Agreement are for convenience only and shall not
be used to interpret any provision of this Agreement. 
 9.10    Survival. All warranties, representations, and
covenants made by Borrower herein, or in any agreement referred to herein or on any certificate, document or other instrument delivered by it or on its behalf under this Agreement, shall be considered to have been relied upon by Administrative Agent
and Lenders, and shall survive the delivery to Lenders of the Notes, regardless of any investigation made by Administrative Agent or any Lender or on its behalf. All statements in any such certificate or other instrument prepared and/or delivered
for the benefit of Administrative Agent and Lenders shall constitute warranties and representations by Borrower hereunder. Except as otherwise expressly provided in this Agreement, all covenants made by Borrower hereunder or under any other
agreement or instrument shall be deemed continuing until all Obligations due under the Loan Documents are satisfied in full. All indemnification obligations under this Agreement shall survive the termination of this Agreement and payment of the
Obligations due under the Loan Documents for a period of two (2) years. 
 9.11    Successors and Assigns.
This Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties. Borrower may not transfer, assign or delegate any of its duties or obligations hereunder. Borrower acknowledges and agrees that any
Lender may at any 

  
 -57- 

 
time, and from time to time, (a) sell participating interests in the Loans, and Lender’s rights hereunder to other financial institutions, and (b) sell, transfer, or assign the
Loans and Lender’s rights hereunder, to any one or more additional banks or financial institutions, subject (as to Lender’s rights under this clause (b)) to Borrower’s written consent, which consent shall not be unreasonably withheld;
provided that, no consent under this clause (b) shall be required if an Event of Default exists at the time of such sale, transfer or assignment. 

9.12    Duplicate Originals. Two (2) or more duplicate originals of this Agreement may be signed by the
parties, each of which shall be an original but all of which together shall constitute one and the same instrument. 

9.13    Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and
no consent to any departure by Borrower or any Subsidiary therefrom, shall be effective unless in writing signed by the Required Lenders and Borrower or the applicable Subsidiary, as the case may be, and acknowledged by the Administrative Agent and
each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or consent shall: 

(a) extend, increase or decrease the Commitment of any Lender or reinstate any Commitment terminated pursuant to
Section 7.2(b) without the written consent of such Lender; 
 (b) postpone any date fixed by this Agreement or any
other Loan Document for any payment of principal, interest, fees or other amounts due to Lenders (or any of them) hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; 

(c) reduce the principal of, or the rate of interest specified herein on, any Loan or any fees or other amounts payable hereunder or under any
other Loan Document, without the written consent of each Lender directly affected thereby; provided, however, that only the consent of the Required Lenders shall be necessary to amend the definition of “Default Rate” or to waive any
obligation of Borrower to pay interest or any fees due hereunder at the Default Rate; 
 (d) change Section 2.19
in a manner that would alter the pro rata sharing of payments required thereby or the order of the application of payments thereunder, in each case, without the written consent of each Lender; 

(e) change any provision of this Section 9.13 or the definition of “Required Lenders” or any other
provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder without the written consent of each Lender; or 

(f) (i) release all or substantially all of the Collateral in any transaction or series of related transactions, (ii) release all or
substantially all of the Guarantors, (iii) subordinate the Obligations hereunder to any other Indebtedness, (iii) except as provided by operation of applicable law, subordinate the Liens on all or substantially all of the Collateral
granted in favor of the Administrative Agent for itself and the other Lenders under the Security Documents to any other Lien, in each case, without the written consent of each Lender; or 

  
 -58- 

 (g) unless also signed by Administrative Agent, no amendment, waiver or consent shall affect the
rights or duties of Administrative Agent under this Agreement or any other Loan Document; 
 provided, further, that notwithstanding anything
to the contrary herein, (i) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code of
the United States supersedes the unanimous consent provisions set forth herein and (ii) the Required Lenders shall determine whether or not to allow Borrower to use cash collateral in the context of a bankruptcy or insolvency proceeding and
such determination shall be binding on all of Lenders. 
 Notwithstanding any provision herein to the contrary, this Agreement may be amended with the
written consent of the Required Lenders, Administrative Agent and Borrower (i) to add one or more additional revolving credit or term loan facilities to this Agreement and to permit the extensions of credit and all related obligations and
liabilities arising in connection therewith from time to time outstanding to share ratably (or on a basis subordinated to the existing facilities hereunder) in the benefits of this Agreement and the other Loan Documents with the obligations and
liabilities from time to time outstanding in respect of the existing facilities hereunder, and (ii) in connection with the foregoing, to permit, as deemed appropriate by Administrative Agent and approved by the Required Lenders, Lenders
providing such additional credit facilities to participate in any required vote or action required to be approved by the Required Lenders or by any other number, percentage or class of Lenders hereunder. 

Notwithstanding any provision herein to the contrary Administrative Agent and Borrower may amend, modify or supplement this Agreement or any other Loan
Document to cure or correct administrative errors or omissions, any ambiguity, omission, defect or inconsistency or to effect administrative changes, and such amendment shall become effective without any further consent of any other party to such
Loan Document so long as (i) such amendment, modification or supplement does not adversely affect the rights of any Lender in any material respect and (ii) Lenders shall have received at least five Business Days’ prior written notice
thereof and Administrative Agent shall not have received, within five Business Days of the date of such notice to Lenders, a written notice from the Required Lenders stating that the Required Lenders object to such amendment. 

9.14    Signatories. Each individual signatory hereto represents and warrants that he is duly authorized to execute
this Agreement on behalf of his principal and that he executes the Agreement in such capacity and not as a party. 

9.15    Third Parties. No rights are intended to be created hereunder, or under any related agreements or documents
for the benefit of any third party donee, creditor or incidental beneficiary of Borrower. Nothing contained in this Agreement shall be construed as a delegation to Lender of Borrower’s duty of performance, including, without limitation,
Borrower’s duties under any account or contract with any other Person. 
 9.16    Discharge of Taxes,
Borrower’s Obligations. Lender, in its sole discretion, shall have the right at any time, and from time to time, with at least ten (10) days prior notice to Borrower if Borrower fail to do so, to: (a) pay for the
performance of any of Borrower’s obligations hereunder, and (b) discharge taxes or Liens, at any time levied or placed on Borrower’s Property in violation of this Agreement unless Borrower is in good faith with due diligence by
appropriate proceedings contesting such taxes or Liens and maintaining proper reserves therefor in accordance with GAAP. Expenses and advances shall be added to the Revolving Credit, and bear interest at the rate applicable to the Revolving Credit,
until reimbursed to Lender. Such payments and advances made by Lender shall not be construed as a waiver by Lender of a Default or Event of Default under this Agreement. 

  
 -59- 

 9.17    Consent to Jurisdiction. Borrower, Administrative Agent and
each Lender each hereby irrevocably consent to the non-exclusive jurisdiction of the Courts of the State of Florida or the United States District Court for the Middle District of Florida, Jacksonville Division
in any and all actions and proceedings whether arising hereunder or under any other agreement or undertaking. Borrower waives any objection which Borrower may have based upon lack of personal jurisdiction, improper venue or forum non conveniens.
Borrower irrevocably agrees to service of process by certified mail, return receipt requested to the address of the appropriate party set forth herein. 

9.18    Additional Documentation. Borrower shall execute and/or re-execute,
and cause any Guarantor or other Person party to any Loan Document, to execute and/or re-execute and to deliver to Administrative Agent or Administrative Agent’s counsel, as may be deemed appropriate, any
document or instrument signed in connection with this Agreement which was incorrectly signed, as well as any document or instrument which should have been signed at or prior to the Closing, but which was not so signed and delivered. Borrower agrees
to comply with any written request by Lender within ten (10) days after receipt by Borrower of such request. 

9.19    Advertisement. Administrative Agent and each Lender, in its sole discretion, shall have the right to
announce and publicize the financing established hereunder, as it deems appropriate, by means and media selected by Administrative Agent or such Lender. Such publication shall include all pertinent information relating to such financing, including
without limitation, the term, purpose, pricing, loan amount, name of Borrower. The form and content of the published information shall be in the sole discretion of Administrative Agent or such Lender and shall be considered the sole and exclusive
property of Administrative Agent or such Lender. All expenses related to publicizing the financing shall be the sole responsibility of Administrative Agent or such Lender. 

9.20    Waiver of Jury Trial. BORROWER AND ADMINISTRATIVE AGENT AND EACH LENDER EACH HEREBY WAIVE ANY AND ALL
RIGHTS IT MAY HAVE TO A JURY TRIAL IN CONNECTION WITH ANY LITIGATION, PROCEEDING OR COUNTERCLAIM ARISING WITH RESPECT TO RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO OR UNDER THE LOAN DOCUMENTS OR WITH RESPECT TO ANY CLAIMS ARISING OUT OF ANY
DISCUSSIONS, NEGOTIATIONS OR COMMUNICATIONS INVOLVING OR RELATED TO ANY PROPOSED RENEWAL, EXTENSION, AMENDMENT, MODIFICATION, RESTRUCTURE, FORBEARANCE, WORKOUT, OR ENFORCEMENT OF THE TRANSACTIONS CONTEMPLATED BY THE LOAN DOCUMENTS. 

9.21    Consequential Damages. Neither Administrative Agent, any Lender nor any agent or attorney of Administrative
Agent or any Lender shall be liable for any consequential damages arising from any breach of contract, tort or other wrong relating to the establishment, administration or collection of the Obligations. 

9.22    Release of Collateral. Notwithstanding anything to the contrary contained herein or in any other Loan
Document, the Administrative Agent is hereby irrevocably authorized by each Lender (without requirement of notice to or consent of any Lender) to take any action requested by the Borrower having the effect of releasing any Collateral or guarantee
obligations (a) to the extent necessary to permit consummation of any transaction not prohibited by any Loan Document or that has been consented to in accordance with the provisions of this Agreement, or (b) under the circumstances
described in the immediately following sentence. At such time as the Loans and the Obligations due under the Loan Documents shall have been paid in full, the Collateral shall be released from the Liens created by the Security Documents, and the
Security Documents and all obligations (other than those expressly stated to survive such termination) of the Administrative Agent and each party under the Security Documents shall terminate, all without delivery of any instrument or performance of
any act by any Person. 

  
 -60- 

 9.23    Confidentiality. 

(a) The Administrative Agent and each Lender agrees to keep confidential all non-public information
provided to it by or on behalf of Borrower, the Administrative Agent or any Lender pursuant to or in connection with this Agreement that is designated by the provider thereof as confidential; provided that nothing herein shall prevent the
Administrative Agent or any Lender from disclosing any such information (i) to the Administrative Agent, any other Lender or any Affiliate thereof, (ii) subject to an agreement to comply with the provisions of this
Section 9.23, to any actual or prospective transferee or any direct or indirect counterparty to any Hedging Agreement (or any professional advisor to such counterparty), (iii) to its employees, directors, agents, attorneys,
accountants, representatives, consultants, auditors and other professional advisors or those of any of its affiliates, (iv) upon the request or demand of any Governmental Authority, (v) in response to any order of any court or other
Governmental Authority or as may otherwise be required pursuant to any Requirement of Law, (vi) if required to do so in connection with any litigation or similar proceeding, (vii) that has been publicly disclosed, (viii) in connection
with the exercise of any remedy hereunder or under any other Loan Document, or (ix) if agreed by Borrower or any Subsidiary of Borrower in its sole discretion, to any other Person. 

(b) Each Lender acknowledges that information furnished to it pursuant to this Agreement or the other Loan Documents may include material non-public information concerning the Borrower and its Subsidiaries and Affiliates and their related parties or their respective securities, and confirms that it has developed compliance procedures regarding the use
of material non-public information and that it will handle such material non-public information in accordance with those procedures and applicable law, including federal
and state securities laws. 
 (c) All information, including requests for waivers and amendments, furnished by Borrower or the
Administrative Agent pursuant to, or in the course of administering, this Agreement or the other Loan Documents will be syndicate-level information, which may contain material non-public information about the
Borrower and its Affiliates and their related parties or their respective securities. Accordingly, each Lender represents to Borrower and the Administrative Agent that it has identified in its administrative questionnaire a credit contact who may
receive information that may contain material non-public information in accordance with its compliance procedures and applicable law, including federal and state securities laws. 

9.24    Patriot Act Notice. Lenders are subject to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56) (signed into law October 26, 2001)) (the “Act”) and hereby notify Borrower and Guarantors that pursuant to the requirements of the Act, Lenders are required to obtain, verify and record
information that identifies Borrower and Guarantors, which information includes the names and addresses of Borrower and Guarantors and other information that will allow Lenders to identify Borrower and Guarantors in accordance with the Act. 

[SIGNATURES TO FOLLOW ON SEPARATE PAGE] 

  
 -61- 

 WITNESS the due execution of this Agreement as a document under seal as of the date first
written above. 
  

			
	RTI SURGICAL, INC., as Borrower
		
	By:	 	 /s/ Robert P. Jordheim

	Name:	 	Robert P. Jordheim
	Title:	 	EVP and Chief Financial Officer

 (Signature Page to Third Amended and Restated Loan Agreement) 

 
			
	TD BANK, N.A., as Administrative Agent
		
	By:	 	 /s/ Mike Nursey

	Name:	 	Mike Nursey
	Title:	 	Central Florida Market President
	
	TD BANK, N.A., as Lender
		
	By:	 	 /s/ Mike Nursey

	Name:	 	Mike Nursey
	Title:	 	Central Florida Market President
	
	FIRST TENNESSEE BANK NATIONAL
	ASSOCIATION, as Lender
		
	By:	 	 /s/ Kristi Lewallen

	Name:	 	Kristi Lewallen
	Title:	 	Director, Specialty Healthcare

 (Signature Page to Third Amended and Restated Loan Agreement) 

 EXHIBIT A 

LENDERS 
  

																			
	 Lender
	  	 Notice Address
	  	Commitments and Applicable Percentages	 
	  	  	Term Loan	 	 	Revolving Credit	 
	  	  	Amount	 	  	Percentage	 	 	Amount	 	  	Percentage	 
	TD Bank, N.A.	  	 9715 N. Gate Parkway
 Jacksonville, Florida
32246
 Attention: Mike Nursey
 Telecopy No.

 
 with copies to:

Rogers Towers, P.A.
 1301 Riverplace Blvd.

Suite 1500
 Jacksonville, Florida 32207

Attention: J. Kirby Chritton
 Telecopy No. 904-396-0663
	  	$	12,687,500	 	  	 	50	% 	 	$	21,250,000	 	  	 	50	% 
						
	First Tennessee Bank National Association	  	 211 Franklin Road
 Suite 300

Brentwood, Tennessee 37027
 Attention: Kristi Lewallen

Telecopy No: (866) 342-2099
	  	$	12,687,500	 	  	 	50	% 	 	$	21,250,000	 	  	 	50	% 

 EXHIBIT B 

AUTHORIZATION CERTIFICATE 

(Borrower Letterhead) 
 Date:
                     
 TD Bank, N.A., as Administrative
Agent 
 9715 N. Gate Parkway 
 Jacksonville, Florida 32246 

Attention:
                                         

Dear                     : 

The following individuals are authorized to request loan advances against RTI Surgical, Inc., a Delaware corporation formerly known as RTI Biologics, Inc.
(“Borrower”) line of credit and transfer funds from any of Borrower’s accounts per written instructions received via fax: 
  

											
	 	 	Authorized Person	 	 	 	Title	  	 	 	Signature
	1.	 	  
	 		 	  
	  		 	  

	2.	 	  
	 		 	  
	  		 	  

	3.	 	  
	 		 	  
	  		 	  

  

			
	Acknowledged and approved:
		
	By:	 	
                     

	Name:	 	
                     

	Title:	 	
                     

 EXHIBIT C 

PERMITTED INDEBTEDNESS 
  

									
	 	  	Current Draw	 	  	Availability	 
	 Domestic Lines of Credit
  

TD Bank
	  	$	35,000,000	 	  	$	7,500,000	 
			
	 AFCO Insurance

Premium Finance
	  	$	1,603,055.20	 	  			
			
	 Long Term Debt
  

TD Bank/Regions Bank
	  	$	47,375,000	 	  			

 EXHIBIT D 

PERMITTED LIENS 
 As to
the Real Property in Alachua, Florida 
  

	 	1.	Declaration of Covenants, Conditions, Restrictions and Easements, recorded in Book 1588, page 2207, Joinder in Book 1588, page 2205, together with First Amendment in Book 1762, page 1883 and Second Amendment in Book
2161, page 1701, together with Designation and Assumption by Successor Developer recorded in Book 2283, page 613 and Book 2283, page 632. 

  

	 	2.	Restrictions, dedications, conditions, reservations, easements and other matters shown on the plat of Progress Center, as recorded in Plat Book M, Page(s) 82. 

 

	 	3.	Restrictions, dedications, conditions, reservations, easements and other matters shown on the plat of Replat Of Progress Center, as recorded in Plat Book P, Page(s) 48. 

 

	 	4.	Agreement between Apalachee Development Company, a Florida corporation, and the State of Florida Department of Community Affairs recorded in Book 1605, Page 1374, as amended in Book 1617, page 613. 

 

	 	5.	Notice of Development Order Approving The Development of Regional Impact known as Progress Center recorded in Book 1692, Page 1378, as Amended in Book 1863, page 331 and Second Amendment in Book 2232, page 2867.

  

	 	6.	Notice of Preliminary Development Agreement recorded in Book 2198, Page 2845. 

  

	 	7.	Covenants, Conditions and Restrictions as set forth in Special Warranty Deed recorded in Book 2264, page 2522. 

  

	 	8.	Cross Ingress-Egress Easement Agreement recorded in Book 2283, Page 642. 

  

	 	9.	Grant of Easement for Ingress, Egress and Public Utilities recorded in Book 3873, Page 1565. 

  

	 	10.	Non-Exclusive Public Utility Easement recorded in Book 4157, Page 2088. 

As to the Real Property in Marquette, Michigan 
  

	 	1.	Terms and Conditions contained in Easement for Storm Sewer in Judgment Amending Plat of River Park Complex as disclosed by instrument recorded in Document Number 2004R-11781. 

 

	 	2.	Deed Restrictions to River Park Complex recorded in Liber 123, Page 907. 

 EXHIBIT E 

COVENANT COMPLIANCE CERTIFICATE 

(Borrower Letterhead) 
 TD Bank, N.A., as
Administrative Agent    
                                         
                                         
                          Date:
                     
 9715 N. Gate Parkway 

Jacksonville, Florida 32246 
 Attention:
                     
 The undersigned,
the President of RTI Surgical, Inc., a Delaware corporation formerly known as RTI Biologics, Inc. (“Borrower”), gives this certificate to TD Bank, N.A., as administrative agent (in such capacity, the “Administrative
Agent”), in accordance with the requirements of Section                      of that certain Third Amended and Restated Loan Agreement,
dated August     , 2017 (as amended, modified, supplemented or restated and in effect from time to time, the “Loan Agreement”), by and among Borrower, lenders and the Administrative Agent. Capitalized terms used in this
Certificate, unless otherwise defined herein, shall have the meanings ascribed to them in the Loan Agreement. 
 1. Based upon my review of
the consolidated balance sheets and statements of income of Borrower for the fiscal period ending             , 20    , copies of which are attached hereto, I hereby
certify that: 
 (a) The Fixed Charge Coverage Ratio of Borrower is
                                        ; 

(b) The Leverage Ratio of Borrower is
                                        ; and

 (c) The Unrestricted Cash of Borrower is
                                        . 

Attached as Schedule A are the details underlying such financial covenant calculations. 

2. No default exists on the date hereof, other than:
                                         [if
none, so state; and 
 3. No Event of Default exists on the date hereof, other than:
                                         [if
none, so state]. 
  

			
	Very truly yours,
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 APPENDIX 1 

CONSOLIDATED EBITDA 
 For purposes
of the financial covenant calculations contemplated by Section 5.12, Borrower’s quarterly Consolidated EBITDA, inclusive of authorized one time charges and excluding EBITDA generated by Borrower’s CTS Business shall be as follows for
the periods indicated: 
  

			
	 For the Quarter ending September 30, 2016
	  	$5,721,000
		
	 For the Quarter ending December 31, 2016
	  	$5,084,000
		
	 For the Quarter ending March 32, 2017
	  	$5,856,000
		
	 For the Quarter ending June 30, 2017
	  	Consolidated EBITDA for the Quarter ending June 30, 2017, inclusive of authorized one time charges less EBITDA generated by Borrower’s CTS Business in such Quarter.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]